estrone has been researched along with Breast Neoplasms in 736 studies
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Postmenopausal breast cancer patients starting adjuvant letrozole were eligible." | 9.69 | Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurem ( Blomqvist, C; Faltinová, M; Haanpää, M; Hämäläinen, E; Lyytinen, H; Mattson, J; Tiitinen, A; Vehmanen, L, 2023) |
| "In patients taking tamoxifen for breast cancer, daily BR-DIM promoted favorable changes in estrogen metabolism and circulating levels of SHBG." | 9.24 | A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. ( Altbach, M; Chalasani, P; Chow, HHS; Galons, JP; Huang, C; Maskarinec, G; Roe, DJ; Stopeck, A; Strom, MB; Thompson, PA; Thomson, CA; Wertheim, BC, 2017) |
| "Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached." | 9.22 | Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. ( Avella, A; Azaro, A; Bellet, M; Bohn, U; Catalán, G; Catalán, R; Ciruelos, E; Climent, MA; Ferrer, R; Fleming, GF; Francis, PA; González-Martin, A; Gray, KP; Láng, I; Lluch, A; Morales, J; Price, KN; Rajasekaran, A; Regan, MM; Vázquez, J, 2016) |
| "Postmenopausal women who were to receive adjuvant anastrozole for resected early breast cancer were studied." | 9.20 | Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. ( Barman, P; Buzdar, AU; Desta, Z; Dudenkov, TT; Flockhart, DA; Goetz, MP; Ingle, JN; Kalari, KR; Northfelt, DW; Perez, EA; Robson, ME; Wang, L; Weinshilboum, RM; Williard, CV, 2015) |
| "To evaluate the influence of the third-generation aromatase inhibitor letrozole (Femara) on breast cancer tissue levels of estrone (E(1)), estradiol (E(2)), and estrone sulfate (E(1)S) in postmenopausal women undergoing primary treatment for locally advanced estrogen receptor/progesterone receptor-positive breast cancers." | 9.13 | Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. ( Aas, T; Duong, NK; Ekse, D; Evans, DB; Geisler, J; Helle, H; Lønning, PE; Nordbø, Y, 2008) |
| "Fifty-four postmenopausal women with estrogen receptor-positive breast cancer receiving aromatase inhibitors (AIs) as part of their adjuvant therapy were randomly assigned to receive either 3 months of anastrozole (1 mg) followed by 3 months of letrozole (2." | 9.13 | Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. ( A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O, 2008) |
| "Rodent models of human breast cancer suggest that the combination of the steroidal aromatase inhibitor exemestane with tamoxifen may have additive activity." | 9.11 | Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. ( Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR; Rogers, E, 2005) |
| "To compare the efficacy, safety and tolerability of letrozole, an advanced non-steroidal aromatase inhibitor, and fadrozole hydrochloride, an older-generation drug in this class, we conducted a randomised double-blind trial in postmenopausal women with advanced breast cancer." | 9.10 | Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. ( Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T, 2003) |
| "Twelve postmenopausal women with estrogen receptor-positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2." | 9.10 | Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. ( Anker, G; Dowsett, M; Geisler, J; Haynes, B; Lønning, PE, 2002) |
| "Droloxifene (3-hydroxytamoxifen) is a novel antiestrogen currently undergoing clinical investigations for treatment of breast cancer patients." | 9.08 | Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. ( Ekse, D; Geisler, J; Hösch, S; Lønning, PE, 1995) |
| "Plasma levels of oestradiol (Oe2), oestrone (Oe1) oestrone sulphate (Oe1S), androstenedione, testosterone, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulphate (DHEAS), sex hormone-binding globulin (SHBG) and the gonadotrophins (FSH and LH) were determined in 20 postmenopausal women with breast cancer treated with the anti-oestrogen droloxifene (3-hydroxytamoxifen)." | 9.08 | Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. ( Geisler, J; Gundersen, S; Haarstad, H; Kvinnsland, S; Lønning, PE; Raabe, N, 1995) |
| "Our results suggest that vorozole is an effective and safe drug for the treatment of advanced postmenopausal breast cancer following tamoxifen failure." | 9.08 | Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study. ( Amoroso, D; Boccardo, F; Brema, F; Cortesi, E; Farris, A; Guida, G; Iacobelli, S; Irtelli, L; Langenaeken, C; Mesiti, M; Mustacchi, G; Nardini, P; Pacini, P, 1997) |
| "Aminoglutethimide (AG) has been the most widely used aromatase inhibitor in breast cancer patients to date." | 9.08 | Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. ( Berntsen, H; Geisler, J; Greaves, JL; Lundgren, S; Lønning, PE, 1998) |
| "Twelve postmenopausal women suffering from advanced breast cancer had plasma estrogens, androgens, cortisol, and gonadotropins determined before therapy and during treatment with megestrol acetate (MA) in oral doses escalated from 40 to 160 mg." | 9.08 | Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. ( Helle, SI; Lonning, PE; Lundgren, S, 1996) |
| "Fadrozole Hydrochloride (CGS 16949A) and Letrozole (CGS 20267), are two of the newest non-steroidal, orally active aromatase inhibitors currently being evaluated as second line treatment of patients with hormone dependent forms of metastatic breast cancer." | 9.07 | Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. ( Demers, LM, 1994) |
| "Serum estradiol, estrone, estrone sulfate and sex hormone binding globulin were measured in 10 postmenopausal patients with advanced breast cancer receiving sequential treatment with medroxyprogesterone acetate and megestrol acetate." | 9.06 | Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--II. A differential effect of megestrol acetate and medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. ( Lundgren, S; Lønning, PE, 1990) |
| "One hundred and one postmenopausal patients with advanced breast cancer were enrolled in a randomized phase II clinical trial to investigate the clinical and hormonal response to aminoglutethimide administered at daily doses of 2 x 125 mg, 3 x 125 mg or 2 x 250 mg, with no addition of hydrocortisone." | 9.06 | Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer. ( Bonfrer, JM; Bruning, PF; de Jong-Bakker, M; Hart, AA; Moolenaar, AJ; Nooijen, WJ; van der Linden, E, 1989) |
| "4-Hydroxyandrostenedione (CGP32349; 4-OHA) is a clinically effective treatment for advanced postmenopausal breast cancer by both the parenteral and p." | 9.06 | Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. ( Coombes, RC; Cunningham, DC; Dehennin, L; Dowsett, M; Evans, S; Hedley, A; Stein, RC, 1989) |
| "A group of 122 postmenopausal patients with histologically proven node-positive primary breast cancer have been randomized to receive aminoglutethimide-hydrocortisone or placebo aminoglutethimide-placebo hydrocortisone for 2 years." | 9.05 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. ( Bettelheim, R; Chilvers, C; Coombes, RC; Dowsett, M; Ford, HT; Gazet, JC; Gordon, C; Powles, TJ; Smith, IE; Zava, D, 1982) |
| "The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid." | 9.05 | Aminoglutethimide dose and hormone suppression in advanced breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983) |
| "The endocrine effects of replacement doses of hydrocortisone in postmenopausal women with advanced breast cancer were compared with the same doses of hydrocortisone plus aminoglutethimide." | 9.05 | Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1984) |
| "Endocrine therapy is a key modality in the management of breast cancer, with current options for postmenopausal women including tamoxifen, aromatase inhibitors and fulvestrant." | 8.87 | Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. ( Coombes, RC; Januszewski, A; Palmieri, C; Stanway, S, 2011) |
| " In the present review, we summarized the action of the 19-nor-progestin nomegestrol acetate (NOMAC) on the sulfatase, 17beta-HSD1 and sulfotransferase activities in the hormone-dependent MCF-7 and T47-D human breast cancer cell lines." | 8.82 | Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. ( Chetrite, G; Meschi, S; Pasqualini, JR; Shields-Botella, J, 2005) |
| " Estrone, one of the mammalian estrogens, has affinity for estrogen receptors (ERα), which are overexpressed in hormone-responsive breast cancers." | 7.96 | Estrone-Decorated Polyion Complex Micelles for Targeted Melittin Delivery to Hormone-Responsive Breast Cancer Cells. ( Chen, F; Kent, B; Raveendran, R; Stenzel, MH, 2020) |
| " In this work, an endogenous ligand, estrone, was used to synthesize doxorubicin-encapsulating liposomes for estrogen receptor (ER)-positive breast cancer therapy with cyanuric chloride (2,4,6 trichloro-1,3,5 triazine) being used as a linking molecule to attach 3-OH group of estrone to the surface of liposomes." | 7.88 | Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy. ( Al Sayah, M; Husseini, GA; Kawak, P; Martins, AM; Paul, V; Salkho, NM; Vitor, RF, 2018) |
| "Estrone-modified glycol chitosan nanoparticles (GCNP-ES) based on the mechanisms of ES-mediated endocytosis and intracellular pH-responsive drug release were developed for the treatment of breast cancer." | 7.88 | Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer. ( Tang, C; Yang, H; Yin, C, 2018) |
| "The level of endogenous estrone, one of the three major naturally occurring estrogens, has a significant correlation with the incidence of post-menopausal breast cancer." | 7.83 | A MALDI-MS-based quantitative analytical method for endogenous estrone in human breast cancer cells. ( Hwang, CH; Jang, KS; Jeong, JH; Kim, BG; Kim, HJ; Kim, KJ; Kim, YG; Lee, YK; Park, HG; Park, SH; Sung, C; Yang, YH, 2016) |
| "Proliferation of two oestrogen receptor-positive breast cancer cell lines (ZR 75-1 and HCC 1500) was investigated after incubation with oestrone (E₁), oestradiol (E₂), oestriol (E₃), and oestetrol (E₄)." | 7.81 | Oestetrol stimulates proliferation and oestrogen receptor expression in breast cancer cell lines: comparison of four oestrogens. ( Fehm, T; Liu, S; Mueck, AO; Neubauer, H; Ruan, X; Schultz, S; Seeger, H, 2015) |
| "Organic Anion Transporting Polypeptides (OATP) are a family of membrane associated transporters that facilitate estrone-3-sulphate (E3S) uptake by hormone dependent, post-menopausal breast cancers." | 7.81 | (125)I-Labelled 2-Iodoestrone-3-sulfate: synthesis, characterization and OATP mediated transport studies in hormone dependent and independent breast cancer cells. ( Allen, C; Banerjee, N; Bendayan, R; Chio, J; Forbes, J; Kelly, R; Stephenson, KA; Valliant, JF; Wu, TR, 2015) |
| "Estrone-3-sulfate (E1S) is thought to be a major estrogen precursor in estrogen receptor (ER)-positive breast cancer." | 7.81 | Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells. ( Ariyoshi, N; Fujisaki, K; Ishii, I; Matsumoto, J; Nagashima, T; Nakanishi, T; Nakatani, Y; Okubo, Y; Sakakibara, M; Shiina, N; Takeda, H; Tamai, I; Yamada, H, 2015) |
| "The urinary ratio 2-hydroxyoestrone/16-hydroxyoestrone (URME), has been proposed in various populations on the world as a risk indicator for breast cancer (BC), however in the Mexican population has never been determined." | 7.80 | [Determination of 2-hydroxyestrone /16α-hydroxyestrone ratio in urine of Mexican women as a risk indicator for breast cancer and its relationship with other risk factors]. ( Godínez Martínez, EY; Juárez González, AR; Lemus Bravo, AE; Rodríguez Ventura, AL; Sámano, R; Santillán Ballesteros, R; Tolentino Dolores, M, 2014) |
| " Here, we present the design, fabrication, optimization, characterization, and biological evaluation of estrone-conjugated noscapine-loaded gelatin nanoparticles (Nos-ES-GN) for targeting estrogen-receptor-positive breast cancer MCF-7 cells." | 7.80 | Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy. ( Aneja, R; Bharatam, PV; Gundala, SR; Jain, UK; Kasetti, Y; Katyal, A; Madan, J, 2014) |
| "The current study investigates the potential of estrone-3-sulphate (E3S) as a ligand for targeting Organic Anion Transporting Polypeptides (OATP), a family of membrane associated uptake transporters, for detection and diagnosis of hormone dependent breast cancers." | 7.79 | Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. ( Allen, C; Banerjee, N; Bendayan, R; Fonge, H; Mikhail, A; Reilly, RM, 2013) |
| "To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer." | 7.78 | Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. ( A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L, 2012) |
| "17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) converts estrone (E1) into estradiol (E2) and is expressed in many steroidogenic tissues and breast cancer cell lines." | 7.78 | A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone. ( Ayan, D; Maltais, R; Poirier, D; Roy, J, 2012) |
| "Breast cancer resistance protein (BCRP/ABCG2), an ATP-binding cassette half transporter, confers multidrug resistance (MDR) to a series of antitumor agents such as mitoxantrone, daunorubicin, SN-38, and topotecan, and often limits the efficacy of chemotherapy." | 7.76 | Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. ( Gao, P; Gao, Y; Li, G; Wang, H; Wei, F; Wei, L; Yin, D; Yu, J; Zhang, X; Zhang, Y; Zhou, G, 2010) |
| " Thus, we evaluated the correlation between plasma leptin concentrations and total body aromatization (TBA) as well as plasma levels of estrone (E(1)), estradiol (E(2)) and estrone sulfate (E(1)S) in postmenopausal breast cancer patients." | 7.74 | Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. ( Dowsett, M; Ekse, D; Geisler, J; Haynes, B; Lønning, PE, 2007) |
| "We measured serum levels of estrone (E1), estradiol (E2), dehydroepiandrosterone sulfate (DHEAS), and sex hormone-binding globulin (SHBG) in 142 postmenopausal women aged 50 and over with primary breast cancer who had undergone surgical treatment, and investigated the heterogeneity in the relations of endogenous sex hormone levels to hormone receptor status, using the case-series study method." | 7.74 | Relation of serum levels of estrogen and dehydroepiandrosterone sulfate to hormone receptor status among postmenopausal women with breast cancer. ( Fujiya, T; Inoue, H; Kakugawa, Y; Minami, Y; Tateno, H, 2007) |
| "Pre- and postmenopausal patients with breast cancer were screened for mutation of the BRCAI gene and estrogens and leptin levels were measured." | 7.73 | BRCA1 mutation, leptin and estrogen levels in breast cancer patients. ( Chudecka-Glaz, A; Górski, B; Rzepka-Górska, I; Tarnowski, B, 2005) |
| " To test this hypothesis, we determined plasma hormone levels (n=9) and in vivo aromatization (n=3) in postmenopausal women suffering from advanced breast cancer before and during treatment (4 weeks) with diethylstilbestrol (DES) 5mg three times daily." | 7.73 | Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients. ( Anker, G; Dowsett, M; Ekse, D; Geisler, J; Haynes, B; Helle, H; Lønning, PE, 2005) |
| "The aim of the study is to suppress the progress of estrogen-dependent breast cancer by inhibiting the membrane transporter, which mediates the internalization of estrone-3-sulfate as estrogen precursor in the cancer cells." | 7.73 | Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. ( Irokawa, M; Nozawa, T; Suzuki, M; Tamai, I; Tsuji, A; Yabuuchi, H, 2005) |
| "Breast cancer resistance protein (BCRP), an adenosine triphosphate-binding cassette transporter, confers resistance to a series of anticancer reagents, including mitoxantrone, SN-38 and topotecan." | 7.71 | Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. ( Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T, 2002) |
| "It has been suggested that alterations in estradiol (E(2)) metabolism, resulting in increased production of 16alpha-hydroxyestrone (16alpha-OHE(1)), is associated with an increased risk of breast cancer." | 7.71 | Regulation of cell cycle and cyclins by 16alpha-hydroxyestrone in MCF-7 breast cancer cells. ( Gallo, MA; Klinge, CM; Lewis, JS; Thomas, T; Thomas, TJ, 2001) |
| "It has been hypothesized that the ratio of urinary 2-hydroxyestrone to 16alpha-hydroxyestrone (2-OHE1/16alpha-OHE1 represents a biomarker for breast cancer risk; the lower the ratio the higher the risk." | 7.71 | Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women. ( Bernstein, L; Gentzschein, E; London, S; Pike, MC; Stanczyk, FZ; Tseng, CC; Ursin, G; Yang, D, 2002) |
| "Recent clinical trials suggest that tamoxifen (TAM) is a preventive agent for breast cancer, however, the mechanism is unknown." | 7.71 | A proposed mechanism of tamoxifen in breast cancer prevention. ( Bender, W; Yu, FL, 2002) |
| " As sulphamoylation of oestrogens enhances their potency and bioavailability we have synthesized 2-methoxyoestrone-3-O-sulphamate (2-MeOEMATE) and compared its ability to inhibit the proliferation of breast cancer cells with that of 2-methoxyoestrone (2-MeOE1)." | 7.70 | The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. ( Hejaz, HA; MacCarthy-Morrogh, L; Packham, G; Potter, BV; Purohit, A; Reed, MJ; Walden, L, 2000) |
| " In the present investigation we have examined the ability of 2-methoxyestrone (2-MeOE1), 2-methoxyestradiol (2-MeOE2), 2-methoxyestrone-3-O-sulfamate (2-MeOEMATE), and a number of related compounds, to inhibit 2-deoxy-D-[1-(3)H]-glucose uptake in MCF-7 breast cancer cells." | 7.70 | Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate. ( Hejaz, HA; Potter, BV; Purohit, A; Reed, MJ; Singh, A, 2000) |
| "The formation of oestrone sulphate has been examined in MCF-7 (oestrogen receptor positive, ER+) and MDA-MB-231 (ER negative, ER-) breast cancer cells." | 7.70 | The regulation of oestrone sulphate formation in breast cancer cells. ( de Giovani, CV; Purohit, A; Reed, MJ, 1999) |
| "The evaluation of estrogens (estrone, estradiol, and their sulfates) in the breast tissue of post-menopausal patients with breast cancer indicates high levels, particularly of estrone sulfate (E1S) which is 15-25 times higher than in the plasma." | 7.69 | Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. ( Blacker, C; Botella, J; Chetrite, G; Delalonde, L; Feinstein, MC; Maloche, C; Nguyen, BL; Paris, J; Pasqualini, JR; Talbi, M, 1995) |
| "Using different hormone-dependent (MCF-7, T-47D) and hormone-independent (MDA-MB-231, Hs-578S, MDA-MB-436) human breast cancer cells, the interconversion estrone (E1)<-->estradiol (E2) was explored." | 7.69 | Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020). ( Chetrite, G; Nguyen, BL; Pasqualini, JR, 1995) |
| "Estrone sulphate (E1S) may be an important estrogen source in breast cancers, particularly in postmenopausal women." | 7.69 | Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. ( Adlercreutz, H; Ekse, D; Fotsis, T; Johannessen, DC; Lien, EA; Lønning, PE, 1995) |
| "This report concerns the evaluation of various estrogens, estrone (El), estradiol (E2), and estrone sulfate (E1S), as well as E1S-sulfatase and aromatase activities in pre- and postmenopausal women with breast cancer." | 7.69 | Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. ( Blacker, C; Chetrite, G; Delalonde, L; Feinstein, MC; Maloche, C; Pasqualini, JR; Talbi, M, 1996) |
| " Several lines of evidence indicate that the major source of estrogen in breast cancer cells may be from conversion of estrone sulfate to estrone by the enzyme estrone sulfatase." | 7.69 | Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives. ( Jagannathan, S; Li, PK; Rhodes, ME; Selcer, KW, 1996) |
| " The major source of estrogen in breast cancer cells may be the conversion of estrone sulfate to estrone by the enzyme estrone sulfatase." | 7.69 | Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines. ( Hegde, PV; Li, PK; Selcer, KW, 1997) |
| "In the present studies, the concentrations (mammary tissue and plasma) of estrone (E1), estradiol (E2) and their sulfates (E1S and E2S), as well as the sulfatase and aromatase activities, were evaluated in patients with breast fibroadenomas." | 7.69 | Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. ( Chetrite, G; Cortes-Prieto, J; Pasqualini, JR; Ruiz, A; Talbi, M, 1997) |
| "The estrogen-sensitive human breast cancer cell line ZR-75-1 was used to study the regulation of 17 beta-hydroxysteroid dehydrogenase (17 beta HSD), the enzyme responsible for the interconversion of estrone (E1) and estradiol (E2)." | 7.68 | Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. ( Couture, P; Labrie, F; Simard, J; Thériault, C, 1993) |
| "The influence of the aromatase inhibitor 4-hydroxyandrostenedione (4OHA) given intramuscularly on the peripheral aromatisation of androstenedione into oestrone was investigated in postmenopausal women with breast cancer and compared with the suppression of plasma oestradiol (E2)." | 7.68 | The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. ( Dowsett, M; Jacobs, S; Jones, AL; Lonning, PE; MacNeill, F; Powles, TJ, 1992) |
| "Twenty-eight and 24 patients with advanced breast cancer were treated with Aminoglutethimide (AG) or AG + Tamoxifen (AG + TAM) from June 1984 to June 1989, respectively." | 7.68 | [Aminoglutethimide and aminoglutethimide+tamoxifen treatment for advanced breast cancer]. ( Hisamatsu, K; Nomura, Y; Tashiro, H, 1992) |
| "Aminoglutethimide is effective in the treatment of breast cancer in postmenopausal patients as a result of its inhibition of aromatase." | 7.68 | Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion. ( Cantwell, BM; Dowsett, M; Harris, AL; Mehta, A, 1991) |
| "The ovarian and pituitary functions of 64 operable breast cancer patients undergoing adjuvant therapy with cytotoxic chemotherapy and/or tamoxifen were investigated." | 7.68 | The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer. ( Akami, T; Honjyo, H; Mitsuo, M; Naitoh, K; Oka, T; Okada, H; Yamamoto, T; Yasumura, T, 1990) |
| "The effect of treatment with the aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA) on the peripheral conversion of androstenedione to estrone has been examined in eight postmenopausal women with advanced breast cancer." | 7.68 | Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. ( Coldham, NG; Ghilchik, MW; James, VH; Lai, LC; Owen, AM; Purohit, A; Reed, MJ; Shaikh, NA; Singh, A, 1990) |
| "Values were determined by means of a ligand binding assay using 17-FE (17-fluoresceinated estrone) in 53 breast cancer patients." | 7.68 | [Fixation of fluorescent estrone derivative on human breast cancer cells. Correlation with age, menopause status and histopathology]. ( Alamy, H; Baltali, E; Bouih, A; el Gueddari, B; el Hafed, A; Kettani, F; Morchid, M; Souadka, A; Souadka, F; Wydadi, M, 1990) |
| "The estrogen responsive human breast cancer MCF-7 cell culture was examined for its response to 2-hydroxyestrone a principal metabolite of estradiol." | 7.67 | Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. ( Bradlow, HL; Fishman, J; Huh, MM; Schneider, J, 1984) |
| "The interactions of 16 alpha-hydroxyestrone (16 alpha-OHE1), a metabolite of estradiol (E2), with estrogen receptors (ERs) were compared in this study to the classic E2-receptor mechanism in human breast cancer cells MCF-7 in culture." | 7.67 | Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. ( Fishman, J; Swaneck, GE, 1988) |
| "The clinical and endocrine effects of low-dose aminoglutethimide without hydrocortisone in patients with advanced breast cancer were investigated." | 7.67 | Low-dose aminoglutethimide in treatment of advanced breast cancer. ( Bozek, T; Carr, L; Dowsett, M; Gazet, JC; Jeffcoate, SL; Kurkure, A; McKinna, JA; Smith, IE; Stuart-Harris, R, 1984) |
| "About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs." | 7.67 | Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984) |
| "Plasma level, plasma clearance, production rate and interconversions of oestrone and oestrone sulphate were measured in six breast cancer patients receiving aminoglutethimide therapy." | 7.67 | Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. ( Johannessen, DC; Lønning, PE; Thorsen, T, 1989) |
| "Estrone sulfate (E1-S) in the serum and tissues of patients with breast cancer or endometrial cancer was measured by a direct radioimmunoassay without hydrolysis." | 7.67 | Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer. ( Honjo, H; Naitoh, K; Nambara, T; Ogino, Y; Urabe, M; Yamamoto, T; Yasumura, T, 1989) |
| "This study was undertaken to investigate whether miconazole (MCZ), an antifungal agent, inhibits aromatase activity in human breast cancer tissue preparations (n = 6)." | 7.67 | In vivo and in vitro effects of the antifungal agent miconazole on estrogen biosynthesis in human breast cancer. ( Fukuoka, M; Okada, H; Yamamoto, T; Yasumura, T, 1989) |
| "The activities of aromatase and estrone sulfatase which are important enzymes involved in the local production of estrogen in breast cancer tissue were measured to examine their availability in endocrine therapy and their clinical significance." | 7.67 | [Local production of estrogen via aromatase and estrone sulfatase in breast cancer tissue]. ( Utsumi, T, 1989) |
| "The possibility that medroxyprogesterone acetate (MPA) is clinically effective at least in part by its suppression of adrenal steroidogenesis and a resultant reduction of circulating oestrogen levels was investigated in 49 postmenopausal patients with advanced breast cancer." | 7.67 | The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients. ( Dowsett, M; Jeffcoate, SL; Lal, A; Smith, IE, 1987) |
| "Reports of estrone (E1) and dehydroepiandrosterone (DHEA) sulfatase (sulfohydrolase) activities within many human breast cancers have prompted us to undertake the identification and partial characterization of these enzyme activities within MCF-7 human breast cancer cells." | 7.67 | The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. ( MacIndoe, JH, 1988) |
| "5 mg, twice a day) aminoglutethimide (AG), without hydrocortisone (HC), escalating at monthly intervals to a conventional dose of AG (500 mg twice a day) combined with HC, were studied in 33 postmenopausal breast cancer patients." | 7.67 | Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. ( D'Souza, A; Donaldson, A; Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE; Stuart-Harris, R, 1985) |
| "Estrone and estradiol-17 beta concentration in breast cancer tissue are reported to be an order of magnitude higher than those of circulating plasma in breast cancer patients." | 7.67 | [Serum estrone sulfate levels in patients with breast cancer]. ( Honjyo, H; Oka, T; Okada, H; Yasumura, T, 1988) |
| "In this small study, the effect of aminoglutethimide on the disposition of oestrogens in women with advanced breast cancer was investigated using bolus injections of 4-[14C]-oestradiol and 6,7-[3H]-oestrone sulphate, alone or in combination." | 7.67 | Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. ( Kvinnsland, S; Lønning, PE; Thorsen, T; Ueland, PM, 1987) |
| "The conversion of 1 beta [3H] androstenedione to estrone in the presence of NADPH by breast cancer homogenates was assessed in tumors from 35 subjects together with estrogen and progesterone receptor concentration." | 7.67 | Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance. ( Bezwoda, WR; Dansey, R; Esser, JD; Mansoor, N, 1987) |
| "Five men with advanced breast cancer were treated with aminoglutethimide (AG) plus replacement dose hydrocortisone." | 7.67 | Role of aminoglutethimide in male breast cancer. ( Dowsett, M; Harris, AL; Smith, IE; Stuart-Harris, R, 1986) |
| "Aminoglutethimide without glucocorticoid has been shown to be a clinically effective treatment for postmenopausal breast cancer in low dosage (250 mg day-1)." | 7.67 | Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. ( Dowsett, M; Jeffcoate, SL; Santen, RJ; Santner, SJ; Smith, IE, 1985) |
| "Oestrone sulphate, the oestrogen in highest concentration in the plasma, may play a role in the induction and growth of breast cancers." | 7.67 | Oestrone sulphate, adipose tissue, and breast cancer. ( Hawkins, RA; Killen, E; Thomson, ML, 1985) |
| "Postmenopausal women with metastatic breast cancer were treated with trilostane, initially 240 mg daily increasing after 3 days to 480 mg daily and after a further three days to 960 mg daily." | 7.67 | Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone. ( Beardwell, CG; Bu'lock, D; Hindley, AC; St John, J; Wilkinson, PM, 1985) |
| "Peripheral serum levels of cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulphate (DHA-S), oestradiol-17 beta and total oestrone were measured in 17 postmenopausal breast cancer patients and on age-matched healthy controls." | 7.66 | Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients. ( Carlström, K; Sköldefors, H; Theve, NO; Wallgren, A; Wilking, N, 1982) |
| "Urine levels of three major estrogens and of pregnanediol were measured for 76 nulliparous daughters of breast cancer patients and for 115 control women of similar age and parity." | 7.66 | Elevated urine estrogen and pregnanediol levels in daughters of breast cancer patients. ( Brown, JB; Garas, J; MacMahon, B; Papaioannou, A; Trichopoulos, D, 1981) |
| "Urine samples were analyzed for estrone (E1), estradiol (E2), and Estriol (E3) to test the hypothesis that women diagnosed with benign breast disease (high risk for breast cancer?) will have lower estriol proportions (E3/E1 + E2 + E3) than a comparison control group." | 7.66 | Benign breast disease: estriol proportions and family history of breast cancer. ( Elinson, L; Morgan, RW; Vakil, DV, 1981) |
| "The daily excretion of estrone, estradiol, and estriol was determined for 22 normal women and 35 women with primary breast cancer." | 7.66 | Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer. ( Dao, TL; Lonergan, PA; Morreal, CE; Nemoto, T, 1979) |
| "To determine if delta 1-testololactone can inhibit the peripheral aromatization of androstenedione (delta), nine postmenopausal women with metastatic breast cancer were studied before and after 2 weeks of therapy with 250 mg of the drug, given every 6 h by mouth." | 7.66 | Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using delta 1-testololactone. ( Barone, RM; Judd, HL; Shamonki, IM; Siiteri, PK, 1979) |
| "The ability of breast cancer cells in long-term tissue culture to aromatize androstenedione to estrone and estradiol was examined." | 7.66 | Failure of breast cancer cells in long-term culture to aromatize androstenedione. ( D'Agata, R; Lippman, ME; Loriaux, DL; Monaco, ME, 1978) |
| "The concentrations of estrone (E1), androstenedione (A), testosterone (T) and sex-hormone-binding globulin (SHBG) in the serum were determined in 122 postmenopausal women, unselected with respect to age and stage of disease and with a newly diagnosed breast cancer." | 7.66 | Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls. ( Adami, HO; Johansson, ED; Vegelius, J; Victor, A, 1979) |
| "We have infused [6,7-3H]estrone or [6,7-3H]estradiol and [4-14C]estriol into seven women who had had breast cancer and into five normal postmenopausal women." | 7.66 | Estriol production rates and breast cancer. ( Longcope, C; Pratt, JH, 1978) |
| "The metabolism of estradiol, its production rate and the urinary excretion rate of its metabolites were studied in 5 women patients with breast cancer, 2 of whom were postmenopausal and 3 were ovariectomized, both before and after a period of 7beta,17alpha-dimethyltestosterone (calusterone) therapy." | 7.65 | 7beta,17alpha-Dimethyltestosterone (calusterone)-induced changes in the metabolism, production rate, and excretion of estrogens in women with breast cancer: a possible mechanism of action. ( Fishman, J; Hellman, L, 1976) |
| "The effects of estrone, estradiol, and estriol on MCF-7 human breast cancer are compared." | 7.65 | Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. ( Bolan, G; Lippman, M; Monaco, ME, 1977) |
| "Fifty-nine postmenopausal women with advanced breast cancer were treated with tamoxifen (antiestrogen), 20 mg orally twice a day for at least 2 months." | 7.65 | Tamoxifen (antiestrogen) therapy in advanced breast cancer. ( Kennedy, BJ; Kiang, DT, 1977) |
| "In two laboratory mammary cancer models, the combination of the aromatase inactivator exemestane plus tamoxifen gives a higher response rate than is found with either agent alone." | 6.71 | Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. ( Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR, 2005) |
| "Letrozole appears to be a very promising new antiaromatase drug." | 6.68 | Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. ( Bisagni, G; Cocconi, G; Fraschini, F; Pfister, C; Scaglione, F; Trunet, PF, 1996) |
| "In about one-third of advanced breast cancers, estrogen deprivation causes tumor regression." | 6.68 | Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. ( Blankenstein, RA; de Jong, PC; Donker, TH; Maitimu-Smeele, I; Nortier, HW; Slee, PH; Thijssen, JH; van de Ven, J, 1997) |
| "In postmenopausal breast cancer (BC) patients, tamoxifen (TAM) is frequently used in first-line therapy, and for those relapsing under TAM, aromatase inhibitors would be the drug of choice." | 6.68 | A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. ( Amichetti, M; Attili, A; Bajetta, E; Barni, S; Bichisao, E; Bolelli, GF; Bombardieri, E; Buzzoni, R; Comella, G; D'Aprile, M; Ferrari, L; Jirillo, A; Martinetti, A; Noberasco, C; Schieppati, G; Zilembo, N, 1997) |
| "For oestrone only, there was a significant effect of dose (on-treatment means: 0." | 6.67 | Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. ( Coombes, RC; Dowsett, M; Moore, J; Powles, TJ; Rubens, R; Smith, IE; Smithers, D; Trunet, PF, 1994) |
| "40), but not for MPA and estrone, indicating better adrenal suppression by higher MPA dosage and plasma levels." | 6.66 | Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer. ( Doorenbos, H; Sleijfer, DT; Sluiter, WJ; van Veelen, H; Willemse, PH, 1985) |
| "Comparative studies in breast cancer tissues show that the sulphatase pathway is 50-300 times more important than that of the aromatase pathway." | 6.39 | Control and expression of oestrone sulphatase activities in human breast cancer. ( Chetrite, G; Nestour, EL; Pasqualini, JR, 1996) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 6.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "Frailty syndrome is associated with poor outcomes, morbidity and premature mortality." | 5.72 | Plasma Aromatase Activity Index, Gonadotropins and Estrone Are Associated with Frailty Syndrome in Post-Menopausal Women with Breast Cancer. ( Avellán-Castillo, O; Cauli, O; García-Sánchez, J; Mafla-España, MA; Tejedor-Cabrera, C; Torregrosa, MD, 2022) |
| "Treatment with estrone, but not 17β-estradiol, and HSD17B14 overexpression both stimulate an EMT, matrigel invasion, and lung, bone, and liver metastasis in estrogen-receptor-positive (ER+) breast cancer models, while HSD17B14 knockdown reverses the EMT." | 5.72 | Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis. ( Diaz-Ruano, AB; Ince, TA; Nunes de Paiva, V; Picon-Ruiz, M; Qureshi, R; Sho, M; Slingerland, J; Van Booven, D, 2022) |
| "Postmenopausal breast cancer patients starting adjuvant letrozole were eligible." | 5.69 | Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurem ( Blomqvist, C; Faltinová, M; Haanpää, M; Hämäläinen, E; Lyytinen, H; Mattson, J; Tiitinen, A; Vehmanen, L, 2023) |
| "To test for the association with breast cancer risk, we carried out follow-up genotyping in 90,916 cases and 89,893 controls from the Breast Cancer Association Consortium." | 5.62 | CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. ( Ahearn, TU; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arndt, V; Aronson, KJ; Augustinsson, A; Baynes, C; Beckmann, MW; Benitez, J; Bermisheva, M; Blomqvist, C; Boeckx, B; Bogdanova, NV; Bojesen, SE; Bolla, MK; Brauch, H; Brenner, H; Burwinkel, B; Campa, D; Canzian, F; Castelao, JE; Chang-Claude, J; Chanock, SJ; Chenevix-Trench, G; Clarke, CL; Conroy, DM; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dennis, J; Dörk, T; Dos-Santos-Silva, I; Dunning, AM; Easton, DF; Eliassen, AH; Engel, C; Evans, DG; Fasching, PA; Figueroa, J; Fletcher, O; Floris, G; Flyger, H; Freeman, LEB; Gago-Dominguez, M; Gapstur, SM; García-Closas, M; Gaudet, MM; Giles, GG; Gilham, C; Goldberg, MS; González-Neira, A; Guénel, P; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hart, SN; Hooning, MJ; Hopper, JL; Howell, A; Howie, AF; Hunter, DJ; Jager, A; Jakubowska, A; John, EM; Johnson, N; Jones, ME; Kaaks, R; Kapoor, PM; Keeman, R; Khusnutdinova, E; Kitahara, CM; Kosma, VM; Koutros, S; Kraft, P; Kristensen, VN; Kurian, AW; Lambrechts, D; Le Marchand, L; Linet, M; Lubiński, J; Maguire, S; Mannermaa, A; Manoukian, S; Margolin, S; Martens, JWM; Mavroudis, D; Mayes, R; Meindl, A; Milne, RL; Morra, A; Neuhausen, SL; Nevanlinna, H; Newman, WG; Nielsen, SF; Nordestgaard, BG; Obi, N; Olshan, AF; Olson, JE; Olsson, H; Orban, E; Orr, N; Park-Simon, TW; Peterlongo, P; Peto, J; Pharoah, PDP; Plaseska-Karanfilska, D; Pylkäs, K; Rennert, G; Rennert, HS; Ruddy, KJ; Saloustros, E; Sandler, DP; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Schoemaker, MJ; Scott, C; Shu, XO; Simard, J; Smichkoska, S; Sohn, C; Southey, MC; Spinelli, JJ; Stone, J; Swerdlow, AJ; Tamimi, RM; Taylor, JA; Tollenaar, RAEM; Tomczyk, K; Tomlinson, I; Troester, MA; Truong, T; Vachon, CM; van Veen, EM; Wang, Q; Wang, SS; Weinberg, CR; Wendt, C; Wildiers, H; Winqvist, R; Wolk, A; Zheng, W; Ziogas, A, 2021) |
| "Breast cancer is one of the most frequent malignancies in the female population." | 5.56 | Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer. ( Bao, H; Chen, H; Chen, J; Cong, D; Jia, J; Li, Q; Li, Y; Liu, Z; Luan, X; Lv, Z; Meng, Q; Pei, J; Ren, Z; Sun, F; Tang, H; Wang, L; Yang, Y; Zhao, W; Zhou, X, 2020) |
| "E1Cs have been associated with breast cancer risk and may contribute to tumor progression since STS is expressed in breast cancer where its activity exceeds that of aromatase." | 5.46 | SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. ( Barman, P; Batzler, A; Buzdar, AU; Carlson, EE; Dudenkov, TM; Goetz, MP; Ibrahim-Zada, I; Ingle, JN; Jenkins, GD; Kalari, KR; Kubo, M; Moreno-Aspita, A; Nakamura, Y; Northfelt, DW; Pietrzak, TL; Robson, ME; Wang, L; Weinshilboum, RM; Williard, CV, 2017) |
| "This issue is important for breast cancer survivors since clinical recommendations suggest maintaining low hormone levels primarily via pharmacologic agents." | 5.36 | Dietary fat, tamoxifen use and circulating sex hormones in postmenopausal breast cancer survivors. ( Ballard-Barbash, R; Baumgartner, KB; Baumgartner, RN; Bernstein, L; Gilliland, F; McTiernan, A; Neuhouser, ML; Nojomi, M; Stanczyk, F, 2010) |
| "Estrone (ES) was anchored as ligand on to stealth liposome (ES-SL-DOX) for targeting to ERs." | 5.36 | A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. ( Mehta, A; Mishra, N; Paliwal, R; Paliwal, SR; Vyas, SP, 2010) |
| "It is hypothesized that breast cancers arising in postmenopausal women with high serum estrogens levels are more likely to be estrogen receptor (ER)-positive." | 5.32 | Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. ( Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanji, Y, 2003) |
| "This study analyzes the association of breast cancer risk with estrogen metabolism, expressed as the ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone, in a prospective nested case-control study." | 5.31 | Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. ( Berrino, F; Bradlow, HL; Freudenheim, JL; Krogh, V; Micheli, A; Muti, P; Schünemann, HJ; Sepkovic, DW; Stanulla, M; Trevisan, M; Yang, J, 2000) |
| "The role that E1S has in breast cancer development remains unclear." | 5.31 | Modulation of oestrone sulphate formation and hydrolysis in breast cancer cells by breast cyst fluid from British and Hungarian women. ( Budai, B; de Winkel, A; Ghilchik, MW; Parish, D; Purohit, A; Reed, MJ; Szamel, I; Wang, DY; Willemsen, EL, 2000) |
| "Estrone and E(1)S were converted into E(2), and all three estrogen fractions were finally measured by the same highly sensitive and specific radioimmunoassay using estradiol-6-(O-carboxymethyl)-oximino-2-(2--iodo-histamine) as a ligand." | 5.31 | A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. ( Berntsen, H; Geisler, J; Lonning, PE, 2000) |
| "Transforming growth factor beta (TGF-beta) is a multifunctional regulator of cellular growth and differentiation in many cell types and has a growth inhibitory effect on mammary epithelial cells." | 5.31 | Effect of transforming growth factor beta 2 on oestrogen metabolism in the MCF-7 breast cancer cell line. ( Erbas, H; Lai, LC, 2000) |
| "Serum and urine were collected from 65 breast cancer patients and 36 controls after an overnight fast." | 5.30 | Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. ( Foo, SC; Ho, GH; Ji, CY; Luo, XW; Ng, EH, 1998) |
| "Many breast tumors are hormone dependent, and there is evidence that hydrolysis of estrone sulfate (E1S) to estrone, by estrone sulfatase, is an important source of the estrogen which is found in tumors." | 5.29 | Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer. ( Duncan, L; Howarth, NM; Potter, BV; Purohit, A; Reed, MJ, 1993) |
| "Estradiol levels in breast tumors from post-menopausal women are similar to those in pre-menopausal women even though plasma estrogens are much lower after the menopause." | 5.29 | Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. ( Ohlsson-Wilhelm, B; Santen, RJ; Santner, SJ, 1993) |
| "Estrone did not cause any mutagens in the test used." | 5.28 | In vitro synthesis of 16 alpha-hydroxyestrone by female rat liver microsomes: its possible role in the etiology of breast cancer. ( Arts, CJ; de Bie, AT; van den Berg, H; Wilmer, JW, 1990) |
| "Ketoconazole was poorly tolerated due to gastrointestinal toxicity." | 5.27 | High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. ( Cantwell, BM; Dowsett, M; Harris, AL, 1988) |
| "Local formation of estradiol in human breast tumors could provide a more important source of estrogen than is delivered from plasma." | 5.27 | Estrone sulfate: a potential source of estradiol in human breast cancer tissues. ( Feil, PD; Leszczynski, D; Manni, A; Santen, RJ; Santner, SJ; Wright, C, 1986) |
| " Analysis of the dose-response curves shows induction by Oe2 to be 10 times and 50 times greater than Oe3 and Oe4, respectively." | 5.26 | Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture. ( Bayard, F; Jozan, S; Kreitmann, B, 1981) |
| "In patients taking tamoxifen for breast cancer, daily BR-DIM promoted favorable changes in estrogen metabolism and circulating levels of SHBG." | 5.24 | A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. ( Altbach, M; Chalasani, P; Chow, HHS; Galons, JP; Huang, C; Maskarinec, G; Roe, DJ; Stopeck, A; Strom, MB; Thompson, PA; Thomson, CA; Wertheim, BC, 2017) |
| "Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached." | 5.22 | Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. ( Avella, A; Azaro, A; Bellet, M; Bohn, U; Catalán, G; Catalán, R; Ciruelos, E; Climent, MA; Ferrer, R; Fleming, GF; Francis, PA; González-Martin, A; Gray, KP; Láng, I; Lluch, A; Morales, J; Price, KN; Rajasekaran, A; Regan, MM; Vázquez, J, 2016) |
| "Postmenopausal women who were to receive adjuvant anastrozole for resected early breast cancer were studied." | 5.20 | Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. ( Barman, P; Buzdar, AU; Desta, Z; Dudenkov, TT; Flockhart, DA; Goetz, MP; Ingle, JN; Kalari, KR; Northfelt, DW; Perez, EA; Robson, ME; Wang, L; Weinshilboum, RM; Williard, CV, 2015) |
| "We examined how an aerobic exercise intervention influenced circulating estradiol, estrone, sex hormone-binding globulin (SHBG), androstenedione, and testosterone levels, which may be involved in the association between physical activity and breast cancer risk." | 5.14 | Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. ( Ballard-Barbash, R; Boyd, NF; Brant, RF; Campbell, KL; Courneya, KS; Friedenreich, CM; Irwin, ML; Jones, CA; Karvinen, KH; McNeely, ML; McTiernan, A; Stanczyk, FZ; Terry, T; Wang, Q; Woolcott, CG; Yaffe, MJ; Yasui, Y, 2010) |
| "To evaluate the influence of the third-generation aromatase inhibitor letrozole (Femara) on breast cancer tissue levels of estrone (E(1)), estradiol (E(2)), and estrone sulfate (E(1)S) in postmenopausal women undergoing primary treatment for locally advanced estrogen receptor/progesterone receptor-positive breast cancers." | 5.13 | Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. ( Aas, T; Duong, NK; Ekse, D; Evans, DB; Geisler, J; Helle, H; Lønning, PE; Nordbø, Y, 2008) |
| "Fifty-four postmenopausal women with estrogen receptor-positive breast cancer receiving aromatase inhibitors (AIs) as part of their adjuvant therapy were randomly assigned to receive either 3 months of anastrozole (1 mg) followed by 3 months of letrozole (2." | 5.13 | Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. ( A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O, 2008) |
| "Some epidemiologic studies reported an association between a low ratio of urinary 2-hydroxyestrogens (2-hydroxyestradiol + 2-hydroxyestrone) to 16alpha-hydroxyestrone (2:16OHE(1)) and increased breast cancer risk." | 5.11 | The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption. ( Adlercreutz, H; Greany, KA; Kurzer, MS; Nettleton, JA; Thomas, W; Wangen, KE, 2005) |
| "We conducted a pilot study assessing the effects of the selective estrogen receptor modulator, tamoxifen, on the pharmacokinetics, pharmacodynamics, and safety of the steroidal, irreversible aromatase inhibitor (AI), exemestane, when the two were coadministered in postmenopausal women with metastatic breast cancer." | 5.11 | Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. ( Asnis, AG; Duncan, B; Francis, D; Hortobagyi, GN; Rivera, E; Schaaf, LJ; Valero, V, 2004) |
| "Rodent models of human breast cancer suggest that the combination of the steroidal aromatase inhibitor exemestane with tamoxifen may have additive activity." | 5.11 | Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. ( Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR; Rogers, E, 2005) |
| "To compare the efficacy, safety and tolerability of letrozole, an advanced non-steroidal aromatase inhibitor, and fadrozole hydrochloride, an older-generation drug in this class, we conducted a randomised double-blind trial in postmenopausal women with advanced breast cancer." | 5.10 | Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. ( Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T, 2003) |
| "Twelve postmenopausal women with estrogen receptor-positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2." | 5.10 | Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. ( Anker, G; Dowsett, M; Geisler, J; Haynes, B; Lønning, PE, 2002) |
| " The alternative product of estrogen metabolism, 2-hydroxyestrone, does not exhibit estrogenic properties in breast tissue, and lower values of the ratio 2-hydroxyestrone:16alpha-hydroxyestrone (2:16) in urine may be an endocrine biomarker for greater breast cancer risk." | 5.09 | Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. ( Fowke, JH; Hebert, JR; Longcope, C, 2000) |
| "Droloxifene (3-hydroxytamoxifen) is a novel antiestrogen currently undergoing clinical investigations for treatment of breast cancer patients." | 5.08 | Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. ( Ekse, D; Geisler, J; Hösch, S; Lønning, PE, 1995) |
| "Plasma levels of oestradiol (Oe2), oestrone (Oe1) oestrone sulphate (Oe1S), androstenedione, testosterone, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulphate (DHEAS), sex hormone-binding globulin (SHBG) and the gonadotrophins (FSH and LH) were determined in 20 postmenopausal women with breast cancer treated with the anti-oestrogen droloxifene (3-hydroxytamoxifen)." | 5.08 | Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. ( Geisler, J; Gundersen, S; Haarstad, H; Kvinnsland, S; Lønning, PE; Raabe, N, 1995) |
| "Our results suggest that vorozole is an effective and safe drug for the treatment of advanced postmenopausal breast cancer following tamoxifen failure." | 5.08 | Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study. ( Amoroso, D; Boccardo, F; Brema, F; Cortesi, E; Farris, A; Guida, G; Iacobelli, S; Irtelli, L; Langenaeken, C; Mesiti, M; Mustacchi, G; Nardini, P; Pacini, P, 1997) |
| "Aminoglutethimide (AG) has been the most widely used aromatase inhibitor in breast cancer patients to date." | 5.08 | Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. ( Berntsen, H; Geisler, J; Greaves, JL; Lundgren, S; Lønning, PE, 1998) |
| "Twelve postmenopausal women suffering from advanced breast cancer had plasma estrogens, androgens, cortisol, and gonadotropins determined before therapy and during treatment with megestrol acetate (MA) in oral doses escalated from 40 to 160 mg." | 5.08 | Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. ( Helle, SI; Lonning, PE; Lundgren, S, 1996) |
| "Fadrozole Hydrochloride (CGS 16949A) and Letrozole (CGS 20267), are two of the newest non-steroidal, orally active aromatase inhibitors currently being evaluated as second line treatment of patients with hormone dependent forms of metastatic breast cancer." | 5.07 | Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. ( Demers, LM, 1994) |
| "Serum levels of cortisol (C), androstenedione (A), dehydroepiandrosterone (D), estrone (E1) and estradiol (E2) were chosen as parameters to compare the bioavailability of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in postmenopausal patients with advanced breast cancer." | 5.06 | Adrenal steroids as parameters of the bioavailability of MA and MPA. ( Dikkeschei, LD; Sleijfer, DT; Tjabbes, T; van Veelen, H; Willemse, PH, 1990) |
| "Serum estradiol, estrone, estrone sulfate and sex hormone binding globulin were measured in 10 postmenopausal patients with advanced breast cancer receiving sequential treatment with medroxyprogesterone acetate and megestrol acetate." | 5.06 | Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--II. A differential effect of megestrol acetate and medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. ( Lundgren, S; Lønning, PE, 1990) |
| "One hundred and one postmenopausal patients with advanced breast cancer were enrolled in a randomized phase II clinical trial to investigate the clinical and hormonal response to aminoglutethimide administered at daily doses of 2 x 125 mg, 3 x 125 mg or 2 x 250 mg, with no addition of hydrocortisone." | 5.06 | Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer. ( Bonfrer, JM; Bruning, PF; de Jong-Bakker, M; Hart, AA; Moolenaar, AJ; Nooijen, WJ; van der Linden, E, 1989) |
| "4-Hydroxyandrostenedione (CGP32349; 4-OHA) is a clinically effective treatment for advanced postmenopausal breast cancer by both the parenteral and p." | 5.06 | Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. ( Coombes, RC; Cunningham, DC; Dehennin, L; Dowsett, M; Evans, S; Hedley, A; Stein, RC, 1989) |
| "A group of 122 postmenopausal patients with histologically proven node-positive primary breast cancer have been randomized to receive aminoglutethimide-hydrocortisone or placebo aminoglutethimide-placebo hydrocortisone for 2 years." | 5.05 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. ( Bettelheim, R; Chilvers, C; Coombes, RC; Dowsett, M; Ford, HT; Gazet, JC; Gordon, C; Powles, TJ; Smith, IE; Zava, D, 1982) |
| "The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid." | 5.05 | Aminoglutethimide dose and hormone suppression in advanced breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983) |
| "The endocrine effects of replacement doses of hydrocortisone in postmenopausal women with advanced breast cancer were compared with the same doses of hydrocortisone plus aminoglutethimide." | 5.05 | Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1984) |
| "Aminoglutethimide (AG) has antitumor activity in disseminated breast cancer similar to that of surgical adrenalectomy." | 5.05 | The role of aromatase inhibitors in breast cancer. ( Powles, TJ, 1983) |
| "Endocrine therapy is a key modality in the management of breast cancer, with current options for postmenopausal women including tamoxifen, aromatase inhibitors and fulvestrant." | 4.87 | Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. ( Coombes, RC; Januszewski, A; Palmieri, C; Stanway, S, 2011) |
| " In the present review, we summarized the action of the 19-nor-progestin nomegestrol acetate (NOMAC) on the sulfatase, 17beta-HSD1 and sulfotransferase activities in the hormone-dependent MCF-7 and T47-D human breast cancer cell lines." | 4.82 | Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. ( Chetrite, G; Meschi, S; Pasqualini, JR; Shields-Botella, J, 2005) |
| "The risk for breast cancer increased statistically significantly with increasing concentrations of all sex hormones examined: total estradiol, free estradiol, non-sex hormone-binding globulin (SHBG)-bound estradiol (which comprises free and albumin-bound estradiol), estrone, estrone sulfate, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and testosterone." | 4.81 | Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. ( Appleby, P; Barnes, I; Key, T; Reeves, G, 2002) |
| "Aromatase inhibitors used in breast cancer, are drugs that inhibit the transformation of androstenedione and testosterone, respectively in estradiol and estrone." | 4.80 | [Aromatase inhibitors]. ( Bonneterre, J; Feutrie, ML, 1999) |
| "The issue of the role of 2-hydroxyestrone (2-OHE1) in breast cancer has been the subject of considerable controversy as to whether it is carcinogenic or anticarcinogenic." | 4.79 | 2-hydroxyestrone: the 'good' estrogen. ( Bradlow, HL; Osborne, MP; Sepkovic, DW; Telang, NT, 1996) |
| " Serum and urinary estrone sulfate (E1-S) in pregnancy and non-pregnancy were analyzed." | 4.78 | [Endogenous levels and dynamics of estrogen sulfates--physiological and pathological roles of estrone sulfate and estradiol 17-sulfate]. ( Honjo, H, 1992) |
| " Occult hypothyroidism reduces the rate of oestrogen inactivation by C2 hydroxylation, and 15-20% of women have low rates of C16 hydroxylation to oestriol." | 4.76 | Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. ( Lemon, HM, 1980) |
| " Mechanisms protecting from breast cancer are thought to be due to the mitotic rest of mammary epithelium (low deoxyribonucleic acid synthesis), as encountered during pregnancy and lactation, and to the actions of estriol and progesterone in opposing the "carcinogenic" estradiol and estrone." | 4.75 | Breast cancer: potentially predisposing and protecting factors. Role of pregnancy, lactation, and endocrine status. ( Messer, RH; Vorherr, H, 1978) |
| "Currently there are no assays that can simultaneously quantify serum levels of the third-generation aromatase inhibitors (AIs): letrozole, anastrozole, and exemestane, and the ultra-low levels of estrogens in postmenopausal breast cancer patients on AI treatment." | 4.12 | Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. ( Almås, B; Bertelsen, BE; Geisler, J; Hagland, M; Helland, T; Lende, TH; Lønning, PE; Mellgren, G; Sagen, JV; Søiland, H; Viste, K, 2022) |
| " Estrone, one of the mammalian estrogens, has affinity for estrogen receptors (ERα), which are overexpressed in hormone-responsive breast cancers." | 3.96 | Estrone-Decorated Polyion Complex Micelles for Targeted Melittin Delivery to Hormone-Responsive Breast Cancer Cells. ( Chen, F; Kent, B; Raveendran, R; Stenzel, MH, 2020) |
| "In this study, estrone was used as targeting functionality in chitosan nanoparticles (DoxEs-CSEsNPs) carrying doxorubicin-estrone conjugate for dual targeted intracellular delivery to breast cancer cells." | 3.96 | Dual cancer targeting using estrogen functionalized chitosan nanoparticles loaded with doxorubicin-estrone conjugate: A quality by design approach. ( Kurmi, BD; Paliwal, R; Paliwal, SR, 2020) |
| " Using this method, estradiol, estrone, cortisone and cortisol were quantified in adipose tissue from women with and without breast cancer." | 3.91 | Simultaneous quantification of estrogens and glucocorticoids in human adipose tissue by liquid-chromatography-tandem mass spectrometry. ( Andrew, R; Denver, N; Diorio, C; Durocher, F; Homer, NZM; Laforest, S; Nguyen, S; Pelletier, M; Poirier, B; Tchernof, A; Walker, BR, 2019) |
| " Herein, we assessed if oestrogens, including oestrone (E1), oestradiol (E2) and oestriol (E3), are associated with A-FABP in the obesity-related BC development." | 3.91 | A-FABP and oestrogens are independently involved in the development of breast cancer. ( Hao, J; Kong, M; Li, B; Sauter, ER; Yan, X, 2019) |
| " In this work, an endogenous ligand, estrone, was used to synthesize doxorubicin-encapsulating liposomes for estrogen receptor (ER)-positive breast cancer therapy with cyanuric chloride (2,4,6 trichloro-1,3,5 triazine) being used as a linking molecule to attach 3-OH group of estrone to the surface of liposomes." | 3.88 | Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy. ( Al Sayah, M; Husseini, GA; Kawak, P; Martins, AM; Paul, V; Salkho, NM; Vitor, RF, 2018) |
| "Estrone-modified glycol chitosan nanoparticles (GCNP-ES) based on the mechanisms of ES-mediated endocytosis and intracellular pH-responsive drug release were developed for the treatment of breast cancer." | 3.88 | Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer. ( Tang, C; Yang, H; Yin, C, 2018) |
| " We added a breast cancer PRS using 67 single nucleotide polymorphisms, MD, and circulating testosterone, estrone sulfate, and prolactin levels to existing risk models." | 3.88 | Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study. ( Colditz, GA; Eliassen, AH; Hankinson, SE; Joshi, AD; Kraft, P; Lindstrom, S; Qian, J; Rice, M; Rosner, BA; Tamimi, RM; Tworoger, SS; Willett, WC; Zhang, X, 2018) |
| "The level of endogenous estrone, one of the three major naturally occurring estrogens, has a significant correlation with the incidence of post-menopausal breast cancer." | 3.83 | A MALDI-MS-based quantitative analytical method for endogenous estrone in human breast cancer cells. ( Hwang, CH; Jang, KS; Jeong, JH; Kim, BG; Kim, HJ; Kim, KJ; Kim, YG; Lee, YK; Park, HG; Park, SH; Sung, C; Yang, YH, 2016) |
| "We measured urinary concentrations of estradiol and estrone (parent estrogens) and 13 estrogen metabolites formed by irreversible hydroxylation at the C-2, C-4, or C-16 positions of the steroid ring in a nested case-control study of 399 postmenopausal invasive breast cancer case participants and 399 matched control participants from the population-based Shanghai Women's Health Study cohort." | 3.83 | Endogenous Estrogens, Estrogen Metabolites, and Breast Cancer Risk in Postmenopausal Chinese Women. ( Boyd-Morin, J; Cai, Q; Chow, WH; Gail, MH; Gao, YT; Hoover, RN; Ji, BT; Li, H; Matthews, CE; Moore, SC; Ou Shu, X; Rothman, N; Ruggieri, D; Xu, X; Yang, G; Yu, K; Zheng, W; Ziegler, RG, 2016) |
| "Proliferation of two oestrogen receptor-positive breast cancer cell lines (ZR 75-1 and HCC 1500) was investigated after incubation with oestrone (E₁), oestradiol (E₂), oestriol (E₃), and oestetrol (E₄)." | 3.81 | Oestetrol stimulates proliferation and oestrogen receptor expression in breast cancer cell lines: comparison of four oestrogens. ( Fehm, T; Liu, S; Mueck, AO; Neubauer, H; Ruan, X; Schultz, S; Seeger, H, 2015) |
| "Organic Anion Transporting Polypeptides (OATP) are a family of membrane associated transporters that facilitate estrone-3-sulphate (E3S) uptake by hormone dependent, post-menopausal breast cancers." | 3.81 | (125)I-Labelled 2-Iodoestrone-3-sulfate: synthesis, characterization and OATP mediated transport studies in hormone dependent and independent breast cancer cells. ( Allen, C; Banerjee, N; Bendayan, R; Chio, J; Forbes, J; Kelly, R; Stephenson, KA; Valliant, JF; Wu, TR, 2015) |
| "Estrone-3-sulfate (E1S) is thought to be a major estrogen precursor in estrogen receptor (ER)-positive breast cancer." | 3.81 | Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells. ( Ariyoshi, N; Fujisaki, K; Ishii, I; Matsumoto, J; Nagashima, T; Nakanishi, T; Nakatani, Y; Okubo, Y; Sakakibara, M; Shiina, N; Takeda, H; Tamai, I; Yamada, H, 2015) |
| "We examined the associations of invasive breast cancer risk with circulating 2-hydroxyestrone (2-OHE1), 16α-hydroxyestrone (16α-OHE1), and the 2-OHE1:16α-OHE1 ratio in a case-control study of postmenopausal women nested within two prospective cohorts: the New York University Women's Health Study (NYUWHS) and the Northern Sweden Mammary Screening Cohort (NSMSC), with adjustment for circulating levels of estrone, and additional analyses by tumor estrogen receptor (ER) status." | 3.80 | Circulating estrogen metabolites and risk of breast cancer in postmenopausal women. ( Afanasyeva, Y; Arslan, AA; Chen, Y; Hallmans, G; Koenig, KL; Lenner, P; Lundin, E; Shore, RE; Toniolo, P; Zeleniuch-Jacquotte, A, 2014) |
| "The urinary ratio 2-hydroxyoestrone/16-hydroxyoestrone (URME), has been proposed in various populations on the world as a risk indicator for breast cancer (BC), however in the Mexican population has never been determined." | 3.80 | [Determination of 2-hydroxyestrone /16α-hydroxyestrone ratio in urine of Mexican women as a risk indicator for breast cancer and its relationship with other risk factors]. ( Godínez Martínez, EY; Juárez González, AR; Lemus Bravo, AE; Rodríguez Ventura, AL; Sámano, R; Santillán Ballesteros, R; Tolentino Dolores, M, 2014) |
| "Accurately quantifying parent estrogens (PE) estrone (E1) and estradiol (E2) and their metabolites (EM) within breast tissue and serum may permit detailed investigations of their contributions to breast carcinogenesis among BRCA1/2 mutation carriers." | 3.80 | Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. ( Falk, RT; Gail, MH; Gierach, GL; Greene, MH; Guttmann, A; Loud, JT; Nichols, K; Veenstra, TD; Xu, X, 2014) |
| " Here, we present the design, fabrication, optimization, characterization, and biological evaluation of estrone-conjugated noscapine-loaded gelatin nanoparticles (Nos-ES-GN) for targeting estrogen-receptor-positive breast cancer MCF-7 cells." | 3.80 | Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy. ( Aneja, R; Bharatam, PV; Gundala, SR; Jain, UK; Kasetti, Y; Katyal, A; Madan, J, 2014) |
| "Two-thirds of newly diagnosed hormone-dependent (HR?) breast cancers are detected in post-menopausal patients where estrone-3-sulphate (E3S) is the predominant source for tumour estradiol." | 3.80 | Expression of membrane transporters and metabolic enzymes involved in estrone-3-sulphate disposition in human breast tumour tissues. ( Allen, C; Banerjee, N; Bendayan, R; Miller, N, 2014) |
| "Clinical levels of tamoxifen metabolites in postmenopausal breast cancer patients previously genotyped for CYP2D6 were used in vitro along with clinical estrogen levels (estrone and estradiol) in postmenopausal patients determined in previous studies." | 3.80 | Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients. ( Bhatta, P; Curpan, RF; Fernandes, DJ; Jordan, VC; Korostyshevskiy, VR; Maximov, PY; McDaniel, RE, 2014) |
| "The current study investigates the potential of estrone-3-sulphate (E3S) as a ligand for targeting Organic Anion Transporting Polypeptides (OATP), a family of membrane associated uptake transporters, for detection and diagnosis of hormone dependent breast cancers." | 3.79 | Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. ( Allen, C; Banerjee, N; Bendayan, R; Fonge, H; Mikhail, A; Reilly, RM, 2013) |
| "We have prospectively tested the effects of simvastatin on the pharmacokinetics of anastrozole and on estrogen concentrations in postmenopausal women with hormone receptor-positive breast cancer who were receiving adjuvant anastrozole." | 3.78 | Effect of simvastatin on the pharmacokinetics of anastrozole. ( Bao, T; Blackford, AL; Stearns, V, 2012) |
| "To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer." | 3.78 | Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. ( A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L, 2012) |
| "17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) converts estrone (E1) into estradiol (E2) and is expressed in many steroidogenic tissues and breast cancer cell lines." | 3.78 | A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone. ( Ayan, D; Maltais, R; Poirier, D; Roy, J, 2012) |
| " Vegetarians showed a lower fat/fiber ratio, a higher intake of total and cereal fiber (g/d)/body weight (kg), a significantly lower level of plasma estrone-sulfate, estradiol, free-estradiol, free-testosterone, and ring D oxygenated estrogens, and a significantly higher level of sex-hormone-binding-globulin than BC subjects." | 3.77 | Diets and hormonal levels in postmenopausal women with or without breast cancer. ( Adlercreutz, H; Aubertin-Leheudre, M; Hämäläinen, E, 2011) |
| "Breast cancer resistance protein (BCRP/ABCG2), an ATP-binding cassette half transporter, confers multidrug resistance (MDR) to a series of antitumor agents such as mitoxantrone, daunorubicin, SN-38, and topotecan, and often limits the efficacy of chemotherapy." | 3.76 | Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. ( Gao, P; Gao, Y; Li, G; Wang, H; Wei, F; Wei, L; Yin, D; Yu, J; Zhang, X; Zhang, Y; Zhou, G, 2010) |
| "Salivary hormone levels of testosterone (T), Estradiol (E2), Progesterone (P), Estriol (E3), Estrone (E1), DHEAS and Cortisol (C) were measured by Enzyme Immunoassay (EIA) in 357 women with histologically verified breast cancer and 184 age-matched control women." | 3.76 | Low salivary testosterone levels in patients with breast cancer. ( Antsaklis, A; Dimitrakakis, C; Glaser, R; Marinopoulos, S; Tsigginou, A; Zava, D, 2010) |
| " The present study was undertaken to assess the presence of potential cancer biomarkers, their variation among individuals at high risk for breast cancer, and differences associated with menopause and tamoxifen treatment." | 3.76 | Breast ductal lavage for assessment of breast cancer biomarkers. ( Bryk, M; Chatterton, RT; Habe-Evans, M; Khan, SA; Parker, NP; Scholtens, DM, 2010) |
| "The 2:16 OHE ratio (2-hydroxyestrone/16-alpha-hydroxyestrone) in women at high risk for breast cancer was similar to that observed in the breast cancer group (1." | 3.75 | Urinary estrogen metabolites in women at high risk for breast cancer. ( Ahrendt, G; Garte, S; Im, A; Lloyd, S; Ragin, C; Taioli, E; Vogel, VG, 2009) |
| "It has been proposed that a shift toward 2-hydroxyestrone from 16alpha-hydroxyestrone metabolic pathway may be inversely associated with breast cancer risk because 2-hydroxyestrone is thought to be less genotoxic and estrogenic than 16alpha-hydroxyestrone." | 3.75 | Circulating estrogen metabolites and risk for breast cancer in premenopausal women. ( Afanasyeva, Y; Arslan, AA; Koenig, KL; Shore, RE; Toniolo, P; Zeleniuch-Jacquotte, A, 2009) |
| "We examined associations between polymorphisms in genes related to estrogen metabolism (CYP1B1 codon 432G --> C rs#1056836, CYP1B1 codon 453A --> G rs#1800440, COMT codon 158G --> A rs#4680) and biosynthesis (CYP17 T --> C promoter rs#743572, CYP19 exon 4 TTTA repeat) and urinary estrogen metabolites (2-hydroxyestrogens (2-OHE), 16alpha-hydroxyestrone (16alpha-OHE1), and their ratio) in a pilot study of 64 pre- and post-menopausal women with a family history of breast cancer." | 3.74 | Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer. ( Ahsan, H; Bradlow, HL; Chen, Y; Greenlee, H; Gurvich, I; Kabat, GC; Kibriya, MG; Santella, RM; Senie, RT; Sepkovic, DW; Wang, Q, 2007) |
| " In 50 untreated healthy postmenopausal women and 48 untreated postmenopausal breast cancer patients, we measured serum levels of testosterone (T), sex hormone-binding globulin (SHBG), estrone (E(1)) and adrenal androgens; and additionally, in the breast cancer patients, cortisol and corticosteroid-binding globulin and endocrine data related to breast proliferation (assessed using the Ki-67/MIB-1 monoclonal antibody) and PR levels (determined by enzyme immunoassay) in the breast cancer tissue." | 3.74 | Associations between serum testosterone levels, cell proliferation and progesterone receptor content in normal and malignant breast tissue in postmenopausal women. ( Carlström, K; Hofling, M; Löfgren, L; Söderqvist, G; von Schoultz, E, 2008) |
| " Thus, we evaluated the correlation between plasma leptin concentrations and total body aromatization (TBA) as well as plasma levels of estrone (E(1)), estradiol (E(2)) and estrone sulfate (E(1)S) in postmenopausal breast cancer patients." | 3.74 | Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. ( Dowsett, M; Ekse, D; Geisler, J; Haynes, B; Lønning, PE, 2007) |
| "We measured serum levels of estrone (E1), estradiol (E2), dehydroepiandrosterone sulfate (DHEAS), and sex hormone-binding globulin (SHBG) in 142 postmenopausal women aged 50 and over with primary breast cancer who had undergone surgical treatment, and investigated the heterogeneity in the relations of endogenous sex hormone levels to hormone receptor status, using the case-series study method." | 3.74 | Relation of serum levels of estrogen and dehydroepiandrosterone sulfate to hormone receptor status among postmenopausal women with breast cancer. ( Fujiya, T; Inoue, H; Kakugawa, Y; Minami, Y; Tateno, H, 2007) |
| " We have successfully applied this technique to determine the seven estrogen conjugates in urine samples of a pregnant woman and found unique concentration changes of six estrogen conjugates at different stages of pregnancy while the concentration of estriol-3-glucuronide (E3-3G) remained constant." | 3.74 | Hydrophilic interaction liquid chromatography-tandem mass spectrometry determination of estrogen conjugates in human urine. ( Li, XF; Qin, F; Sawyer, MB; Zhao, YY, 2008) |
| "It has been suggested that a low level of the 2-hydroxyestrogen metabolites (2-OHE) and a high level of 16alpha-hydroxyestrone (16alpha-OHE1) are associated with an enhanced risk of breast cancer." | 3.73 | Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. ( Loft, S; Olsen, A; Overvad, K; Thomsen, BL; Tjonneland, A; Wellejus, A, 2005) |
| "Most, but not all, studies have found that women with a high urinary 2-hydroxyestrogen (2OHE) to 16alpha-hydroxyestrone (16alphaOHE1) ratio are at reduced risk for breast cancer and have a better prognosis." | 3.73 | Moderate coffee and alcohol consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: a pilot study comparing pre- and post-operative levels. ( Bågeman, E; Ingvar, C; Jernström, H; Klug, TL; Rose, C, 2006) |
| "Pre- and postmenopausal patients with breast cancer were screened for mutation of the BRCAI gene and estrogens and leptin levels were measured." | 3.73 | BRCA1 mutation, leptin and estrogen levels in breast cancer patients. ( Chudecka-Glaz, A; Górski, B; Rzepka-Górska, I; Tarnowski, B, 2005) |
| " To test this hypothesis, we determined plasma hormone levels (n=9) and in vivo aromatization (n=3) in postmenopausal women suffering from advanced breast cancer before and during treatment (4 weeks) with diethylstilbestrol (DES) 5mg three times daily." | 3.73 | Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients. ( Anker, G; Dowsett, M; Ekse, D; Geisler, J; Haynes, B; Helle, H; Lønning, PE, 2005) |
| "The aim of the study is to suppress the progress of estrogen-dependent breast cancer by inhibiting the membrane transporter, which mediates the internalization of estrone-3-sulfate as estrogen precursor in the cancer cells." | 3.73 | Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. ( Irokawa, M; Nozawa, T; Suzuki, M; Tamai, I; Tsuji, A; Yabuuchi, H, 2005) |
| " In whole body studies in postmenopausal women with breast cancer the conversion of oestrone (E1) to E2 (4." | 3.73 | The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. ( Allan, GM; Chander, SK; Day, JM; Fischer, DS; Lawrence, HR; Newman, SP; Potter, BV; Purohit, A; Reed, MJ; Tutill, HJ; Vicker, N, 2006) |
| "Estrone sulfate was statistically significantly associated with breast cancer risk among women with low (< 1." | 3.73 | Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? ( Eliassen, AH; Hankinson, SE; Missmer, SA; Tworoger, SS, 2006) |
| "Breast cancer resistance protein (BCRP), an ATP-binding cassette transporter, confers resistance to a series of anticancer agents such as SN-38, mitoxantrone, and topotecan." | 3.72 | Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. ( Imai, Y; Sugimoto, Y; Tsukahara, S; Tsuruo, T; Ueda, K, 2003) |
| "Breast cancer resistance protein (BCRP), an ATP-binding cassette transporter, confers resistance to a series of anticancer reagents such as mitoxantrone, 7-ethyl-10-hydroxycamptothecin, and topotecan." | 3.72 | Breast cancer resistance protein exports sulfated estrogens but not free estrogens. ( Asada, S; Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T, 2003) |
| "We studied the associations between body mass index (BMI), body fat mass, and percent body fat, measured by dual-energy x-ray absorptiometry scan, waist circumference, and waist-to-hip circumference ratio, with concentrations of estrone, estradiol, testosterone, SHBG, dehydroepiandrosterone sulfate, free estradiol, and free testosterone in 505 postmenopausal women in western Washington and New Mexico with incident stage 0 to IIIA breast cancer." | 3.72 | Adiposity and sex hormones in postmenopausal breast cancer survivors. ( Ballard-Barbash, R; Baumgartner, R; Bernstein, L; Gilliland, F; Irwin, M; McTiernan, A; Rajan, KB; Stanczyk, FZ; Tworoger, SS; Yasui, Y, 2003) |
| "The risk of breast cancer was associated with the highest versus lowest quartiles of estrone, OR: 2." | 3.72 | Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). ( Agren, A; Berglund, G; Janzon, L; Johansson, R; Kaaks, R; Lenner, P; Manjer, J, 2003) |
| " Most of the new sulfamates inhibited the enzymatic hydrolysis of estrone sulfate in MDA-MB 231 breast cancer cells with IC(50) values between 2 nM and 1 microM." | 3.72 | 2-phenylindole sulfamates: inhibitors of steroid sulfatase with antiproliferative activity in MCF-7 breast cancer cells. ( Liebl, R; von Angerer, E; Walter, G, 2004) |
| "Breast cancer resistance protein (BCRP), an adenosine triphosphate-binding cassette transporter, confers resistance to a series of anticancer reagents, including mitoxantrone, SN-38 and topotecan." | 3.71 | Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. ( Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T, 2002) |
| "It has been hypothesized that women who metabolize their endogenous estrogens predominantly via 16(alpha)-hydroxylation rather than via 2-hydroxylation and, as a result, have a low ratio of 2-hydroxyestrone (2-OHE1):16(alpha)-hydroxyestrone (16(alpha)-OHE1) are at an increased risk of breast cancer." | 3.71 | Urinary estrogen metabolites and mammographic parenchymal patterns in postmenopausal women. ( Bradlow, HL; De Stavola, B; dos Santos Silva, I; Linos, A; Linos, D; Riza, E; Sepkovic, DW, 2001) |
| "It has been suggested that alterations in estradiol (E(2)) metabolism, resulting in increased production of 16alpha-hydroxyestrone (16alpha-OHE(1)), is associated with an increased risk of breast cancer." | 3.71 | Regulation of cell cycle and cyclins by 16alpha-hydroxyestrone in MCF-7 breast cancer cells. ( Gallo, MA; Klinge, CM; Lewis, JS; Thomas, T; Thomas, TJ, 2001) |
| "It has been hypothesized that the ratio of urinary 2-hydroxyestrone to 16alpha-hydroxyestrone (2-OHE1/16alpha-OHE1 represents a biomarker for breast cancer risk; the lower the ratio the higher the risk." | 3.71 | Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women. ( Bernstein, L; Gentzschein, E; London, S; Pike, MC; Stanczyk, FZ; Tseng, CC; Ursin, G; Yang, D, 2002) |
| "Uptake and local formation of oestrone (E1) were studied in vivo by a double isotopic technique in normal and malignant breast tissues from 24 postmenopausal women with breast cancer." | 3.71 | Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. ( Berstein, LM; Larionov, AA; Miller, WR, 2002) |
| "Recent clinical trials suggest that tamoxifen (TAM) is a preventive agent for breast cancer, however, the mechanism is unknown." | 3.71 | A proposed mechanism of tamoxifen in breast cancer prevention. ( Bender, W; Yu, FL, 2002) |
| "The development of inhibitors to block the formation of estrone and 5-androstenediol from sulfated precursors is an important new strategy for the treatment of breast cancer." | 3.71 | Non-steroidal and steroidal sulfamates: new drugs for cancer therapy. ( Barrow, D; Hejaz, HA; Nicholson, RI; Potter, BV; Purohit, A; Reed, MJ; Woo, LW, 2001) |
| "The effects of simultaneous administration of some binary mixtures of seven natural and synthetic oestrogenic substances (17beta-estradiol, estrone, bisphenol A, butylbenzyl phthalate, endosulfan, methoxychlor and pentachlorophenol) on the cellular proliferation of human breast cancer MCF-7 cells in-vitro (a modified E-screen assay) have been measured." | 3.71 | Response of MCF-7 human breast cancer cells to some binary mixtures of oestrogenic compounds in-vitro. ( Ide, K; Ishida, M; Suzuki, T, 2001) |
| "To determine the effects of aromatase inhibitors on oestrogen uptake, in situ aromatase activity and endogenous oestrogens in the breast, postmenopausal women with large primary ER-rich breast cancers have been treated neoadjuvantly for 3 months with either letrozole (2." | 3.71 | Local endocrine effects of aromatase inhibitors within the breast. ( Dixon, JM; Miller, WR, 2001) |
| "EM-652 exerts pure antiestrogenic activity in the mammary gland and endometrium, while tamoxifen, the antiestrogen most widely used for the treatment of breast cancer, exerts mixed antiestrogenic-estrogenic activity in these tissues." | 3.71 | Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. ( Candas, B; Couillard, S; Gutman, M; Labrie, C; Labrie, F; Roy, J, 2002) |
| "This is the first prospective study of urinary measures of the two major competing pathways of oestrogen metabolism, 16alpha-hydroxyoestrone (16alpha-OHE1) and 2-hydroxyoestrone (2-OHE1), in relation to incident breast cancer risk." | 3.70 | Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. ( Allen, DS; Bradlow, HL; De Stavola, B; Fentiman, I; Kuller, LH; Meilahn, EN; Sepkovic, DW, 1998) |
| "The comparative mitogenic activities of 17beta-estradiol (E2) and four metabolites, 2-hydroxyestradiol (2-OHE2), 2-hydroxyestrone (2-OHE1), 16alpha-hydroxyestradiol (16alpha-OHE2) and 16alpha-hydroxyestrone (16alpha-OHE1) were determined in estrogen receptor (ER)-positive MCF-7 and T47D human breast cancer cells." | 3.70 | Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. ( Gupta, M; McDougal, A; Safe, S, 1998) |
| " As sulphamoylation of oestrogens enhances their potency and bioavailability we have synthesized 2-methoxyoestrone-3-O-sulphamate (2-MeOEMATE) and compared its ability to inhibit the proliferation of breast cancer cells with that of 2-methoxyoestrone (2-MeOE1)." | 3.70 | The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. ( Hejaz, HA; MacCarthy-Morrogh, L; Packham, G; Potter, BV; Purohit, A; Reed, MJ; Walden, L, 2000) |
| " In the present investigation we have examined the ability of 2-methoxyestrone (2-MeOE1), 2-methoxyestradiol (2-MeOE2), 2-methoxyestrone-3-O-sulfamate (2-MeOEMATE), and a number of related compounds, to inhibit 2-deoxy-D-[1-(3)H]-glucose uptake in MCF-7 breast cancer cells." | 3.70 | Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate. ( Hejaz, HA; Potter, BV; Purohit, A; Reed, MJ; Singh, A, 2000) |
| "The formation of oestrone sulphate has been examined in MCF-7 (oestrogen receptor positive, ER+) and MDA-MB-231 (ER negative, ER-) breast cancer cells." | 3.70 | The regulation of oestrone sulphate formation in breast cancer cells. ( de Giovani, CV; Purohit, A; Reed, MJ, 1999) |
| "Preliminary studies suggest that the estrogen metabolite 16 alpha-hydroxyestrone is associated with breast cancer, whereas 2-hydroxyestrone is not." | 3.69 | Urinary estrogen metabolites and breast cancer: a case-control study. ( Bradlow, HL; Chang, CJ; Hu, XP; Kabat, GC; Khalil, A; Rosenblatt, R; Sepkovie, DW; Sparano, JA, 1997) |
| "The evaluation of estrogens (estrone, estradiol, and their sulfates) in the breast tissue of post-menopausal patients with breast cancer indicates high levels, particularly of estrone sulfate (E1S) which is 15-25 times higher than in the plasma." | 3.69 | Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. ( Blacker, C; Botella, J; Chetrite, G; Delalonde, L; Feinstein, MC; Maloche, C; Nguyen, BL; Paris, J; Pasqualini, JR; Talbi, M, 1995) |
| "Using different hormone-dependent (MCF-7, T-47D) and hormone-independent (MDA-MB-231, Hs-578S, MDA-MB-436) human breast cancer cells, the interconversion estrone (E1)<-->estradiol (E2) was explored." | 3.69 | Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020). ( Chetrite, G; Nguyen, BL; Pasqualini, JR, 1995) |
| "Our purpose was to assess breast cancer risk in relation to circulating levels of the two major endogenous estrogens, estrone and estradiol, measured before the clinical onset of the disease." | 3.69 | A prospective study of endogenous estrogens and breast cancer in postmenopausal women. ( Banerjee, S; Koenig, KL; Levitz, M; Pasternack, BS; Shore, RE; Strax, P; Toniolo, PG; Zeleniuch-Jacquotte, A, 1995) |
| "Estrone sulphate (E1S) may be an important estrogen source in breast cancers, particularly in postmenopausal women." | 3.69 | Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. ( Adlercreutz, H; Ekse, D; Fotsis, T; Johannessen, DC; Lien, EA; Lønning, PE, 1995) |
| "A major obstacle to the understanding of the mechanisms of action of aromatase inhibitors in breast cancer is the observation that plasma estrogens are sustained at about 30-50% of their control levels despite 85-95% inhibition of the conversion of tracer androstenedione (A) to estrone (E1)." | 3.69 | A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. ( Ekse, D; Lønning, PE, 1995) |
| "A very low fat, high fiber diet in healthy premenopausal women can reduce estradiol and estrone levels without affecting ovulation, thereby providing a rationale for the prevention of breast cancer through a very low fat, high fiber diet." | 3.69 | Effects of a very low fat, high fiber diet on serum hormones and menstrual function. Implications for breast cancer prevention. ( Ashley, JM; Bagga, D; Barnard, RJ; Geffrey, SP; Heber, D; Korenman, S; Wang, HJ, 1995) |
| "This report concerns the evaluation of various estrogens, estrone (El), estradiol (E2), and estrone sulfate (E1S), as well as E1S-sulfatase and aromatase activities in pre- and postmenopausal women with breast cancer." | 3.69 | Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. ( Blacker, C; Chetrite, G; Delalonde, L; Feinstein, MC; Maloche, C; Pasqualini, JR; Talbi, M, 1996) |
| "To test the hypothesis that high levels of endogenous oestrogens increase the risk for developing breast cancer, concentrations of oestrone, oestradiol and oestriol were measured in 24 h urine samples from 1000 women participants in a prospective study of breast cancer on the island of Guernsey." | 3.69 | A prospective study of urinary oestrogen excretion and breast cancer risk. ( Allen, DS; Brown, JB; Bulbrook, RD; Fentiman, IS; Hermon, C; Key, TJ; Moore, JW; Pike, MC; Wang, DY, 1996) |
| "Serum concentrations of estrone, androstenedione, testosterone, and sex hormone-binding globulin (SHBG) were measured postoperatively in 122 postmenopausal women with incident breast cancer and 122 age-matched population controls." | 3.69 | Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. ( Adami, HO; Carlström, K; Lipworth, L; Mantzoros, C; Trichopoulos, D, 1996) |
| " Several lines of evidence indicate that the major source of estrogen in breast cancer cells may be from conversion of estrone sulfate to estrone by the enzyme estrone sulfatase." | 3.69 | Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives. ( Jagannathan, S; Li, PK; Rhodes, ME; Selcer, KW, 1996) |
| " The major source of estrogen in breast cancer cells may be the conversion of estrone sulfate to estrone by the enzyme estrone sulfatase." | 3.69 | Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines. ( Hegde, PV; Li, PK; Selcer, KW, 1997) |
| "In the present studies, the concentrations (mammary tissue and plasma) of estrone (E1), estradiol (E2) and their sulfates (E1S and E2S), as well as the sulfatase and aromatase activities, were evaluated in patients with breast fibroadenomas." | 3.69 | Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. ( Chetrite, G; Cortes-Prieto, J; Pasqualini, JR; Ruiz, A; Talbi, M, 1997) |
| "Serum dehydroepiandrosterone (DHEA), estrone (E1), and estradiol (E2) levels were prospectively measured in 47 breast cancer patients before and during tamoxifen therapy for 2 years." | 3.69 | Changes in serum estrogen levels in women during tamoxifen therapy. ( Fletcher, WS; Lum, SS; Pommier, RF; Woltering, EA, 1997) |
| "The estrogen-sensitive human breast cancer cell line ZR-75-1 was used to study the regulation of 17 beta-hydroxysteroid dehydrogenase (17 beta HSD), the enzyme responsible for the interconversion of estrone (E1) and estradiol (E2)." | 3.68 | Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. ( Couture, P; Labrie, F; Simard, J; Thériault, C, 1993) |
| "The influence of the aromatase inhibitor 4-hydroxyandrostenedione (4OHA) given intramuscularly on the peripheral aromatisation of androstenedione into oestrone was investigated in postmenopausal women with breast cancer and compared with the suppression of plasma oestradiol (E2)." | 3.68 | The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. ( Dowsett, M; Jacobs, S; Jones, AL; Lonning, PE; MacNeill, F; Powles, TJ, 1992) |
| "Twenty-eight and 24 patients with advanced breast cancer were treated with Aminoglutethimide (AG) or AG + Tamoxifen (AG + TAM) from June 1984 to June 1989, respectively." | 3.68 | [Aminoglutethimide and aminoglutethimide+tamoxifen treatment for advanced breast cancer]. ( Hisamatsu, K; Nomura, Y; Tashiro, H, 1992) |
| "Aminoglutethimide is effective in the treatment of breast cancer in postmenopausal patients as a result of its inhibition of aromatase." | 3.68 | Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion. ( Cantwell, BM; Dowsett, M; Harris, AL; Mehta, A, 1991) |
| "The influence of a new aromatase inhibitor, CGS 16949A on peripheral aromatisation of androstenedione into oestrone was investigated in postmenopausal women with breast cancer." | 3.68 | The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. ( Dowsett, M; Haynes, B; Jacobs, S; Jones, A; Lønning, PE; Powles, T, 1991) |
| "The effect of tamoxifen on the vaginal mucosa and on serum oestrone, oestradiol and gonadotrophin concentrations was investigated in a group of nine postmenopausal women with non-metastatic breast cancer." | 3.68 | Tamoxifen and partial oestrogen agonism in postmenopausal women. ( Burton, R; Castleden, CM; Ekelund, P; Miodrag, A, 1991) |
| "4-Hydroxyandrostenedione (4-OHA) is a specific inhibitor of aromatase activity used for the treatment of breast cancer in post-menopausal women." | 3.68 | Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues. ( Aherne, GW; Chakraborty, J; Ghilchik, MW; Patel, S; Reed, MJ, 1991) |
| "The ovarian and pituitary functions of 64 operable breast cancer patients undergoing adjuvant therapy with cytotoxic chemotherapy and/or tamoxifen were investigated." | 3.68 | The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer. ( Akami, T; Honjyo, H; Mitsuo, M; Naitoh, K; Oka, T; Okada, H; Yamamoto, T; Yasumura, T, 1990) |
| ", conversion of oestrone (E1) to oestradiol (E2), in MCF-7 breast cancer cells." | 3.68 | Effect of breast cyst fluid on oestrogen 17-oxidoreductase activity in MCF-7 breast cancer cells. ( Coldham, NG; Ghilchik, MW; Islam, S; James, VH; Lai, LC; Reed, MJ, 1990) |
| "The effect of treatment with the aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA) on the peripheral conversion of androstenedione to estrone has been examined in eight postmenopausal women with advanced breast cancer." | 3.68 | Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. ( Coldham, NG; Ghilchik, MW; James, VH; Lai, LC; Owen, AM; Purohit, A; Reed, MJ; Shaikh, NA; Singh, A, 1990) |
| "Values were determined by means of a ligand binding assay using 17-FE (17-fluoresceinated estrone) in 53 breast cancer patients." | 3.68 | [Fixation of fluorescent estrone derivative on human breast cancer cells. Correlation with age, menopause status and histopathology]. ( Alamy, H; Baltali, E; Bouih, A; el Gueddari, B; el Hafed, A; Kettani, F; Morchid, M; Souadka, A; Souadka, F; Wydadi, M, 1990) |
| "The influence of oral high dose progestin (medroxyprogesterone acetate, MPA and megestrol acetate, MA) treatment on serum hormone levels was studied in ten postmenopausal women with advanced breast cancer." | 3.68 | Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings. ( Aakvaag, A; Kvinnsland, S; Lundgren, S; Lønning, PE; Utaaker, E, 1990) |
| "The estrogen responsive human breast cancer MCF-7 cell culture was examined for its response to 2-hydroxyestrone a principal metabolite of estradiol." | 3.67 | Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. ( Bradlow, HL; Fishman, J; Huh, MM; Schneider, J, 1984) |
| "Catecholestrogens and especially 2-hydroxyestrone (2OH-E1) are estradiol metabolites locally formed in breast cancer cells." | 3.67 | Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. ( Lefebvre, J; Vandewalle, B, 1989) |
| "The binding of 2-hydroxyestrone (2OH E1), a catecholestrogen which is the main end product of the 2-hydroxylation of estrogen, was investigated in breast cancers." | 3.67 | Catecholestrogen binding sites in breast cancer. ( Bonneterre, J; Lefebvre, J; Peyrat, JP; Vandewalle, B, 1985) |
| "The interactions of 16 alpha-hydroxyestrone (16 alpha-OHE1), a metabolite of estradiol (E2), with estrogen receptors (ERs) were compared in this study to the classic E2-receptor mechanism in human breast cancer cells MCF-7 in culture." | 3.67 | Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. ( Fishman, J; Swaneck, GE, 1988) |
| "The clinical and endocrine effects of low-dose aminoglutethimide without hydrocortisone in patients with advanced breast cancer were investigated." | 3.67 | Low-dose aminoglutethimide in treatment of advanced breast cancer. ( Bozek, T; Carr, L; Dowsett, M; Gazet, JC; Jeffcoate, SL; Kurkure, A; McKinna, JA; Smith, IE; Stuart-Harris, R, 1984) |
| "About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs." | 3.67 | Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984) |
| " Under the experimental conditions used, the rate of conversion of oestrone to oestradiol varied markedly between subjects (6-169 ng oestradiol/mg protein/h), and there was a positive correlation between oestrone reduction and the total body weight of the tissue donor." | 3.67 | 17 Beta-hydroxysteroid dehydrogenase and aromatase activity in breast fat from women with benign and malignant breast tumours. ( Beranek, PA; Folkerd, EJ; Ghilchik, MW; James, VH, 1984) |
| "The endocrinological actions of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex (goserelin) in premenopausal women with advanced breast cancer are reviewed." | 3.67 | Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer. ( Blamey, RW; Nicholson, RI; Read, GF; Robertson, JF; Turkes, A; Walker, KJ; Walker, RF, 1989) |
| "The effect of treatment with the progestogen medroxyprogesterone acetate (MPA) on the peripheral conversion of androstenedione to oestrone and tumour aromatase activity has been examined in post-menopausal women with advanced breast cancer." | 3.67 | The effect of medroxyprogesterone acetate on aromatase and DNA polymerase alpha activities in breast tumours. ( Coldham, NG; Ghilchik, MW; James, VH; Lai, LC; Purohit, A; Reed, MJ; Singh, A, 1989) |
| "Plasma level, plasma clearance, production rate and interconversions of oestrone and oestrone sulphate were measured in six breast cancer patients receiving aminoglutethimide therapy." | 3.67 | Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. ( Johannessen, DC; Lønning, PE; Thorsen, T, 1989) |
| "Estrone sulfate (E1-S) in the serum and tissues of patients with breast cancer or endometrial cancer was measured by a direct radioimmunoassay without hydrolysis." | 3.67 | Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer. ( Honjo, H; Naitoh, K; Nambara, T; Ogino, Y; Urabe, M; Yamamoto, T; Yasumura, T, 1989) |
| "This study was undertaken to investigate whether miconazole (MCZ), an antifungal agent, inhibits aromatase activity in human breast cancer tissue preparations (n = 6)." | 3.67 | In vivo and in vitro effects of the antifungal agent miconazole on estrogen biosynthesis in human breast cancer. ( Fukuoka, M; Okada, H; Yamamoto, T; Yasumura, T, 1989) |
| "Plasma 4-en-androstenedione, testosterone, estradiol and estrone were measured during the day in six healthy postmenopausal women and in six breast cancer patients, three of whom received treatment with glucocorticoids." | 3.67 | Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women. ( Dowsett, M; Hardy, J; Jacobs, S; Lønning, PE; Powles, TJ; Schem, B, 1989) |
| " 3H-Androstenedione and 14C-oestrone were infused into women with advanced breast cancer for 12 hr before operation." | 3.67 | In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione. ( Coldham, NG; Ghilchik, MW; James, VH; Lai, LC; Owen, AM; Reed, MJ; Shaikh, NA, 1989) |
| "The activities of aromatase and estrone sulfatase which are important enzymes involved in the local production of estrogen in breast cancer tissue were measured to examine their availability in endocrine therapy and their clinical significance." | 3.67 | [Local production of estrogen via aromatase and estrone sulfatase in breast cancer tissue]. ( Utsumi, T, 1989) |
| "Plasma levels of estrone and estrone sulfate were measured in 16 postmenopausal women with advanced breast cancer before and during chronic aminoglutethimide therapy." | 3.67 | Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. ( Ekse, D; Johannessen, DC; Lønning, PE; Thorsen, T, 1989) |
| "The endocrine effects of aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily were assessed in 45 postmenopausal women with advanced breast cancer." | 3.67 | Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen. ( Cantwell, BM; Dowsett, M; Farndon, J; Harris, AL; Needham, G; Sainsbury, JR; Wilson, R, 1986) |
| "The possibility that medroxyprogesterone acetate (MPA) is clinically effective at least in part by its suppression of adrenal steroidogenesis and a resultant reduction of circulating oestrogen levels was investigated in 49 postmenopausal patients with advanced breast cancer." | 3.67 | The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients. ( Dowsett, M; Jeffcoate, SL; Lal, A; Smith, IE, 1987) |
| "Reports of estrone (E1) and dehydroepiandrosterone (DHEA) sulfatase (sulfohydrolase) activities within many human breast cancers have prompted us to undertake the identification and partial characterization of these enzyme activities within MCF-7 human breast cancer cells." | 3.67 | The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. ( MacIndoe, JH, 1988) |
| "5 mg, twice a day) aminoglutethimide (AG), without hydrocortisone (HC), escalating at monthly intervals to a conventional dose of AG (500 mg twice a day) combined with HC, were studied in 33 postmenopausal breast cancer patients." | 3.67 | Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. ( D'Souza, A; Donaldson, A; Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE; Stuart-Harris, R, 1985) |
| "Estrone sulfate (E1-S) is quantitatively the main estrogen in human breast cancer tissue." | 3.67 | [Cancer of the breast, mechanism of action of anti-estrogens]. ( Gelly, C; Pasqualini, JR, 1988) |
| "Estrone and estradiol-17 beta concentration in breast cancer tissue are reported to be an order of magnitude higher than those of circulating plasma in breast cancer patients." | 3.67 | [Serum estrone sulfate levels in patients with breast cancer]. ( Honjyo, H; Oka, T; Okada, H; Yasumura, T, 1988) |
| "The activity of the oestradiol-17 beta hydroxysteroid dehydrogenase in human endometrial and breast cancer specimens was determined by the NAD-dependent conversion of oestradiol-17 beta to oestrone." | 3.67 | Quantitative determination of oestradiol-17 beta hydroxysteroid dehydrogenase: increased sensitivity by HPLC separation of the hormones permits the measurement of enzyme activity in cryostat sections. ( Knuppen, R; Vollmer, G; Wünsche, WO, 1988) |
| "Cortisol and steroids with progestational or androgenic activity were studied to determine the effects of these steroids on the conversion of androstenedione (A) to estrone (E1) in human cultured breast carcinoma cells." | 3.67 | Steroid modulation of aromatase activity in human cultured breast carcinoma cells. ( Blackstein, M; Daniilescu, D; Kharlip, L; Killinger, DW; Perel, E, 1988) |
| "In this small study, the effect of aminoglutethimide on the disposition of oestrogens in women with advanced breast cancer was investigated using bolus injections of 4-[14C]-oestradiol and 6,7-[3H]-oestrone sulphate, alone or in combination." | 3.67 | Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. ( Kvinnsland, S; Lønning, PE; Thorsen, T; Ueland, PM, 1987) |
| "The conversion of 1 beta [3H] androstenedione to estrone in the presence of NADPH by breast cancer homogenates was assessed in tumors from 35 subjects together with estrogen and progesterone receptor concentration." | 3.67 | Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance. ( Bezwoda, WR; Dansey, R; Esser, JD; Mansoor, N, 1987) |
| "After infusion of 3H-oestradiol or 3H-oestrone into post-menopausal women with breast cancer, there was a significant uptake of both steroids by breast tumour and normal tissue." | 3.67 | A comparison of the in vivo uptake and metabolism of 3H-oestrone and 3H-oestradiol by normal breast and breast tumour tissues in post-menopausal women. ( Beranek, PA; Bonney, RC; Ghilchik, MW; James, VH; McNeill, JM; Reed, MJ; Robinson, DJ, 1986) |
| "Five men with advanced breast cancer were treated with aminoglutethimide (AG) plus replacement dose hydrocortisone." | 3.67 | Role of aminoglutethimide in male breast cancer. ( Dowsett, M; Harris, AL; Smith, IE; Stuart-Harris, R, 1986) |
| "Levels of circulating estrone (E1), estradiol (E2), androst-4-ene-3,17-dione (Adione), 3,5,3'-triiodothyronine (T3), thyroxine (T4), and sex hormone-binding globulin (SHBG) were measured in 10 obese postmenopausal patients with breast cancer and in 10 obese postmenopausal control subjects matched for age, body size, and menopausal status." | 3.67 | Decrease of circulating level of SHBG in postmenopausal obese women as a risk factor in breast cancer: reversible effect of weight loss. ( Cardillo, LR; del Carmen Cremona, M; Enriori, CL; Etkin, AE; Orsini, W; Reforzo-Membrives, J, 1986) |
| "Aminoglutethimide without glucocorticoid has been shown to be a clinically effective treatment for postmenopausal breast cancer in low dosage (250 mg day-1)." | 3.67 | Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. ( Dowsett, M; Jeffcoate, SL; Santen, RJ; Santner, SJ; Smith, IE, 1985) |
| "Oestrone sulphate, the oestrogen in highest concentration in the plasma, may play a role in the induction and growth of breast cancers." | 3.67 | Oestrone sulphate, adipose tissue, and breast cancer. ( Hawkins, RA; Killen, E; Thomson, ML, 1985) |
| "Postmenopausal women with metastatic breast cancer were treated with trilostane, initially 240 mg daily increasing after 3 days to 480 mg daily and after a further three days to 960 mg daily." | 3.67 | Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone. ( Beardwell, CG; Bu'lock, D; Hindley, AC; St John, J; Wilkinson, PM, 1985) |
| "Peripheral serum levels of cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulphate (DHA-S), oestradiol-17 beta and total oestrone were measured in 17 postmenopausal breast cancer patients and on age-matched healthy controls." | 3.66 | Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients. ( Carlström, K; Sköldefors, H; Theve, NO; Wallgren, A; Wilking, N, 1982) |
| "Ovarian and adrenal function were studied in premenopausal breast cancer patients before and at intervals during adjuvant therapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), CMF plus prednisone (CMFP), or CMFP plus tamoxifen (CMFPT)." | 3.66 | Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. ( Davis, TE; Rose, DP, 1980) |
| "Estradiol receptor (ER) and progesterone receptor (PR) content along with the cytosol and plasma estrone and estradiol levels in 15 premenopausal and 26 postmenopausal women with breast cancer in different clinical stages (T123, N01, M0) were measured." | 3.66 | Estradiol and progesterone receptor levels in human breast cancer in relation to cytosol and plasma estrogen level. ( Anghel, C; Drafta, D; Gangură, M; Neacşu, E; Panaitescu, G; Prişcu, A; Schindler, AE; Stroe, E, 1983) |
| "Urine levels of three major estrogens and of pregnanediol were measured for 76 nulliparous daughters of breast cancer patients and for 115 control women of similar age and parity." | 3.66 | Elevated urine estrogen and pregnanediol levels in daughters of breast cancer patients. ( Brown, JB; Garas, J; MacMahon, B; Papaioannou, A; Trichopoulos, D, 1981) |
| "Human breast cancer cells (MCF-7, maintained in long-term culture) contain separate estrogen receptors specific for either 17 beta-estradiol or estrone." | 3.66 | Estrone receptor formation during the processing of estradiol-receptor complex in MCF-7 cells. ( Brooks, SC; Hansen, ER, 1982) |
| "To evaluate the in vivo effect of delta 1-testololactone on peripheral aromatization, studies were performed on seven postmenopausal women with metastatic breast cancer." | 3.66 | In vivo effects of delta 1-testololactone on peripheral aromatization. ( Barone, RM; Gambone, JC; Judd, HL; Lasley, BL; Laufer, LR; Monfort, SL, 1982) |
| "Incubation studies have been carried out using normal breast tissue and breast tissue from patients with gynecomastia, mammary dysplasia and breast carcinoma to determine the pattern of androstenedione metabolism." | 3.66 | Androgen metabolism in male and female breast tissue. ( Davis, S; Killinger, DW; Perel, E, 1981) |
| "Urine samples were analyzed for estrone (E1), estradiol (E2), and Estriol (E3) to test the hypothesis that women diagnosed with benign breast disease (high risk for breast cancer?) will have lower estriol proportions (E3/E1 + E2 + E3) than a comparison control group." | 3.66 | Benign breast disease: estriol proportions and family history of breast cancer. ( Elinson, L; Morgan, RW; Vakil, DV, 1981) |
| "To study the contribution of adrenal glands to circulating estrogens in woman, the concentrations of estrone (E1), estradiol-17 beta (E2), and estriol (E3) in adrenal and peripheral venous blood were measured by radioimmunoassay and the grandular secretion of estrogens after ACTH stimulation was investigated by analyzing the adrenal vein levels of these steroids in patients with breast cancer who were undergoing a therapeutic adrenal operation." | 3.66 | Adrenal contribution to circulating estrogens in woman. ( Akamine, Y; Ibayashi, H; Kato, K; Nomura, Y; Wasada, T, 1978) |
| "The daily excretion of estrone, estradiol, and estriol was determined for 22 normal women and 35 women with primary breast cancer." | 3.66 | Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer. ( Dao, TL; Lonergan, PA; Morreal, CE; Nemoto, T, 1979) |
| "To determine if delta 1-testololactone can inhibit the peripheral aromatization of androstenedione (delta), nine postmenopausal women with metastatic breast cancer were studied before and after 2 weeks of therapy with 250 mg of the drug, given every 6 h by mouth." | 3.66 | Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using delta 1-testololactone. ( Barone, RM; Judd, HL; Shamonki, IM; Siiteri, PK, 1979) |
| "Estrone and estradiol levels in tumor tissue cytosols were determined in 11 premenopausal and 20 postmenopausal women at the same time that 17 beta-hydroxysteroid dehydrogenase and estrogen receptors (ER) were carried out on their breast cancers." | 3.66 | Relationship between estrogen receptors, 17 beta-hydroxysteroid dehydrogenase and estrogen content in human breast cancer. ( Abul-Hajj, YJ, 1979) |
| "The ability of breast cancer cells in long-term tissue culture to aromatize androstenedione to estrone and estradiol was examined." | 3.66 | Failure of breast cancer cells in long-term culture to aromatize androstenedione. ( D'Agata, R; Lippman, ME; Loriaux, DL; Monaco, ME, 1978) |
| "The concentrations of estrone (E1), androstenedione (A), testosterone (T) and sex-hormone-binding globulin (SHBG) in the serum were determined in 122 postmenopausal women, unselected with respect to age and stage of disease and with a newly diagnosed breast cancer." | 3.66 | Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls. ( Adami, HO; Johansson, ED; Vegelius, J; Victor, A, 1979) |
| "Aminoglutethimide and dexamethasone were administered for 3 months to 11 postmenopausal women with advanced breast cancer." | 3.66 | Medical adrenalectomy and plasma steroids in advanced breast carcinoma. ( Brown, PW; Lawrence, W; Newsome, HH; Terz, JJ, 1978) |
| "Population surveys have demonstrated an inverse relationship between breast cancer incidence rates and the urine "estriol ratio," the concentration of estriol relative to the sum of the concentrations of estrone and estradiol." | 3.66 | Estrogen profiles of premenopausal women with breast cancer. ( Brown, J; Cole, P; Cramer, D; MacMahon, B; Paffenbarger, R; Yen, S, 1978) |
| "To examine the hypothesis that familial breast cancer risk is related to estrogen metabolism, we analyzed urines of daughters of breast cancer patients and their matched controls for estrone (E1), estradiol (E2), and estriol (E3)." | 3.66 | Estrogen profiles in young women: effect of maternal history of breast cancer. ( Brown, JB; Elinson, L; Morgan, RW; Vakil, DV, 1978) |
| "We have infused [6,7-3H]estrone or [6,7-3H]estradiol and [4-14C]estriol into seven women who had had breast cancer and into five normal postmenopausal women." | 3.66 | Estriol production rates and breast cancer. ( Longcope, C; Pratt, JH, 1978) |
| "The metabolism of estradiol, its production rate and the urinary excretion rate of its metabolites were studied in 5 women patients with breast cancer, 2 of whom were postmenopausal and 3 were ovariectomized, both before and after a period of 7beta,17alpha-dimethyltestosterone (calusterone) therapy." | 3.65 | 7beta,17alpha-Dimethyltestosterone (calusterone)-induced changes in the metabolism, production rate, and excretion of estrogens in women with breast cancer: a possible mechanism of action. ( Fishman, J; Hellman, L, 1976) |
| " The excess is reflected in obesity and the consequent overproduction of estrone, a natural but carcinogenic human estrogen." | 3.65 | Diet and cancer of endocrine target organs. ( Cole, P; Cramer, D, 1977) |
| "The effects of estrone, estradiol, and estriol on MCF-7 human breast cancer are compared." | 3.65 | Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. ( Bolan, G; Lippman, M; Monaco, ME, 1977) |
| "Fifty-nine postmenopausal women with advanced breast cancer were treated with tamoxifen (antiestrogen), 20 mg orally twice a day for at least 2 months." | 3.65 | Tamoxifen (antiestrogen) therapy in advanced breast cancer. ( Kennedy, BJ; Kiang, DT, 1977) |
| "Women at elevated risk for breast cancer are motivated to reduce their risk." | 2.80 | Women In Steady Exercise Research (WISER) Sister: study design and methods. ( Adelman, J; Bryan, CJ; DiGiovanni, L; Domchek, S; Fenderson, D; Galantino, ML; Good, J; Grant, L; Hwang, WT; Kontos, D; Kurzer, MS; Morales, K; Salvatore, D; Schmitz, KH; Schnall, M; Stopfer, J; Sturgeon, K; Williams, NI; Wu, S, 2015) |
| "Statistically significant elevations in breast cancer risk were seen with greater pretreatment levels of total estradiol (P trend = ." | 2.78 | Sex hormone levels and risk of breast cancer with estrogen plus progestin. ( Anderson, G; Cauley, JA; Chlebowski, RT; Cummings, SR; Farhat, GN; Grady, D; Huang, AJ; Jackson, R; Lacroix, AZ; Lane, DS; Lee, JS; Manson, JE; Parimi, N; Phillips, L; Simon, MS; Vittinghoff, E, 2013) |
| " Pharmacokinetic and pharmacodynamic data for plasma estrogens, raloxifene, exemestane, and their metabolites were collected at the end of single-agent therapy and during combination therapy." | 2.73 | Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. ( Asnis, A; Borgen, P; Dang, C; Dickler, MN; Duncan, BA; Heerdt, A; Hudis, C; Lake, D; Moasser, M; Norton, L; Panageas, K; Poggesi, I; Robson, M; Traina, TA, 2008) |
| "Breast cancer is the most common malignancy in women with high mortality." | 2.72 | Breast Cancer: Targeting of Steroid Hormones in Cancerogenesis and Diagnostics. ( Kostecká, Z; Očenáš, P; Salayová, A; Valko-Rokytovská, M, 2021) |
| " STX64 was administered orally (nine patients at 5 mg and five patients at 20 mg) as an initial dose followed 1 week later by 3 x 2 weekly cycles, with each cycle comprising daily dosing for 5 days followed by 9 days off treatment." | 2.72 | Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. ( Coombes, RC; Dobbs, N; Elliott, M; Kulinskaya, E; Potter, BV; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Sufi, S; Vigushin, D; Ward, R; Wilson, RH; Woo, LW, 2006) |
| "Whether these changes influence breast cancer risk is currently unknown." | 2.71 | Diet and sex hormones in girls: findings from a randomized controlled clinical trial. ( Barton, BA; Buckman, DW; Chandler, DW; Dorgan, JF; Franklin, FA; Friedman, LA; Greenhut, SF; Hunsberger, SA; Kwiterovich, PO; Lasser, NL; Lauer, RM; McMahon, RP; Patterson, BH; Schatzkin, A; Snetselaar, LG; Stevens, VJ; Taylor, PR; Van Horn, L; Yanovski, JA, 2003) |
| "In two laboratory mammary cancer models, the combination of the aromatase inactivator exemestane plus tamoxifen gives a higher response rate than is found with either agent alone." | 2.71 | Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. ( Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR, 2005) |
| "There is increasing evidence that dietary factors may play a role in the production, metabolism, and bioavailability of sex hormones and their impact on target tissues." | 2.70 | The specific role of isoflavones on estrogen metabolism in premenopausal women. ( Allen, K; Cantor, A; Cox, CE; Kumar, NB; Riccardi, D, 2002) |
| "The odds ratio of breast cancer with the Msp1 homozygous variant was 8." | 2.69 | Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. ( Bradlow, HL; Ganguly, S; Garbers, SV; Garte, SJ; Osborne, MP; Sepkovic, DW; Taioli, E; Trachman, J, 1999) |
| "Letrozole appears to be a very promising new antiaromatase drug." | 2.68 | Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. ( Bisagni, G; Cocconi, G; Fraschini, F; Pfister, C; Scaglione, F; Trunet, PF, 1996) |
| "In about one-third of advanced breast cancers, estrogen deprivation causes tumor regression." | 2.68 | Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. ( Blankenstein, RA; de Jong, PC; Donker, TH; Maitimu-Smeele, I; Nortier, HW; Slee, PH; Thijssen, JH; van de Ven, J, 1997) |
| "20 evaluable postmenopausal advanced breast cancer patients were randomly given exemestane 0." | 2.68 | The minimal effective exemestane dose for endocrine activity in advanced breast cancer. ( Artale, S; Bajetta, E; Bartoli, C; Buzzoni, R; Danesini, GM; Ferrari, L; Greco, M; Mariani, L; Martinetti, A; Noberasco, C; Paolini, J; Spagnoli, I; Zilembo, N, 1997) |
| "In postmenopausal breast cancer (BC) patients, tamoxifen (TAM) is frequently used in first-line therapy, and for those relapsing under TAM, aromatase inhibitors would be the drug of choice." | 2.68 | A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. ( Amichetti, M; Attili, A; Bajetta, E; Barni, S; Bichisao, E; Bolelli, GF; Bombardieri, E; Buzzoni, R; Comella, G; D'Aprile, M; Ferrari, L; Jirillo, A; Martinetti, A; Noberasco, C; Schieppati, G; Zilembo, N, 1997) |
| "For oestrone only, there was a significant effect of dose (on-treatment means: 0." | 2.67 | Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. ( Coombes, RC; Dowsett, M; Moore, J; Powles, TJ; Rubens, R; Smith, IE; Smithers, D; Trunet, PF, 1994) |
| "40), but not for MPA and estrone, indicating better adrenal suppression by higher MPA dosage and plasma levels." | 2.66 | Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer. ( Doorenbos, H; Sleijfer, DT; Sluiter, WJ; van Veelen, H; Willemse, PH, 1985) |
| "In postmenopausal women with breast carcinoma, plasma and urinary oestrogens remain detectable following surgical adrenalectomy or hypophysectomy." | 2.65 | Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy. ( Samojlik, E; Santen, RJ; Worgul, TJ, 1984) |
| "Eight breast cancer studies have used these assays with prospectively collected blood or urine samples." | 2.52 | Epidemiologic studies of estrogen metabolism and breast cancer. ( Fuhrman, BJ; Matthews, CE; Moore, SC; Ziegler, RG, 2015) |
| "Epidemiological studies have examined breast cancer risk in relation to sex hormone concentrations measured by different methods: "extraction" immunoassays (with prior purification by organic solvent extraction, with or without column chromatography), "direct" immunoassays (no prior extraction or column chromatography), and more recently with mass spectrometry-based assays." | 2.52 | Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies. ( Appleby, PN; Barrett-Connor, E; Brinton, LA; Cauley, JA; Cologne, J; Dorgan, JF; Fourkala, EO; Fuhrman, BJ; Gapstur, SM; Gaudet, MM; Giles, GG; Grant, EJ; Gunter, MJ; Hallmans, G; Hankinson, SE; Helzlsouer, KJ; Henderson, BE; Hida, A; Kaaks, R; Key, TJ; Koenig, K; Kolonel, LN; Krogh, V; Laughlin, GA; Le Marchand, L; Manjer, J; Menon, U; Muti, P; Ohishi, W; Reeves, GK; Riboli, E; Rinaldi, S; Rohan, TE; Schairer, C; Sieri, S; Strickler, HD; Travis, RC; Tworoger, SS; Zeleniuch-Jacquotte, A; Ziegler, RG, 2015) |
| "More than 60 percents of breast cancers occur in post menopausal women and most of their initial stages are hormone dependent." | 2.46 | [Steroid sulfatase inhibitor]. ( Ishida, H; Nakata, T; Shiotsu, Y, 2010) |
| "STS expression is increased in breast tumors and has prognostic significance." | 2.43 | Steroid sulfatase: molecular biology, regulation, and inhibition. ( Newman, SP; Potter, BV; Purohit, A; Reed, MJ; Woo, LW, 2005) |
| "The activity of the enzyme network in breast cancer tissue is modified by a variety of factors like growth factors and cytokines." | 2.42 | Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. ( Geisler, J, 2003) |
| " The possibility does exist that the SHBG level increase and the IGF-I bioavailability decrease, caused by oral CEE, balance the increased estrogen stimulation on breast tissue." | 2.40 | Conjugated estrogens and breast cancer risk. ( Ambroggio, S; Biglia, N; Campagnoli, C; Sismondi, P, 1999) |
| "Comparative studies in breast cancer tissues show that the sulphatase pathway is 50-300 times more important than that of the aromatase pathway." | 2.39 | Control and expression of oestrone sulphatase activities in human breast cancer. ( Chetrite, G; Nestour, EL; Pasqualini, JR, 1996) |
| "One-third of the cases of breast cancer in postmenopausal women are hormone-dependent and the lesions regress upon treatment with antiestrogens or inhibition of estrogen biosynthesis." | 2.37 | Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. ( Feil, PD; Leszczynski, D; Manni, A; Santen, RJ; Santner, SJ; Tilson-Mallet, N; Wright, C, 1986) |
| "The incidence of breast cancer is discussed with regard to dietary habits, geographic location, and economic status." | 2.37 | Dietary fat and breast cancer. ( Smith, RE, 1987) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 2.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "Thus, steroid indices of relative cancer risk or responsiveness must be constructed with due attention to obesity, one of many important variables." | 2.35 | Hormones, nutrition, and cancer. ( Lipsett, MB, 1975) |
| "Estrogens increase breast cancer risk through estrogen receptor (ER)-mediated pathway activation." | 1.72 | Estrogenic Activity and Risk of Invasive Breast Cancer Among Postmenopausal Women in the Nurses' Health Study. ( Bertone-Johnson, ER; Eliassen, AH; Hankinson, SE; Holder, EX; Houghton, SC; Liu, Z; Qian, J; Sanchez, SS; Smith, MT; Tworoger, SS, 2022) |
| "Frailty syndrome is associated with poor outcomes, morbidity and premature mortality." | 1.72 | Plasma Aromatase Activity Index, Gonadotropins and Estrone Are Associated with Frailty Syndrome in Post-Menopausal Women with Breast Cancer. ( Avellán-Castillo, O; Cauli, O; García-Sánchez, J; Mafla-España, MA; Tejedor-Cabrera, C; Torregrosa, MD, 2022) |
| "Treatment with estrone, but not 17β-estradiol, and HSD17B14 overexpression both stimulate an EMT, matrigel invasion, and lung, bone, and liver metastasis in estrogen-receptor-positive (ER+) breast cancer models, while HSD17B14 knockdown reverses the EMT." | 1.72 | Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis. ( Diaz-Ruano, AB; Ince, TA; Nunes de Paiva, V; Picon-Ruiz, M; Qureshi, R; Sho, M; Slingerland, J; Van Booven, D, 2022) |
| "To test for the association with breast cancer risk, we carried out follow-up genotyping in 90,916 cases and 89,893 controls from the Breast Cancer Association Consortium." | 1.62 | CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. ( Ahearn, TU; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arndt, V; Aronson, KJ; Augustinsson, A; Baynes, C; Beckmann, MW; Benitez, J; Bermisheva, M; Blomqvist, C; Boeckx, B; Bogdanova, NV; Bojesen, SE; Bolla, MK; Brauch, H; Brenner, H; Burwinkel, B; Campa, D; Canzian, F; Castelao, JE; Chang-Claude, J; Chanock, SJ; Chenevix-Trench, G; Clarke, CL; Conroy, DM; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dennis, J; Dörk, T; Dos-Santos-Silva, I; Dunning, AM; Easton, DF; Eliassen, AH; Engel, C; Evans, DG; Fasching, PA; Figueroa, J; Fletcher, O; Floris, G; Flyger, H; Freeman, LEB; Gago-Dominguez, M; Gapstur, SM; García-Closas, M; Gaudet, MM; Giles, GG; Gilham, C; Goldberg, MS; González-Neira, A; Guénel, P; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hart, SN; Hooning, MJ; Hopper, JL; Howell, A; Howie, AF; Hunter, DJ; Jager, A; Jakubowska, A; John, EM; Johnson, N; Jones, ME; Kaaks, R; Kapoor, PM; Keeman, R; Khusnutdinova, E; Kitahara, CM; Kosma, VM; Koutros, S; Kraft, P; Kristensen, VN; Kurian, AW; Lambrechts, D; Le Marchand, L; Linet, M; Lubiński, J; Maguire, S; Mannermaa, A; Manoukian, S; Margolin, S; Martens, JWM; Mavroudis, D; Mayes, R; Meindl, A; Milne, RL; Morra, A; Neuhausen, SL; Nevanlinna, H; Newman, WG; Nielsen, SF; Nordestgaard, BG; Obi, N; Olshan, AF; Olson, JE; Olsson, H; Orban, E; Orr, N; Park-Simon, TW; Peterlongo, P; Peto, J; Pharoah, PDP; Plaseska-Karanfilska, D; Pylkäs, K; Rennert, G; Rennert, HS; Ruddy, KJ; Saloustros, E; Sandler, DP; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Schoemaker, MJ; Scott, C; Shu, XO; Simard, J; Smichkoska, S; Sohn, C; Southey, MC; Spinelli, JJ; Stone, J; Swerdlow, AJ; Tamimi, RM; Taylor, JA; Tollenaar, RAEM; Tomczyk, K; Tomlinson, I; Troester, MA; Truong, T; Vachon, CM; van Veen, EM; Wang, Q; Wang, SS; Weinberg, CR; Wendt, C; Wildiers, H; Winqvist, R; Wolk, A; Zheng, W; Ziogas, A, 2021) |
| "Breast cancer is one of the most frequent malignancies in the female population." | 1.56 | Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer. ( Bao, H; Chen, H; Chen, J; Cong, D; Jia, J; Li, Q; Li, Y; Liu, Z; Luan, X; Lv, Z; Meng, Q; Pei, J; Ren, Z; Sun, F; Tang, H; Wang, L; Yang, Y; Zhao, W; Zhou, X, 2020) |
| "E1Cs have been associated with breast cancer risk and may contribute to tumor progression since STS is expressed in breast cancer where its activity exceeds that of aromatase." | 1.46 | SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. ( Barman, P; Batzler, A; Buzdar, AU; Carlson, EE; Dudenkov, TM; Goetz, MP; Ibrahim-Zada, I; Ingle, JN; Jenkins, GD; Kalari, KR; Kubo, M; Moreno-Aspita, A; Nakamura, Y; Northfelt, DW; Pietrzak, TL; Robson, ME; Wang, L; Weinshilboum, RM; Williard, CV, 2017) |
| "However, data on associations with breast cancer survival are limited." | 1.43 | Associations of sex steroid hormones with mortality in women with breast cancer. ( Ballard, R; Baumgartner, KB; Baumgartner, RN; Bernstein, L; Campbell, K; Duggan, C; McTiernan, A; Neuhouser, ML; Stanczyk, F, 2016) |
| "Genotyping this SNP in 1,008 breast cancer, 1,128 lung cancer, and 347 CLL patients, we found that rs45446698 was associated with breast cancer mortality (HR, 1." | 1.43 | Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer. ( Ashworth, A; Broderick, P; Catovsky, D; De Ieso, P; Dos-Santos-Silva, I; Dudbridge, F; Eisen, T; Fletcher, O; Goldsmith, C; Houlston, RS; Johnson, N; Matakidou, A; Migliorini, G; Orr, N; Peto, J; Ross, G, 2016) |
| "The role of DHT in breast cancer cell proliferation is demonstrated by its independent suppression of cell growth in the presence of a physiological concentration of estradiol (E2)." | 1.42 | Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer. ( Doillon, CJ; Gérard, C; Lin, SX; Poirier, D; Thériault, JF; Wang, X, 2015) |
| "We recruited 235 women with breast cancer who were prescribed AI therapy." | 1.42 | Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors. ( Brier, MJ; Chambless, D; DeMichele, A; Gross, R; Mao, JJ; Su, HI, 2015) |
| "Each hormone was associated with breast cancer risk (odds ratio doubling, 0." | 1.40 | Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. ( Colditz, GA; Eliassen, AH; Hankinson, SE; Kraft, P; Qian, J; Rosner, BA; Tworoger, SS; Willett, WC; Zhang, X, 2014) |
| "Two groups of breast cancer patients (53±2 years) in clinical remission receiving no specific therapy were examined: group 1, with BRCA1 gene mutations (N=11) and group 2, without mutations of this kind (N=11)." | 1.38 | Endocrine metabolic disorders in patients with breast cancer, carriers of BRCA1 gene mutations. ( Berstein, LM; Boyarkina, MP; Imyanitov, EN; Kovalenko, IG; Poroshina, TE; Semiglazov, VF; Vasilyev, DA, 2012) |
| "However, women with ER-/PR- breast cancers had lower circulating levels of all measured sex steroid hormones and higher SHBG levels than women with ER+/PR+ breast cancers and controls." | 1.38 | Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women. ( Brinton, LA; Falk, RT; Figueroa, JD; Garcia-Closas, M; Gentzschein, E; Ioffe, OB; Lissowska, J; Sherman, ME; Stanczyk, FZ, 2012) |
| "We genotyped 46 breast cancer patients for rs6493497 and rs7176005 status and assessed the potential association between CYP19 SNP status and (i) CYP19 mRNA levels in tumour and normal breast tissue, and (ii) estrogen levels in plasma, tumour and normal breast tissue." | 1.38 | Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. ( Knappskog, S; Lønning, PE; Straume, AH, 2012) |
| "Estrone, a bioligand, was anchored on the surface of pH-sensitive liposome for drug targeting to ERs." | 1.38 | Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. ( Agrawal, GP; Gupta, PN; Pal, HC; Paliwal, R; Paliwal, SR; Saxena, AK; Sharma, PR; Vyas, SP, 2012) |
| "Women had a twofold increased breast cancer risk if ERα SB (odds ratio (OR), 2." | 1.38 | Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. ( Burnell, M; Dawnay, A; Ford, J; Fourkala, EO; Gentry-Maharaj, A; Gunu, R; Hasenbrink, G; Jacobs, I; Lichtenberg-Fraté, H; Menon, U; Soromani, C; Widschwendter, M; Zaikin, A, 2012) |
| "The role of alcohol and breast cancer risk in Asians has not been well studied." | 1.38 | Alcohol and breast cancer risk among Asian-American women in Los Angeles County. ( Razavi, P; Stancyzk, FZ; Tseng, CC; Vigen, C; Wu, AH, 2012) |
| "Dehydroepiandrosterone was most abundant in all samples, and exhibited a similar pattern as Adione and Aenediol." | 1.37 | Sex steroid hormones in pairs of tumor and serum from breast cancer patients and pathobiological role of androstene-3β, 17β-diol. ( Harada, N; Hayashi, S; Hirose, M; Honma, N; Horiguchi, S; Kuroi, K; Saji, S; Utsumi, T, 2011) |
| "This issue is important for breast cancer survivors since clinical recommendations suggest maintaining low hormone levels primarily via pharmacologic agents." | 1.36 | Dietary fat, tamoxifen use and circulating sex hormones in postmenopausal breast cancer survivors. ( Ballard-Barbash, R; Baumgartner, KB; Baumgartner, RN; Bernstein, L; Gilliland, F; McTiernan, A; Neuhouser, ML; Nojomi, M; Stanczyk, F, 2010) |
| "The concentration of estradiol (E(2)) in breast tumors is significantly higher than that in plasma, particularly in postmenopausal women." | 1.36 | Intratumoral estrogen disposition in breast cancer. ( A'Hern, R; Dowsett, M; Geisler, J; Haynes, BP; Helle, H; Lønning, PE; Smith, IE; Straume, AH, 2010) |
| "Estrone (ES) was anchored as ligand on to stealth liposome (ES-SL-DOX) for targeting to ERs." | 1.36 | A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. ( Mehta, A; Mishra, N; Paliwal, R; Paliwal, SR; Vyas, SP, 2010) |
| "Many breast tumors are hormone-dependent, and estrogens, especially estradiol (E2), have a pivotal role in their growth and development." | 1.35 | Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core. ( Alho-Richmond, S; Huhtinen, K; Johansson, N; Karkola, S; Koskimies, P; Lilienkampf, A; Vihko, K; Wähälä, K, 2009) |
| "Among postmenopausal women, breast cancer risk is inversely associated with circulating levels of 2-hydroxyestrone but directly associated with levels of 16alpha-hydroxyestrone, according to most studies." | 1.35 | Ethnicity, body size, and estrogen levels in postmenopausal Hispanic and non-Hispanic white women. ( Byers, T; Lezotte, D; Risendal, B; Wacker, M; Westerlind, K, 2009) |
| "Interestingly, treatment of breast cancer cells in vitro with the PXR agonist rifampin induced OATP1A2 expression in a time-dependent and concentration-dependent manner." | 1.35 | Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. ( Ho, RH; Kim, RB; Meyer zu Schwabedissen, HE; Tirona, RG; Yip, CS, 2008) |
| "During breast cancer progression, a substantial increase in chromosomal aberrations is observed in the transition from ductal hyperplasia to carcinoma in situ." | 1.35 | A prospective study of relative telomere length and postmenopausal breast cancer risk. ( De Vivo, I; Hankinson, SE; Hunter, DJ; Kraft, P; Prescott, J; Wong, JY, 2009) |
| "It is often overexpressed in breast cancer and endometriosis." | 1.35 | Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells. ( Bey, E; Frotscher, M; Hartmann, RW; Kruchten, P; Marchais-Oberwinkler, S; Oster, A; Werth, R, 2009) |
| ") daily, and on day 35 the mice were dosed additionally with 20 mg/kg STX1040 s." | 1.35 | 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. ( Allan, GM; Chander, SK; Day, JM; Foster, PA; Lawrence, HR; Newman, SP; Parsons, MF; Potter, BV; Purohit, A; Reed, MJ; Tutill, HJ; Vicker, N, 2008) |
| " Dose-response studies in the same rat model demonstrated that more than 90% inhibition of STS activity in tumors was necessary to induce tumor shrinkage." | 1.34 | A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models. ( Akinaga, S; Anazawa, H; Ishida, H; Kuwabara, T; Li, PK; Murakata, C; Nakata, T; Sato, N; Shiotsu, Y; Suzuki, M; Takebayashi, M; Tanaka, H; Terasaki, Y, 2007) |
| "Study participants from the Long Island Breast Cancer Study Project provided a spot urine specimen and completed a comprehensive interviewer-administered questionnaire." | 1.33 | Estrogen metabolism and breast cancer. ( Bradlow, HL; Britton, JA; Gammon, MD; Kabat, GC; Neugut, AI; O'Leary, ES; Sepkovic, DW; Teitelbaum, SL; Terry, MB, 2006) |
| "Estrogens produced within breast tumors may play a pivotal role in growth stimulation of the breast cancer cells." | 1.33 | Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. ( Lykkesfeldt, AE; Sonne-Hansen, K, 2005) |
| " A dose-response relationship in the inhibitory effect of this compound further confirmed the validity of the model for testing the drug candidates in vivo." | 1.33 | Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. ( Huhtinen, K; Husen, B; Kangas, L; Messinger, J; Poutanen, M; Thole, H, 2006) |
| "However, a "direct effect" of E(2) in breast cancerization has not yet been demonstrated." | 1.33 | Estradiol as an anti-aromatase agent in human breast cancer cells. ( Chetrite, GS; Pasqualini, JR, 2006) |
| "Androstenediol levels were associated with risk (p-trend = 0." | 1.33 | Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women. ( Adly, L; Fears, T; Hill, D; Hoover, RN; Mies, C; Schairer, C; Sherman, ME; Sturgeon, SR; Ziegler, RG, 2006) |
| "After adjusting for age, known breast cancer risk factors and lifestyle factors, the mean levels of testosterone, estrogen, and SHBG varied across populations (Ps < or = 0." | 1.33 | Racial/ethnic differences in postmenopausal endogenous hormones: the multiethnic cohort study. ( Haiman, CA; Henderson, BE; Le Marchand, L; Setiawan, VW; Stanczyk, FZ, 2006) |
| "Incident breast cancer cases between 25 and 65 years of age (n=110) were identified from hospital or population tumor registries in Shanghai, China." | 1.32 | Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. ( Bradlow, HL; Cheng, JR; Fowke, JH; Gao, YT; Jin, F; Qi, D; Shu, XO; Zheng, W, 2003) |
| "The women with breast cancer showed a significantly lower 2-hydroxyestrone to 16 alpha-hydroxyestrone ratio than control women on HRT (1." | 1.32 | Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer. ( Alvarez-Vasquez, RB; Axelrod, D; Bradlow, HL; Frenkel, K; Newman, MC; Sepkovic, DW; Zumoff, B, 2003) |
| "Incident breast cancers were confirmed by medical records and pathology reports during an average follow-up of 8." | 1.32 | Estrogen metabolites and the risk of breast cancer in older women. ( Bauer, DC; Cauley, JA; Cummings, SR; Danielson, ME; Kuller, LH; Ljung, BM; Zmuda, JM, 2003) |
| "The presence of estrone sulfatase in breast tumors and the high levels of circulating estrone sulfate may contribute the major portion of estrogen synthesized locally in breast tissues through conversion of estrone sulfate to estrone by the enzyme." | 1.32 | Steroidal oxathiazine inhibitors of estrone sulfatase. ( Chao, WR; Peters, RH; Sato, B; Shigeno, K; Tanabe, M; Zaveri, NT, 2003) |
| " The D-ring metabolites did not show such clear biphasic patterns, in most of them the stimulatory effect prevailed at the highest dosage used." | 1.32 | The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. ( Lippert, C; Mueck, AO; Seeger, H, 2003) |
| "The results showed that breast cancer risk was elevated with increasing levels of estrone and testosterone (p for trend < 0." | 1.32 | Plasma sex steroid hormones and breast cancer risk in Chinese women. ( Dai, Q; Gao, YT; Jin, F; Li, BD; Shi, R; Shu, XO; Yu, H; Zheng, W, 2003) |
| "It is hypothesized that breast cancers arising in postmenopausal women with high serum estrogens levels are more likely to be estrogen receptor (ER)-positive." | 1.32 | Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. ( Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanji, Y, 2003) |
| "More than two-thirds of breast cancers occur in post-menopausal women, and depend on the estrogens for their proliferation and survival." | 1.32 | Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. ( Akinaga, S; Ishida, H; Li, PK; Murakata, C; Nakata, T; Saeki, T; Sasano, H; Shiotsu, Y; Suzuki, T; Takashima, S, 2003) |
| "Associations of genotypes with breast cancer risk were evaluated in the case-control study and with hormone levels in the postmenopausal women using multiple linear regression with assay batch, body mass index, parity, peri- or postmenopausal status, and age band as covariates." | 1.32 | Polymorphisms associated with circulating sex hormone levels in postmenopausal women. ( Day, NE; Dowsett, M; Dunning, AM; Easton, DF; Folkerd, E; Healey, CS; Kelemen, L; Luben, RN; Novik, KL; Ogata, S; Pharoah, PD; Ponder, BA; Tee, L, 2004) |
| "The risk of ER- breast cancer tumors may vary by UGT or SULT genotype." | 1.32 | UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. ( Aiello, EJ; Ballard-Barbash, R; Bigler, J; Lin, MG; McTiernan, A; McVarish, L; Porter, P; Rajan, KB; Sparks, R; Stanczyk, FZ; Tworoger, SS; Ulrich, CM; Yasui, Y; Yuan, X, 2004) |
| "Recent smoking cessation was associated with a high OR in top categories of estrone, 4." | 1.32 | Smoking is associated with postmenopausal breast cancer in women with high levels of estrogens. ( Johansson, R; Lenner, P; Manjer, J, 2004) |
| "Nor has the relation between breast cancer risk and postmenopausal progesterone levels been investigated." | 1.32 | Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. ( Barbieri, RL; Eliassen, AH; Hankinson, SE; Missmer, SA, 2004) |
| "Twenty-one breast cancer cases, all collected from January 1986 to January 1988 at the M." | 1.31 | Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. ( Agostara, B; Amoroso, M; Bellavia, V; Carruba, G; Castagnetta, LA; Granata, OM; Miele, M; Ravazzolo, B; Traina, A, 2002) |
| "This study analyzes the association of breast cancer risk with estrogen metabolism, expressed as the ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone, in a prospective nested case-control study." | 1.31 | Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. ( Berrino, F; Bradlow, HL; Freudenheim, JL; Krogh, V; Micheli, A; Muti, P; Schünemann, HJ; Sepkovic, DW; Stanulla, M; Trevisan, M; Yang, J, 2000) |
| "These data demonstrate that LNCaP prostate cancer cells contain a steryl sulfatase with properties similar to that found in human breast cancer cells, and that the activity of this enzyme can be blocked by known steryl sulfatase inhibitors." | 1.31 | Inhibition of steryl sulfatase activity in LNCaP human prostate cancer cells. ( Kabler, H; Li, PK; Sarap, J; Selcer, KW; Xiao, Z, 2002) |
| "The role that E1S has in breast cancer development remains unclear." | 1.31 | Modulation of oestrone sulphate formation and hydrolysis in breast cancer cells by breast cyst fluid from British and Hungarian women. ( Budai, B; de Winkel, A; Ghilchik, MW; Parish, D; Purohit, A; Reed, MJ; Szamel, I; Wang, DY; Willemsen, EL, 2000) |
| "Estrone and E(1)S were converted into E(2), and all three estrogen fractions were finally measured by the same highly sensitive and specific radioimmunoassay using estradiol-6-(O-carboxymethyl)-oximino-2-(2--iodo-histamine) as a ligand." | 1.31 | A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. ( Berntsen, H; Geisler, J; Lonning, PE, 2000) |
| "Transforming growth factor beta (TGF-beta) is a multifunctional regulator of cellular growth and differentiation in many cell types and has a growth inhibitory effect on mammary epithelial cells." | 1.31 | Effect of transforming growth factor beta 2 on oestrogen metabolism in the MCF-7 breast cancer cell line. ( Erbas, H; Lai, LC, 2000) |
| "Anastrozole, 1 mg/day, was given once daily for 16 days." | 1.31 | Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women. ( Donaldson, K; Dowsett, M; Tsuboi, M; Wong, J; Yates, R, 2000) |
| "The ability of breast tumors to synthesize sex steroid hormones is well recognized and their local production is thought to play a role in breast cancer development and growth." | 1.31 | Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. ( Mady, EA; Ossman, AA; Ramadan, EE, 2000) |
| "Using T-47D breast cancer cells, evidence was obtained that the sulphated metabolites of tibolone could continue to inhibit E1-STS activity after removal of the drugs and extensive washing of cells." | 1.31 | Inhibition of oestrone sulphatase activity by tibolone and its metabolites. ( Hooymans, C; Malini, B; Newman, SP; Purohit, A, 2002) |
| "Serum and urine were collected from 65 breast cancer patients and 36 controls after an overnight fast." | 1.30 | Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. ( Foo, SC; Ho, GH; Ji, CY; Luo, XW; Ng, EH, 1998) |
| "Risk of breast cancer was positively and significantly associated with serum levels of estrogens and androgens." | 1.30 | Serum sex hormone levels are related to breast cancer risk in postmenopausal women. ( Campbell, WS; Dorgan, JF; Falk, RT; Franz, C; Kahle, L; Longcope, C; Miller, R; Schatzkin, A; Stephenson, HE; Tangrea, JA, 1997) |
| "In all, 10 RCCs were associated with breast carcinoma; 4, with endometrial carcinoma; and 3, with ovarian carcinoma." | 1.30 | Multiple primary tumors: 17 cases of renal-cell carcinoma associated with primary tumors involving different steroid-hormone target tissues. ( De Vico, A; Di Silverio, F; Flammia, GP; Mariani, M; Sciarra, A, 1997) |
| "As part of a case-control study of breast cancer in Asian-American women, 12-h overnight urine samples were obtained, and a methodological study was conducted to identify laboratories capable of assaying urinary hormones." | 1.30 | Reproducibility and validity of radioimmunoassays for urinary hormones and metabolites in pre- and postmenopausal women. ( Adlercreutz, H; Donaldson, JL; Falk, RT; Fears, TR; Fillmore, CM; Gail, MH; Hoover, RN; Kiura, P; Rossi, SC; Stanczyk, F; Vaught, JB; Wahala, K; Ziegler, RG, 1999) |
| "Two-hundred and six breast cancer cases were histologically confirmed breast cancer diagnoses at the Cancer Institute in Chennai (Madras), India." | 1.30 | A study on serum carotenoid levels in breast cancer patients of Indian women in Chennai (Madras), India. ( Gajalakshmi, KC; Ito, Y; Sasaki, R; Shanta, V; Suzuki, K, 1999) |
| "Although women with a family history of breast cancer tended to have higher estrogen levels compared with women without such history, the differences were not statistically significant." | 1.29 | Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States). ( Colditz, GA; Hankinson, SE; Hunter, DJ; Longcope, C; Manson, JE; Speizer, FE; Stampfer, MJ; Willett, WC, 1995) |
| "In the estrogen-sensitive ZR-75-1 human breast cancer cell line, this estradiol derivative has no estrogenic activity at 30 nM and only a minimal estrogenic activity (10% above the basal level) at 1 microM." | 1.29 | N-butyl, N-methyl, 11-[3',17' beta-(dihydroxy)-1',3',5'(10')-estratrien-16' alpha-yl]-9(R/S)-bromo undecanamide: synthesis and 17 beta-HSD inhibiting, estrogenic and antiestrogenic activities. ( Labrie, F; Pelletier, JD; Poirier, D, 1994) |
| "UISO-BCA-1 human breast carcinoma cell lines, established and characterized in our own laboratory, were used to study both oxidative and reductive pathways of 17 beta-hydroxysteroid dehydrogenase (17 beta-OH-SDH)." | 1.29 | Regulation of 17 beta-hydroxysteroid dehydrogenase in a newly-established human breast carcinoma cell line. ( Das Gupta, TK; Mehta, RR, 1993) |
| "Many breast tumors are hormone dependent, and there is evidence that hydrolysis of estrone sulfate (E1S) to estrone, by estrone sulfatase, is an important source of the estrogen which is found in tumors." | 1.29 | Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer. ( Duncan, L; Howarth, NM; Potter, BV; Purohit, A; Reed, MJ, 1993) |
| "Estradiol levels in breast tumors from post-menopausal women are similar to those in pre-menopausal women even though plasma estrogens are much lower after the menopause." | 1.29 | Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. ( Ohlsson-Wilhelm, B; Santen, RJ; Santner, SJ, 1993) |
| "The presence of PSA in breast cancers is associated with the presence of steroid-hormone receptors and may be a favourable prognostic indicator." | 1.29 | Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. ( Erbas, H; Lai, LC; Lennard, TW; Peaston, RT, 1996) |
| "The expression of aromatase by breast cancer cells and the role of locally produced estrogen in the stimulation of tumor growth has been controversial." | 1.29 | Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. ( Brodie, A; Dabbs, DJ; Lu, Q; Nakmura, J; Savinov, A; Weisz, J; Wolz, G; Yue, W, 1996) |
| "Estrone did not cause any mutagens in the test used." | 1.28 | In vitro synthesis of 16 alpha-hydroxyestrone by female rat liver microsomes: its possible role in the etiology of breast cancer. ( Arts, CJ; de Bie, AT; van den Berg, H; Wilmer, JW, 1990) |
| "We have previously shown that human breast cancer is autonomous in the regulation of its intra-tissue oestradiol concentration." | 1.28 | On the significance of in situ production of oestrogens in human breast cancer tissue. ( Blankenstein, MA; Daroszewski, J; Donker, GH; Maitimu-Smeele, I; Milewicz, A; Thijssen, JH, 1992) |
| "Treatment with Danazol had no significant effect on tissue levels of 3H E1S or on the CRE1S E1 or MCR-E1S." | 1.28 | The origin of oestrone sulphate in normal and malignant breast tissues in postmenopausal women. ( Ghilchik, MW; Purohit, A; Reed, MJ; Riaz, AA, 1992) |
| " On subsequent repeated dosing with PyG, both the Km (4." | 1.28 | Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. ( Coombes, RC; Dowsett, M; Griggs, LJ; Haynes, BP; Jarman, M; Jones, A; Lønning, PE; Mehta, A; Powles, T; Stein, R, 1991) |
| "Human breast cancer cells are used extensively for the study of steroid hormone action." | 1.28 | Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal (Huma 7) and malignant (MCF-7 and ZR-75-1) human breast cells in culture. ( Back, DJ; Rudland, PS; Wild, MJ, 1991) |
| "Estrone sulfate (E1-S) has been shown to be quantitatively the most important estrogen in peripheral blood." | 1.28 | [Tissue culture and estrogen, to clarify the roles of estrone sulfate]. ( Honjo, H; Kitawaki, J; Naitoh, K; Ogino, Y; Okada, H; Urabe, M; Yamamoto, T; Yasuda, J, 1989) |
| "Human breast carcinomas contain aromatase, the enzyme necessary for the conversion of androgens to estrogens." | 1.27 | Biological significance of aromatase activity in human breast tumors. ( Feil, PD; Santen, RJ; Santner, SJ; Tilson-Mallett, N, 1983) |
| "In a 10-year incidence survey of breast cancer in the City of Boston, 14 cases in American Chinese women were observed, while approximately 13 were expected on the basis of age-specific incidence in the white population." | 1.27 | The effect of westernization on urine estrogens, frequency of ovulation, and breast cancer risk. A study of ethnic Chinese women in the Orient and the USA. ( Brown, J; Cole, P; MacMahon, B; Trichopoulos, D; Yen, S, 1984) |
| "We report two cases of metastatic breast cancer occurring in two postmenopausal women." | 1.27 | Two partial remissions induced by an LHRH analogue in two postmenopausal women with metastatic breast cancer. ( Guiochet, N; Keiling, R; Schwartz, L, 1988) |
| "Ketoconazole was poorly tolerated due to gastrointestinal toxicity." | 1.27 | High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. ( Cantwell, BM; Dowsett, M; Harris, AL, 1988) |
| "The human mammary cancer cell line MCF-7 in culture was used to study the effect of tamoxifen and its derivatives: 4-hydroxytamoxifen (4-OH-Tam), N-desmethyltamoxifen (Dem-Tam) and cis-tamoxifen (cis-Tam) on the uptake and conversion of [3H]estrone sulfate (3H-E1S) to estradiol (E2)." | 1.27 | Effect of tamoxifen and tamoxifen derivatives on the conversion of estrone sulfate to estradiol in the MCF-7 mammary cancer cell line. ( Gelly, C; Pasqualini, JR, 1988) |
| "Local formation of estradiol in human breast tumors could provide a more important source of estrogen than is delivered from plasma." | 1.27 | Estrone sulfate: a potential source of estradiol in human breast cancer tissues. ( Feil, PD; Leszczynski, D; Manni, A; Santen, RJ; Santner, SJ; Wright, C, 1986) |
| "Twenty-five patients with metastatic breast cancer received greater than 80 endocrine cycles and greater than 300 courses of chemotherapy by this protocol; two-thirds of these patients had previously failed other endocrine or chemotherapy regimens." | 1.27 | Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity. ( Benz, C; DeGregorio, M; Drakes, T; Gandara, D; Miller, B; Monroe, S; Wilbur, B, 1987) |
| "Aminoglutethimide (AG) is a potent inhibitor of aromatization in placental microsomes and in peripheral tissues in postmenopausal women." | 1.26 | Resistance of the ovary to blockade of aromatization with aminoglutethimide. ( Samojlik, E; Santen, RJ; Wells, SA, 1980) |
| " Analysis of the dose-response curves shows induction by Oe2 to be 10 times and 50 times greater than Oe3 and Oe4, respectively." | 1.26 | Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture. ( Bayard, F; Jozan, S; Kreitmann, B, 1981) |
| "Studies of aromatase activity in breast carcinoma cells in culture over a period of 8 hr demonstrated progressive estrone formation." | 1.26 | Aromatase in human breast carcinoma. ( Blackstein, ME; Killinger, DW; Perel, E, 1982) |
| "When estrone was incubated in a similar manner, a nonpolar metabolite was formed, but it was the lipoidal derivative of estradiol, not estrone." | 1.26 | Lipoidal derivative of estradiol: the biosynthesis of a nonpolar estrogen metabolite. ( Hochberg, RB; Schatz, F, 1981) |
| "Some estriol precursors were less inhibitory of breast cancer development among 23 other estrogens and androgens, progestins and glucocorticoids tested." | 1.26 | Clinical and experimental aspects of the anti-mammary carinogenic activity of estriol. ( Lemon, HM, 1977) |
| " Requisites of such therapy are a through history to establish a real need, a complete gynecologic examination with a Pap smear before therapy begins and annually afterward, use of the smallest daily dose of estrogen that gives the desired effect, and periodic attempts to reduce the dosage or stop the hormone." | 1.26 | Estrogens for the menopause. Maximizing benefits, minimizing risks. ( Seller, JC, 1977) |
| "Findings disclosed that our breast cancer-affected patient showed a distinctive hormonal pattern characterized by significant elevation throughout the cycle of plasma estrone, estradiol, and prolactin." | 1.26 | Endocrine profile in a patient with familial breast cancer: a case-control study. ( Fishman, J; Harris, RE; Lynch, HT; Lynch, JF; Maloney, K; Marrero, K, 1979) |
| "Women who had had breast cancer were compared to a group of normal controls and were also found to have similar blood production rates for estriol, estrone, and estradiol." | 1.26 | Relationship between urine and plasma estrogen ratios. ( Longcope, C; Pratt, JH, 1978) |
| "Androstenedione was converted to estrone and, to a lesser extent, to 17beta-estradiol by crude homogenates, minces, fat-free particulate fractions (1,000-100,000 time g) and isolated fat cells obtained from abdominal, breast or axillary fat." | 1.25 | Aromatization of androgens by human abdominal and breast fat tissue. ( Nimrod, A; Ryan, KJ, 1975) |
| "In patients with breast and prostate cancer hormone excretion patterns differ in a similar way from patterns in persons without cancer." | 1.24 | HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL. ( HOPKINS, CE; MARMORSTON, J; STERN, E; WEINER, JM, 1964) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 302 (41.03) | 18.7374 |
| 1990's | 143 (19.43) | 18.2507 |
| 2000's | 155 (21.06) | 29.6817 |
| 2010's | 109 (14.81) | 24.3611 |
| 2020's | 27 (3.67) | 2.80 |
| Authors | Studies |
|---|---|
| Knebel, NG | 1 |
| von Angerer, E | 3 |
| DaSilva, JN | 1 |
| van Lier, JE | 1 |
| Wiese, TE | 1 |
| Polin, LA | 1 |
| Palomino, E | 1 |
| Brooks, SC | 6 |
| Imai, Y | 3 |
| Tsukahara, S | 3 |
| Ishikawa, E | 2 |
| Tsuruo, T | 3 |
| Sugimoto, Y | 4 |
| Ueda, K | 1 |
| Asada, S | 1 |
| Nussbaumer, P | 1 |
| Winiski, AP | 1 |
| Billich, A | 1 |
| Allan, GM | 3 |
| Lawrence, HR | 3 |
| Cornet, J | 1 |
| Bubert, C | 1 |
| Fischer, DS | 3 |
| Vicker, N | 4 |
| Smith, A | 1 |
| Tutill, HJ | 3 |
| Purohit, A | 30 |
| Day, JM | 3 |
| Mahon, MF | 2 |
| Reed, MJ | 43 |
| Potter, BV | 21 |
| Cadot, C | 3 |
| Laplante, Y | 3 |
| Kamal, F | 1 |
| Luu-The, V | 1 |
| Poirier, D | 9 |
| Fournier, MA | 1 |
| Lilienkampf, A | 1 |
| Karkola, S | 1 |
| Alho-Richmond, S | 1 |
| Koskimies, P | 1 |
| Johansson, N | 1 |
| Huhtinen, K | 2 |
| Vihko, K | 1 |
| Wähälä, K | 3 |
| Phan, CM | 1 |
| Liu, Y | 1 |
| Kim, BM | 1 |
| Mostafa, Y | 1 |
| Taylor, SD | 1 |
| Yadav, MR | 1 |
| Barmade, MA | 1 |
| Tamboli, RS | 1 |
| Murumkar, PR | 1 |
| Green, T | 1 |
| See, J | 1 |
| Schauch, M | 1 |
| Reil, J | 1 |
| Glover, M | 1 |
| Brix, J | 1 |
| Gerry, A | 1 |
| Li, K | 1 |
| Newman, M | 1 |
| Gahler, RJ | 1 |
| Wood, S | 1 |
| Thomson, CA | 1 |
| Chow, HHS | 1 |
| Wertheim, BC | 1 |
| Roe, DJ | 1 |
| Stopeck, A | 1 |
| Maskarinec, G | 4 |
| Altbach, M | 1 |
| Chalasani, P | 1 |
| Huang, C | 1 |
| Strom, MB | 1 |
| Galons, JP | 1 |
| Thompson, PA | 1 |
| Chang, VC | 1 |
| Cotterchio, M | 1 |
| Boucher, BA | 1 |
| Jenkins, DJA | 1 |
| Mirea, L | 1 |
| McCann, SE | 1 |
| Thompson, LU | 1 |
| Arslan, AA | 2 |
| Koenig, KL | 3 |
| Lenner, P | 3 |
| Afanasyeva, Y | 2 |
| Shore, RE | 3 |
| Chen, Y | 5 |
| Lundin, E | 1 |
| Toniolo, P | 2 |
| Hallmans, G | 2 |
| Zeleniuch-Jacquotte, A | 4 |
| Samavat, H | 1 |
| Kurzer, MS | 4 |
| Ruan, X | 2 |
| Seeger, H | 4 |
| Wallwiener, D | 1 |
| Huober, J | 1 |
| Mueck, AO | 4 |
| Godínez Martínez, EY | 1 |
| Santillán Ballesteros, R | 1 |
| Lemus Bravo, AE | 1 |
| Sámano, R | 1 |
| Tolentino Dolores, M | 1 |
| Rodríguez Ventura, AL | 1 |
| Juárez González, AR | 1 |
| Ziegler, RG | 8 |
| Fuhrman, BJ | 4 |
| Moore, SC | 2 |
| Matthews, CE | 2 |
| Gheldiu, AM | 1 |
| Popa, DS | 1 |
| Loghin, F | 1 |
| Vlase, L | 1 |
| Oh, H | 1 |
| Khodr, ZG | 1 |
| Sherman, ME | 3 |
| Palakal, M | 1 |
| Pfeiffer, RM | 2 |
| Linville, L | 1 |
| Geller, BM | 1 |
| Vacek, PM | 1 |
| Weaver, DL | 1 |
| Chicoine, RE | 1 |
| Falk, RT | 7 |
| Horne, HN | 1 |
| Papathomas, D | 1 |
| Patel, DA | 1 |
| Xiang, J | 1 |
| Xu, X | 6 |
| Veenstra, T | 1 |
| Hewitt, SM | 1 |
| Shepherd, JA | 1 |
| Brinton, LA | 5 |
| Figueroa, JD | 3 |
| Gierach, GL | 2 |
| Raeside, JI | 1 |
| Atkinson, C | 1 |
| Newton, KM | 1 |
| Aiello Bowles, EJ | 1 |
| Lehman, CD | 1 |
| Stanczyk, FZ | 19 |
| Westerlind, KC | 2 |
| Li, L | 2 |
| Lampe, JW | 1 |
| Wacker, M | 1 |
| Risendal, B | 1 |
| Westerlind, K | 1 |
| Lezotte, D | 1 |
| Byers, T | 1 |
| Im, A | 1 |
| Vogel, VG | 1 |
| Ahrendt, G | 1 |
| Lloyd, S | 1 |
| Ragin, C | 1 |
| Garte, S | 1 |
| Taioli, E | 2 |
| Telang, NT | 3 |
| Li, G | 2 |
| Sepkovic, DW | 10 |
| Bradlow, HL | 21 |
| Wong, GY | 1 |
| Schairer, C | 3 |
| Gail, MH | 5 |
| Boyd-Morin, J | 2 |
| Sue, LY | 1 |
| Buys, SS | 1 |
| Isaacs, C | 1 |
| Keefer, LK | 2 |
| Veenstra, TD | 4 |
| Berg, CD | 1 |
| Hoover, RN | 6 |
| Heak, S | 1 |
| Morimoto, Y | 2 |
| Custer, L | 1 |
| Franke, AA | 3 |
| Berstein, LM | 2 |
| Boyarkina, MP | 1 |
| Vasilyev, DA | 1 |
| Poroshina, TE | 1 |
| Kovalenko, IG | 1 |
| Imyanitov, EN | 1 |
| Semiglazov, VF | 1 |
| Castagnetta, LA | 3 |
| Granata, OM | 3 |
| Traina, A | 1 |
| Ravazzolo, B | 1 |
| Amoroso, M | 1 |
| Miele, M | 1 |
| Bellavia, V | 1 |
| Agostara, B | 1 |
| Carruba, G | 3 |
| Fowke, JH | 2 |
| Qi, D | 1 |
| Shu, XO | 3 |
| Gao, YT | 3 |
| Cheng, JR | 1 |
| Jin, F | 2 |
| Zheng, W | 4 |
| Jernström, H | 3 |
| Klug, TL | 2 |
| Narod, SA | 2 |
| Rinaldi, S | 4 |
| Moret, CN | 1 |
| Kaaks, R | 6 |
| Biessy, C | 1 |
| Déchaud, H | 1 |
| Peeters, PH | 3 |
| van Noord, PA | 2 |
| Alvarez-Vasquez, RB | 1 |
| Axelrod, D | 1 |
| Frenkel, K | 1 |
| Newman, MC | 1 |
| Zumoff, B | 6 |
| Markushin, Y | 1 |
| Zhong, W | 2 |
| Cavalieri, EL | 2 |
| Rogan, EG | 2 |
| Small, GJ | 1 |
| Yeung, ES | 1 |
| Jankowiak, R | 1 |
| Cauley, JA | 4 |
| Zmuda, JM | 1 |
| Danielson, ME | 1 |
| Ljung, BM | 1 |
| Bauer, DC | 2 |
| Cummings, SR | 2 |
| Kuller, LH | 5 |
| Lippert, TH | 1 |
| Dalessandri, KM | 1 |
| Firestone, GL | 1 |
| Fitch, MD | 1 |
| Bjeldanes, LF | 1 |
| Lewis, JS | 2 |
| Thomas, TJ | 2 |
| Pestell, RG | 1 |
| Albanese, C | 1 |
| Gallo, MA | 2 |
| Thomas, T | 2 |
| Nettleton, JA | 1 |
| Greany, KA | 1 |
| Thomas, W | 1 |
| Wangen, KE | 1 |
| Adlercreutz, H | 8 |
| Bentz, AT | 1 |
| Schneider, CM | 1 |
| Wellejus, A | 1 |
| Olsen, A | 2 |
| Tjonneland, A | 1 |
| Thomsen, BL | 1 |
| Overvad, K | 2 |
| Loft, S | 1 |
| Fentiman, IS | 2 |
| Hanby, A | 1 |
| Allen, DS | 3 |
| Key, T | 3 |
| Meilahn, EN | 2 |
| Kabat, GC | 3 |
| O'Leary, ES | 1 |
| Gammon, MD | 1 |
| Teitelbaum, SL | 1 |
| Britton, JA | 1 |
| Terry, MB | 1 |
| Neugut, AI | 1 |
| Greenlee, H | 1 |
| Wang, Q | 4 |
| Kibriya, MG | 1 |
| Gurvich, I | 1 |
| Senie, RT | 1 |
| Santella, RM | 1 |
| Ahsan, H | 1 |
| Bågeman, E | 1 |
| Ingvar, C | 1 |
| Rose, C | 1 |
| Lee, SU | 1 |
| Rhee, Mc | 1 |
| Min, YK | 1 |
| Kim, SH | 1 |
| Purdy, RH | 1 |
| Moore, PH | 1 |
| Williams, MC | 1 |
| Goldzieher, JW | 1 |
| Paul, SM | 1 |
| Schneider, J | 1 |
| Huh, MM | 1 |
| Fishman, J | 15 |
| Osborne, MP | 3 |
| McGuinness, BJ | 1 |
| Power, MJ | 1 |
| Fottrell, PF | 1 |
| Davis, DL | 1 |
| Lin, G | 1 |
| Sepkovic, D | 2 |
| Tiwari, R | 1 |
| Ursin, G | 5 |
| London, S | 3 |
| Gentzschein, E | 5 |
| Paganini-Hill, A | 2 |
| Ross, RK | 4 |
| Pike, MC | 10 |
| Rossi, SC | 2 |
| Fears, TR | 2 |
| Kiuru, P | 1 |
| Vaught, JB | 2 |
| Donaldson, JL | 2 |
| Fillmore, CM | 2 |
| Siiteri, PK | 5 |
| Chang, CJ | 1 |
| Sparano, JA | 1 |
| Sepkovie, DW | 1 |
| Hu, XP | 1 |
| Khalil, A | 1 |
| Rosenblatt, R | 1 |
| Ho, GH | 1 |
| Luo, XW | 1 |
| Ji, CY | 1 |
| Foo, SC | 1 |
| Ng, EH | 1 |
| De Stavola, B | 2 |
| Fentiman, I | 1 |
| Gupta, M | 1 |
| McDougal, A | 1 |
| Safe, S | 1 |
| Garbers, SV | 1 |
| Trachman, J | 1 |
| Ganguly, S | 1 |
| Garte, SJ | 1 |
| Hejaz, HA | 5 |
| Walden, L | 1 |
| MacCarthy-Morrogh, L | 2 |
| Packham, G | 2 |
| Singh, A | 6 |
| Singhal, H | 1 |
| Guo, L | 1 |
| Mittelman, A | 2 |
| Tiwari, RK | 2 |
| Lu, LJ | 1 |
| Cree, M | 1 |
| Josyula, S | 1 |
| Nagamani, M | 1 |
| Grady, JJ | 1 |
| Anderson, KE | 1 |
| Liu, X | 2 |
| Pisha, E | 2 |
| Constantinou, AI | 1 |
| Hua, Y | 2 |
| Shen, L | 2 |
| van Breemen, RB | 3 |
| Elguindi, EC | 1 |
| Blond, SY | 1 |
| Zhang, F | 3 |
| Bolton, JL | 3 |
| Longcope, C | 6 |
| Hebert, JR | 1 |
| Townsend, PA | 1 |
| Muti, P | 2 |
| Micheli, A | 1 |
| Krogh, V | 2 |
| Freudenheim, JL | 1 |
| Schünemann, HJ | 1 |
| Stanulla, M | 1 |
| Yang, J | 1 |
| Trevisan, M | 1 |
| Berrino, F | 1 |
| Vesprini, D | 1 |
| Riza, E | 1 |
| dos Santos Silva, I | 2 |
| Linos, D | 1 |
| Linos, A | 1 |
| Klinge, CM | 1 |
| Gestl, SA | 1 |
| Green, MD | 1 |
| Shearer, DA | 1 |
| Frauenhoffer, E | 1 |
| Tephly, TR | 1 |
| Weisz, J | 2 |
| Yang, D | 1 |
| Tseng, CC | 2 |
| Bernstein, L | 7 |
| Imoto, S | 1 |
| Swaneck, GE | 2 |
| Arts, CJ | 1 |
| Wilmer, JW | 1 |
| de Bie, AT | 1 |
| van den Berg, H | 1 |
| Thijssen, JH | 17 |
| Blankenstein, MA | 6 |
| Vandewalle, B | 3 |
| Lefebvre, J | 3 |
| Peyrat, JP | 1 |
| Bonneterre, J | 2 |
| Hornez, L | 1 |
| Bertelsen, BE | 1 |
| Viste, K | 1 |
| Helland, T | 1 |
| Hagland, M | 1 |
| Søiland, H | 1 |
| Geisler, J | 15 |
| Lende, TH | 1 |
| Lønning, PE | 32 |
| Sagen, JV | 1 |
| Mellgren, G | 2 |
| Almås, B | 1 |
| Yaghjyan, L | 1 |
| Darville, LNF | 1 |
| Cline, J | 1 |
| Martinez, YC | 1 |
| Rich, S | 1 |
| Austin-Datta, RJ | 1 |
| Koomen, JM | 1 |
| Tworoger, SS | 9 |
| Egan, KM | 1 |
| Holder, EX | 1 |
| Houghton, SC | 1 |
| Sanchez, SS | 1 |
| Eliassen, AH | 8 |
| Qian, J | 3 |
| Bertone-Johnson, ER | 1 |
| Liu, Z | 2 |
| Smith, MT | 1 |
| Hankinson, SE | 14 |
| García-Sánchez, J | 1 |
| Mafla-España, MA | 1 |
| Tejedor-Cabrera, C | 1 |
| Avellán-Castillo, O | 1 |
| Torregrosa, MD | 1 |
| Cauli, O | 1 |
| Horak, IR | 1 |
| Latyshko, NV | 1 |
| Hudkova, OO | 1 |
| Tokarchuk, KO | 1 |
| Kishko, TO | 1 |
| Yusova, OI | 1 |
| Drobot, LB | 1 |
| Tykhomyrov, AA | 1 |
| Nishi, K | 1 |
| Fu, W | 1 |
| Kiyama, R | 1 |
| Van Houdt, M | 1 |
| Han, SN | 1 |
| Pauwels, S | 1 |
| Billen, J | 1 |
| Neven, P | 1 |
| Muñoz, JP | 3 |
| Araya-Osorio, R | 3 |
| Mera-Adasme, R | 3 |
| Calaf, GM | 3 |
| Qureshi, R | 3 |
| Picon-Ruiz, M | 3 |
| Sho, M | 3 |
| Van Booven, D | 3 |
| Nunes de Paiva, V | 3 |
| Diaz-Ruano, AB | 3 |
| Ince, TA | 3 |
| Slingerland, J | 3 |
| Takeda, S | 1 |
| Hirao-Suzuki, M | 1 |
| Aramaki, H | 1 |
| Watanabe, K | 1 |
| Cobos-Ontiveros, LA | 1 |
| Romero-Hernández, LL | 1 |
| Mastranzo-Sánchez, EB | 1 |
| Colín-Lozano, B | 1 |
| Puerta, A | 1 |
| Padrón, JM | 1 |
| Merino-Montiel, P | 1 |
| Vega Baez, JL | 1 |
| Montiel-Smith, S | 1 |
| Ngueta, AD | 1 |
| Roy, J | 3 |
| Maltais, R | 2 |
| Vonka, P | 1 |
| Rarova, L | 1 |
| Bazgier, V | 1 |
| Tichy, V | 1 |
| Kolarova, T | 1 |
| Holcakova, J | 1 |
| Berka, K | 1 |
| Kvasnica, M | 1 |
| Oklestkova, J | 1 |
| Kudova, E | 1 |
| Strnad, M | 1 |
| Hrstka, R | 1 |
| Faltinová, M | 1 |
| Vehmanen, L | 1 |
| Lyytinen, H | 1 |
| Haanpää, M | 1 |
| Hämäläinen, E | 2 |
| Tiitinen, A | 1 |
| Blomqvist, C | 2 |
| Mattson, J | 1 |
| Senobar Tahaei, SA | 1 |
| Kulmány, Á | 1 |
| Minorics, R | 1 |
| Kiss, A | 1 |
| Szabó, Z | 1 |
| Germán, P | 1 |
| Szebeni, GJ | 1 |
| Gémes, N | 1 |
| Mernyák, E | 1 |
| Zupkó, I | 1 |
| Laforest, S | 1 |
| Pelletier, M | 1 |
| Denver, N | 1 |
| Poirier, B | 1 |
| Nguyen, S | 1 |
| Walker, BR | 1 |
| Durocher, F | 1 |
| Homer, NZM | 1 |
| Diorio, C | 1 |
| Tchernof, A | 1 |
| Andrew, R | 1 |
| Tang, H | 1 |
| Chen, J | 3 |
| Wang, L | 4 |
| Li, Q | 1 |
| Yang, Y | 1 |
| Lv, Z | 1 |
| Bao, H | 1 |
| Li, Y | 3 |
| Luan, X | 1 |
| Ren, Z | 1 |
| Zhou, X | 1 |
| Cong, D | 1 |
| Jia, J | 1 |
| Chen, H | 1 |
| Zhao, W | 1 |
| Meng, Q | 1 |
| Sun, F | 1 |
| Pei, J | 1 |
| Li, B | 1 |
| Hao, J | 1 |
| Yan, X | 1 |
| Kong, M | 1 |
| Sauter, ER | 2 |
| Raveendran, R | 1 |
| Chen, F | 2 |
| Kent, B | 1 |
| Stenzel, MH | 1 |
| Richardson, H | 1 |
| Ho, V | 1 |
| Pasquet, R | 1 |
| Singh, RJ | 1 |
| Goetz, MP | 5 |
| Tu, D | 1 |
| Goss, PE | 3 |
| Ingle, JN | 5 |
| Pemp, D | 1 |
| Geppert, LN | 1 |
| Wigmann, C | 1 |
| Kleider, C | 1 |
| Hauptstein, R | 1 |
| Schmalbach, K | 1 |
| Ickstadt, K | 1 |
| Esch, HL | 1 |
| Lehmann, L | 1 |
| Kalari, KR | 3 |
| Barman, P | 3 |
| Shepherd, LE | 1 |
| Ellis, MJ | 1 |
| Buzdar, AU | 4 |
| Robson, ME | 4 |
| Cairns, J | 1 |
| Carlson, EE | 2 |
| Eyman Casey, A | 1 |
| Hoskin, TL | 1 |
| Goodnature, BA | 1 |
| Haddad, TC | 1 |
| Weinshilboum, RM | 4 |
| Kurmi, BD | 1 |
| Paliwal, R | 3 |
| Paliwal, SR | 3 |
| Johnson, N | 4 |
| Maguire, S | 1 |
| Morra, A | 1 |
| Kapoor, PM | 1 |
| Tomczyk, K | 2 |
| Jones, ME | 1 |
| Schoemaker, MJ | 1 |
| Gilham, C | 2 |
| Bolla, MK | 1 |
| Dennis, J | 1 |
| Ahearn, TU | 1 |
| Andrulis, IL | 1 |
| Anton-Culver, H | 1 |
| Antonenkova, NN | 1 |
| Arndt, V | 1 |
| Aronson, KJ | 1 |
| Augustinsson, A | 1 |
| Baynes, C | 1 |
| Freeman, LEB | 1 |
| Beckmann, MW | 1 |
| Benitez, J | 1 |
| Bermisheva, M | 1 |
| Boeckx, B | 1 |
| Bogdanova, NV | 1 |
| Bojesen, SE | 1 |
| Brauch, H | 1 |
| Brenner, H | 1 |
| Burwinkel, B | 1 |
| Campa, D | 1 |
| Canzian, F | 1 |
| Castelao, JE | 1 |
| Chanock, SJ | 1 |
| Chenevix-Trench, G | 1 |
| Clarke, CL | 1 |
| Conroy, DM | 1 |
| Couch, FJ | 1 |
| Cox, A | 1 |
| Cross, SS | 1 |
| Czene, K | 1 |
| Dörk, T | 1 |
| Engel, C | 1 |
| Evans, DG | 1 |
| Fasching, PA | 1 |
| Figueroa, J | 1 |
| Floris, G | 1 |
| Flyger, H | 1 |
| Gago-Dominguez, M | 1 |
| Gapstur, SM | 2 |
| García-Closas, M | 2 |
| Gaudet, MM | 2 |
| Giles, GG | 2 |
| Goldberg, MS | 1 |
| González-Neira, A | 1 |
| Guénel, P | 1 |
| Hahnen, E | 1 |
| Haiman, CA | 3 |
| Håkansson, N | 1 |
| Hall, P | 1 |
| Hamann, U | 1 |
| Harrington, PA | 1 |
| Hart, SN | 1 |
| Hooning, MJ | 1 |
| Hopper, JL | 1 |
| Howell, A | 1 |
| Hunter, DJ | 5 |
| Jager, A | 1 |
| Jakubowska, A | 1 |
| John, EM | 1 |
| Keeman, R | 1 |
| Khusnutdinova, E | 1 |
| Kitahara, CM | 1 |
| Kosma, VM | 1 |
| Koutros, S | 1 |
| Kraft, P | 4 |
| Kristensen, VN | 1 |
| Kurian, AW | 1 |
| Lambrechts, D | 1 |
| Le Marchand, L | 3 |
| Linet, M | 1 |
| Lubiński, J | 1 |
| Mannermaa, A | 1 |
| Manoukian, S | 1 |
| Margolin, S | 1 |
| Martens, JWM | 1 |
| Mavroudis, D | 1 |
| Mayes, R | 1 |
| Meindl, A | 1 |
| Milne, RL | 1 |
| Neuhausen, SL | 1 |
| Nevanlinna, H | 1 |
| Newman, WG | 1 |
| Nielsen, SF | 1 |
| Nordestgaard, BG | 1 |
| Obi, N | 1 |
| Olshan, AF | 1 |
| Olson, JE | 2 |
| Olsson, H | 2 |
| Orban, E | 1 |
| Park-Simon, TW | 1 |
| Peterlongo, P | 1 |
| Plaseska-Karanfilska, D | 1 |
| Pylkäs, K | 1 |
| Rennert, G | 1 |
| Rennert, HS | 1 |
| Ruddy, KJ | 1 |
| Saloustros, E | 1 |
| Sandler, DP | 2 |
| Sawyer, EJ | 1 |
| Schmutzler, RK | 1 |
| Scott, C | 1 |
| Simard, J | 2 |
| Smichkoska, S | 1 |
| Sohn, C | 1 |
| Southey, MC | 1 |
| Spinelli, JJ | 1 |
| Stone, J | 1 |
| Tamimi, RM | 2 |
| Taylor, JA | 2 |
| Tollenaar, RAEM | 1 |
| Tomlinson, I | 1 |
| Troester, MA | 1 |
| Truong, T | 1 |
| Vachon, CM | 1 |
| van Veen, EM | 1 |
| Wang, SS | 2 |
| Weinberg, CR | 1 |
| Wendt, C | 1 |
| Wildiers, H | 1 |
| Winqvist, R | 1 |
| Wolk, A | 2 |
| Ziogas, A | 1 |
| Dunning, AM | 2 |
| Pharoah, PDP | 1 |
| Easton, DF | 2 |
| Howie, AF | 1 |
| Peto, J | 4 |
| Dos-Santos-Silva, I | 3 |
| Swerdlow, AJ | 1 |
| Chang-Claude, J | 1 |
| Schmidt, MK | 1 |
| Orr, N | 3 |
| Fletcher, O | 4 |
| Kornhuber, M | 1 |
| Dunst, S | 1 |
| Schönfelder, G | 1 |
| Oelgeschläger, M | 1 |
| Gonzalo-Encabo, P | 1 |
| McNeil, J | 1 |
| Pérez-López, A | 1 |
| Valades, D | 1 |
| Courneya, KS | 3 |
| Friedenreich, CM | 3 |
| Valko-Rokytovská, M | 1 |
| Očenáš, P | 1 |
| Salayová, A | 1 |
| Kostecká, Z | 1 |
| Thériault, JF | 2 |
| Lin, SX | 6 |
| Hou, C | 1 |
| Lu, G | 1 |
| Zhao, L | 1 |
| Yin, P | 1 |
| Zhu, L | 1 |
| Dudenkov, TM | 1 |
| Kubo, M | 1 |
| Ibrahim-Zada, I | 1 |
| Batzler, A | 2 |
| Jenkins, GD | 1 |
| Pietrzak, TL | 1 |
| Northfelt, DW | 3 |
| Moreno-Aspita, A | 1 |
| Williard, CV | 3 |
| Nakamura, Y | 1 |
| Caceres, S | 1 |
| Monsalve, B | 1 |
| Peña, L | 1 |
| de Andres, PJ | 1 |
| Alonso-Diez, A | 1 |
| Illera, MJ | 1 |
| Woodward, WA | 1 |
| Reuben, JM | 1 |
| Silvan, G | 1 |
| Illera, JC | 1 |
| Salkho, NM | 1 |
| Paul, V | 1 |
| Kawak, P | 1 |
| Vitor, RF | 1 |
| Martins, AM | 1 |
| Al Sayah, M | 1 |
| Husseini, GA | 1 |
| Yang, H | 1 |
| Tang, C | 1 |
| Yin, C | 1 |
| Amr, AEE | 1 |
| El-Naggar, M | 1 |
| Al-Omar, MA | 1 |
| Elsayed, EA | 1 |
| Abdalla, MM | 1 |
| Zhang, X | 4 |
| Rice, M | 1 |
| Rosner, BA | 2 |
| Joshi, AD | 1 |
| Lindstrom, S | 1 |
| Colditz, GA | 6 |
| Willett, WC | 6 |
| Michels, KB | 1 |
| Binder, N | 1 |
| Courant, F | 1 |
| Osterhues, A | 1 |
| Banerjee, N | 4 |
| Fonge, H | 1 |
| Mikhail, A | 1 |
| Reilly, RM | 1 |
| Bendayan, R | 4 |
| Allen, C | 4 |
| Verma, MK | 1 |
| Miki, Y | 1 |
| Abe, K | 1 |
| Suzuki, T | 3 |
| Niikawa, H | 1 |
| Suzuki, S | 1 |
| Kondo, T | 1 |
| Sasano, H | 2 |
| Monroe, KR | 2 |
| Besinque, KH | 1 |
| Farhat, GN | 1 |
| Parimi, N | 1 |
| Chlebowski, RT | 1 |
| Manson, JE | 2 |
| Anderson, G | 1 |
| Huang, AJ | 1 |
| Vittinghoff, E | 1 |
| Lee, JS | 1 |
| Lacroix, AZ | 1 |
| Jackson, R | 1 |
| Grady, D | 1 |
| Lane, DS | 1 |
| Phillips, L | 1 |
| Simon, MS | 1 |
| Harmon, BE | 1 |
| Beckford, F | 1 |
| Dallal, CM | 1 |
| Tice, JA | 1 |
| Buist, DS | 1 |
| Lacey, JV | 1 |
| Hue, TF | 1 |
| Lacroix, A | 1 |
| Lim, VW | 1 |
| Li, J | 1 |
| Gong, Y | 1 |
| Jin, A | 1 |
| Yuan, JM | 1 |
| Yong, EL | 1 |
| Koh, WP | 1 |
| Loud, JT | 2 |
| Nichols, K | 1 |
| Guttmann, A | 1 |
| Greene, MH | 1 |
| Sini, V | 1 |
| Lunardi, G | 2 |
| Cirillo, M | 1 |
| Turazza, M | 1 |
| Bighin, C | 2 |
| Giraudi, S | 1 |
| Levaggi, A | 1 |
| Piccioli, P | 2 |
| Bisagni, G | 3 |
| Gnoni, R | 1 |
| Stridi, G | 1 |
| Porpiglia, M | 2 |
| Picardo, E | 1 |
| Ponzone, R | 2 |
| Marenco, D | 1 |
| Mansutti, M | 2 |
| Puglisi, F | 2 |
| Del Mastro, L | 2 |
| Haynes, BP | 5 |
| Dowsett, M | 41 |
| Hosoda, M | 1 |
| Yamamoto, M | 1 |
| Nakano, K | 1 |
| Hatanaka, KC | 1 |
| Takakuwa, E | 1 |
| Hatanaka, Y | 1 |
| Matsuno, Y | 1 |
| Yamashita, H | 1 |
| Madan, J | 1 |
| Gundala, SR | 1 |
| Kasetti, Y | 1 |
| Bharatam, PV | 1 |
| Aneja, R | 1 |
| Katyal, A | 1 |
| Jain, UK | 1 |
| Miller, N | 1 |
| Yager, JD | 1 |
| Desta, Z | 2 |
| Dudenkov, TT | 1 |
| Perez, EA | 2 |
| Flockhart, DA | 2 |
| Liu, S | 1 |
| Schultz, S | 1 |
| Neubauer, H | 1 |
| Fehm, T | 1 |
| Maximov, PY | 1 |
| McDaniel, RE | 1 |
| Fernandes, DJ | 1 |
| Bhatta, P | 1 |
| Korostyshevskiy, VR | 1 |
| Curpan, RF | 1 |
| Jordan, VC | 1 |
| Key, TJ | 2 |
| Appleby, PN | 1 |
| Reeves, GK | 1 |
| Travis, RC | 1 |
| Helzlsouer, KJ | 1 |
| Dorgan, JF | 5 |
| Riboli, E | 1 |
| Manjer, J | 3 |
| Kolonel, LN | 4 |
| Henderson, BE | 8 |
| Koenig, K | 1 |
| Sieri, S | 1 |
| Barrett-Connor, E | 3 |
| Laughlin, GA | 2 |
| Grant, EJ | 1 |
| Cologne, J | 1 |
| Ohishi, W | 1 |
| Hida, A | 1 |
| Fourkala, EO | 2 |
| Menon, U | 2 |
| Rohan, TE | 1 |
| Strickler, HD | 1 |
| Gunter, MJ | 1 |
| Shu, C | 1 |
| Li, R | 1 |
| Yin, Y | 1 |
| Yin, D | 2 |
| Gu, Y | 1 |
| Ding, L | 1 |
| Chatterton, RT | 3 |
| Muzzio, M | 1 |
| Gann, PH | 1 |
| Kejík, Z | 1 |
| Bříza, T | 1 |
| Králová, J | 1 |
| Mikula, I | 1 |
| Poučková, P | 1 |
| Martásek, P | 1 |
| Král, V | 1 |
| Mehra, NK | 1 |
| Jain, NK | 1 |
| Wu, TR | 1 |
| Chio, J | 1 |
| Kelly, R | 1 |
| Stephenson, KA | 1 |
| Forbes, J | 1 |
| Valliant, JF | 1 |
| Schmitz, KH | 1 |
| Williams, NI | 2 |
| Kontos, D | 1 |
| Schnall, M | 1 |
| Domchek, S | 1 |
| Stopfer, J | 1 |
| Galantino, ML | 1 |
| Hwang, WT | 1 |
| Morales, K | 1 |
| Wu, S | 1 |
| DiGiovanni, L | 1 |
| Salvatore, D | 1 |
| Fenderson, D | 1 |
| Good, J | 1 |
| Sturgeon, K | 1 |
| Grant, L | 1 |
| Bryan, CJ | 1 |
| Adelman, J | 1 |
| Kopp, TI | 1 |
| Lundqvist, J | 1 |
| Petersen, RK | 1 |
| Oskarsson, A | 1 |
| Kristiansen, K | 1 |
| Nellemann, C | 1 |
| Vogel, U | 1 |
| Matsumoto, J | 1 |
| Ariyoshi, N | 1 |
| Sakakibara, M | 1 |
| Nakanishi, T | 2 |
| Okubo, Y | 1 |
| Shiina, N | 1 |
| Fujisaki, K | 1 |
| Nagashima, T | 1 |
| Nakatani, Y | 1 |
| Tamai, I | 4 |
| Yamada, H | 1 |
| Takeda, H | 1 |
| Ishii, I | 1 |
| Harris, HR | 1 |
| Bergkvist, L | 1 |
| Wang, X | 1 |
| Gérard, C | 1 |
| Doillon, CJ | 1 |
| Thomas, MP | 1 |
| Brier, MJ | 1 |
| Chambless, D | 1 |
| Gross, R | 1 |
| Su, HI | 1 |
| DeMichele, A | 1 |
| Mao, JJ | 1 |
| Lundström, E | 1 |
| Conner, P | 1 |
| Naessén, S | 1 |
| Löfgren, L | 3 |
| Carlström, K | 9 |
| Söderqvist, G | 3 |
| Xu, D | 1 |
| Flågeng, MH | 1 |
| Knappskog, S | 3 |
| Gjerde, J | 1 |
| Kapoor, R | 1 |
| Ronnenberg, A | 1 |
| Puleo, E | 1 |
| Seeram, NP | 1 |
| Sturgeon, SR | 2 |
| Neilson, HK | 1 |
| Yasui, Y | 4 |
| Duha, A | 1 |
| MacLaughlin, S | 1 |
| Kallal, C | 1 |
| Forbes, CC | 1 |
| Bellet, M | 1 |
| Gray, KP | 1 |
| Francis, PA | 1 |
| Láng, I | 1 |
| Ciruelos, E | 1 |
| Lluch, A | 1 |
| Climent, MA | 1 |
| Catalán, G | 1 |
| Avella, A | 1 |
| Bohn, U | 1 |
| González-Martin, A | 1 |
| Ferrer, R | 1 |
| Catalán, R | 1 |
| Azaro, A | 1 |
| Rajasekaran, A | 1 |
| Morales, J | 1 |
| Vázquez, J | 1 |
| Fleming, GF | 1 |
| Price, KN | 1 |
| Regan, MM | 1 |
| Duggan, C | 1 |
| Stanczyk, F | 3 |
| Campbell, K | 1 |
| Neuhouser, ML | 2 |
| Baumgartner, RN | 2 |
| Baumgartner, KB | 2 |
| Ballard, R | 1 |
| McTiernan, A | 6 |
| De Ieso, P | 1 |
| Migliorini, G | 1 |
| Broderick, P | 2 |
| Catovsky, D | 1 |
| Matakidou, A | 1 |
| Eisen, T | 1 |
| Goldsmith, C | 1 |
| Dudbridge, F | 1 |
| Ashworth, A | 2 |
| Ross, G | 2 |
| Houlston, RS | 2 |
| Kim, KJ | 1 |
| Kim, HJ | 1 |
| Park, HG | 1 |
| Hwang, CH | 1 |
| Sung, C | 1 |
| Jang, KS | 1 |
| Park, SH | 1 |
| Kim, BG | 1 |
| Lee, YK | 1 |
| Yang, YH | 1 |
| Jeong, JH | 1 |
| Kim, YG | 1 |
| Ou Shu, X | 1 |
| Yu, K | 1 |
| Ji, BT | 1 |
| Chow, WH | 1 |
| Cai, Q | 1 |
| Li, H | 1 |
| Yang, G | 1 |
| Ruggieri, D | 1 |
| Rothman, N | 1 |
| Kim, S | 1 |
| Campbell, J | 1 |
| Yoo, W | 1 |
| Alsayari, A | 1 |
| Kopel, L | 1 |
| Ahmed, MS | 1 |
| Pay, A | 1 |
| Carlson, T | 1 |
| Halaweish, FT | 1 |
| Sood, D | 1 |
| Jain, P | 1 |
| Siskos, AP | 1 |
| Bennett, M | 1 |
| Busana, MC | 1 |
| Keun, HC | 1 |
| Coscia, EB | 1 |
| Sabha, M | 1 |
| Gerenutti, M | 1 |
| Groppo, FC | 1 |
| Bergamaschi, CC | 1 |
| Zhang, Y | 2 |
| Xu, YY | 1 |
| Yao, CB | 1 |
| Li, JT | 1 |
| Zhao, XN | 1 |
| Yang, HB | 1 |
| Zhang, M | 1 |
| Yin, M | 1 |
| Lei, QY | 1 |
| Crandall, CJ | 1 |
| Guan, M | 1 |
| Ursin, GA | 1 |
| Ingles, SA | 2 |
| Greendale, GA | 1 |
| Hofling, M | 1 |
| von Schoultz, E | 1 |
| Missmer, SA | 3 |
| Rancourt, C | 1 |
| Helle, H | 6 |
| Ekse, D | 12 |
| Duong, NK | 3 |
| Evans, DB | 1 |
| Nordbø, Y | 1 |
| Aas, T | 2 |
| MANN, WL | 1 |
| MARTIN, JP | 1 |
| Thomas, JL | 1 |
| Bucholtz, KM | 1 |
| Sun, J | 1 |
| Mack, VL | 1 |
| Kacsoh, B | 1 |
| Meyer zu Schwabedissen, HE | 1 |
| Tirona, RG | 1 |
| Yip, CS | 1 |
| Ho, RH | 1 |
| Kim, RB | 1 |
| De Vivo, I | 3 |
| Prescott, J | 1 |
| Wong, JY | 1 |
| Kruchten, P | 2 |
| Werth, R | 2 |
| Bey, E | 2 |
| Oster, A | 2 |
| Marchais-Oberwinkler, S | 2 |
| Frotscher, M | 2 |
| Hartmann, RW | 2 |
| Olson, AC | 1 |
| Link, JS | 1 |
| Waisman, JR | 1 |
| Kupiec, TC | 1 |
| Mazumdar, M | 1 |
| Fournier, D | 1 |
| Zhu, DW | 2 |
| Wang, H | 1 |
| Wei, L | 1 |
| Yu, J | 1 |
| Gao, Y | 1 |
| Gao, P | 1 |
| Wei, F | 1 |
| Zhou, G | 1 |
| Byrns, MC | 1 |
| Duan, L | 1 |
| Lee, SH | 1 |
| Blair, IA | 1 |
| Penning, TM | 2 |
| Corona, G | 1 |
| Elia, C | 1 |
| Casetta, B | 1 |
| Da Ponte, A | 1 |
| Del Pup, L | 1 |
| Ottavian, E | 1 |
| Toffoli, G | 1 |
| Nojomi, M | 1 |
| Gilliland, F | 3 |
| Ballard-Barbash, R | 5 |
| Woolcott, CG | 1 |
| Brant, RF | 1 |
| Terry, T | 1 |
| Boyd, NF | 1 |
| Yaffe, MJ | 1 |
| Irwin, ML | 1 |
| Jones, CA | 1 |
| Campbell, KL | 1 |
| McNeely, ML | 1 |
| Karvinen, KH | 1 |
| Straume, AH | 3 |
| A'Hern, R | 1 |
| Smith, IE | 16 |
| Schaid, DJ | 1 |
| Weintraub, RA | 1 |
| Mishra, N | 1 |
| Mehta, A | 4 |
| Vyas, SP | 2 |
| Klein, T | 1 |
| Negri, M | 1 |
| Nakata, T | 3 |
| Ishida, H | 3 |
| Shiotsu, Y | 3 |
| Reed, JL | 1 |
| Leidy, HJ | 1 |
| Legro, RS | 1 |
| De Souza, MJ | 1 |
| Maeda, T | 2 |
| Irokawa, M | 2 |
| Arakawa, H | 1 |
| Kuraoka, E | 1 |
| Nozawa, T | 3 |
| Tateoka, R | 1 |
| Itoh, Y | 1 |
| Dimitrakakis, C | 1 |
| Zava, D | 2 |
| Marinopoulos, S | 1 |
| Tsigginou, A | 1 |
| Antsaklis, A | 1 |
| Glaser, R | 1 |
| Stander, A | 1 |
| Joubert, F | 1 |
| Joubert, A | 1 |
| Palmieri, C | 1 |
| Januszewski, A | 1 |
| Stanway, S | 1 |
| Coombes, RC | 8 |
| Hong, Y | 1 |
| Rashid, R | 1 |
| Chen, S | 1 |
| Dunbier, A | 1 |
| Aubertin-Leheudre, M | 1 |
| Parker, NP | 1 |
| Habe-Evans, M | 1 |
| Bryk, M | 1 |
| Scholtens, DM | 1 |
| Khan, SA | 1 |
| Honma, N | 1 |
| Saji, S | 1 |
| Hirose, M | 1 |
| Horiguchi, S | 1 |
| Kuroi, K | 1 |
| Hayashi, S | 1 |
| Utsumi, T | 3 |
| Harada, N | 1 |
| Ioffe, OB | 1 |
| Lissowska, J | 1 |
| Bao, T | 1 |
| Blackford, AL | 1 |
| Stearns, V | 1 |
| Pal, HC | 1 |
| Saxena, AK | 1 |
| Sharma, PR | 1 |
| Gupta, PN | 1 |
| Agrawal, GP | 1 |
| Spiegelman, D | 2 |
| Barbieri, RL | 2 |
| Zaikin, A | 1 |
| Burnell, M | 1 |
| Gentry-Maharaj, A | 1 |
| Ford, J | 1 |
| Gunu, R | 1 |
| Soromani, C | 1 |
| Hasenbrink, G | 1 |
| Jacobs, I | 1 |
| Dawnay, A | 1 |
| Widschwendter, M | 1 |
| Lichtenberg-Fraté, H | 1 |
| Fung, TT | 1 |
| Schulze, MB | 1 |
| Hu, FB | 1 |
| Holmes, MD | 1 |
| Zhang, CY | 1 |
| Yin, DC | 1 |
| Walker, K | 1 |
| Gibson, LJ | 1 |
| Folkerd, E | 3 |
| Haynes, B | 6 |
| Palles, C | 1 |
| Coupland, B | 1 |
| Schoemaker, M | 1 |
| Jones, M | 1 |
| Sawyer, E | 1 |
| Kerin, M | 1 |
| Tomlinson, IP | 1 |
| Zvelebil, M | 1 |
| Chilcott-Burns, S | 1 |
| Simpson, G | 1 |
| Williamson, J | 1 |
| Hillier, SG | 1 |
| Swerdlow, A | 1 |
| Folkerd, EJ | 4 |
| Dixon, JM | 5 |
| Renshaw, L | 2 |
| A'Hern, RP | 2 |
| Ayan, D | 1 |
| Würtz, AM | 1 |
| Tjønneland, A | 1 |
| Christensen, J | 1 |
| Dragsted, LO | 1 |
| Aarestrup, J | 1 |
| Kyrø, C | 1 |
| Bruzzi, P | 1 |
| Notaro, R | 1 |
| Lastraioli, S | 1 |
| Serra, M | 1 |
| Marroni, P | 1 |
| Garrone, O | 1 |
| Cavazzini, G | 1 |
| Clavarezza, M | 1 |
| Wu, AH | 1 |
| Vigen, C | 1 |
| Razavi, P | 1 |
| Stancyzk, FZ | 1 |
| Yared, E | 1 |
| McMillan, TJ | 1 |
| Martin, FL | 1 |
| Larionov, AA | 1 |
| Miller, WR | 6 |
| Thibodeau, PA | 1 |
| Kachadourian, R | 1 |
| Lemay, R | 1 |
| Bisson, M | 1 |
| Day, BJ | 1 |
| Paquette, B | 1 |
| Honma, S | 1 |
| Shimodaira, K | 1 |
| Shimizu, Y | 1 |
| Tsuchiya, N | 1 |
| Saito, H | 1 |
| Yanaihara, T | 1 |
| Okai, T | 1 |
| Selcer, KW | 3 |
| Kabler, H | 1 |
| Sarap, J | 1 |
| Xiao, Z | 1 |
| Li, PK | 6 |
| Stuart, M | 1 |
| Sahmoud, T | 1 |
| Howarth, NM | 4 |
| Robinson, JJ | 1 |
| Peters, RH | 1 |
| Chao, WR | 1 |
| Sato, B | 1 |
| Shigeno, K | 1 |
| Zaveri, NT | 1 |
| Tanabe, M | 1 |
| Tominaga, T | 4 |
| Adachi, I | 1 |
| Sasaki, Y | 1 |
| Tabei, T | 1 |
| Ikeda, T | 1 |
| Takatsuka, Y | 1 |
| Toi, M | 2 |
| Suwa, T | 1 |
| Ohashi, Y | 1 |
| Lippert, C | 1 |
| Yu, FL | 1 |
| Bender, W | 1 |
| Hunsberger, SA | 1 |
| McMahon, RP | 1 |
| Kwiterovich, PO | 1 |
| Lauer, RM | 1 |
| Van Horn, L | 1 |
| Lasser, NL | 1 |
| Stevens, VJ | 1 |
| Friedman, LA | 1 |
| Yanovski, JA | 1 |
| Greenhut, SF | 1 |
| Chandler, DW | 1 |
| Franklin, FA | 1 |
| Barton, BA | 1 |
| Buckman, DW | 1 |
| Snetselaar, LG | 1 |
| Patterson, BH | 1 |
| Schatzkin, A | 3 |
| Taylor, PR | 2 |
| Rabouin, D | 1 |
| Perron, V | 1 |
| N'Zemba, B | 1 |
| C-Gaudreault, R | 1 |
| Bérubé, G | 1 |
| Yu, H | 2 |
| Shi, R | 1 |
| Dai, Q | 1 |
| Li, BD | 1 |
| Chander, SK | 4 |
| Woo, LW | 5 |
| Fenton, JC | 1 |
| Rajan, KB | 2 |
| Irwin, M | 1 |
| Baumgartner, R | 2 |
| Onland-Moret, NC | 2 |
| Grobbee, DE | 2 |
| Miyoshi, Y | 1 |
| Tanji, Y | 1 |
| Taguchi, T | 3 |
| Tamaki, Y | 1 |
| Noguchi, S | 1 |
| Pizzagalli, F | 1 |
| Varga, Z | 1 |
| Huber, RD | 1 |
| Folkers, G | 1 |
| Meier, PJ | 1 |
| St-Pierre, MV | 1 |
| Zhi, L | 1 |
| Tegley, CM | 1 |
| Pio, B | 1 |
| Edwards, JP | 1 |
| Motamedi, M | 1 |
| Jones, TK | 1 |
| Marschke, KB | 1 |
| Mais, DE | 1 |
| Risek, B | 1 |
| Schrader, WT | 1 |
| RAWLINSON, HE | 1 |
| HADFIELD, JI | 1 |
| BAYER, JM | 1 |
| GEISSLER, G | 1 |
| BREUER, H | 1 |
| PULLINGER, BD | 2 |
| JULL, LW | 1 |
| SHUCKSMITH, HS | 1 |
| BONSER, GM | 1 |
| RIVERA, EM | 1 |
| ELIAS, JJ | 1 |
| BERN, HA | 1 |
| NAPALKOV, NP | 1 |
| PITELKA, DR | 1 |
| NISSEN-MEYER, R | 4 |
| SANNER, T | 2 |
| SELLEI, C | 1 |
| KOEROES, Z | 1 |
| ONO, S | 1 |
| DIETRICH, LS | 1 |
| LEMON, HM | 6 |
| PARSONS, L | 2 |
| MOZDEN, PH | 1 |
| STERN, E | 2 |
| HOPKINS, CE | 2 |
| WEINER, JM | 1 |
| MARMORSTON, J | 2 |
| DEMETRIOU, JA | 2 |
| CROWLEY, LG | 4 |
| KUSHINSKY, S | 2 |
| DONOVAN, AJ | 2 |
| KOTIN, P | 2 |
| MACDONALD, I | 1 |
| ROBERTSON, DM | 1 |
| WILLIAMS, DC | 1 |
| PERSSON, BH | 1 |
| RISHOLM, L | 1 |
| CUTTS, JH | 1 |
| NOBLE, RL | 1 |
| UKAI, M | 1 |
| JULL, JW | 1 |
| HEAD, MA | 1 |
| ADAMS, JB | 6 |
| SCHUBERT, K | 3 |
| BACIGALUPO, G | 3 |
| ROSNER, F | 1 |
| LEE, SL | 1 |
| OLINA, A | 1 |
| MYERS, SM | 1 |
| Johansson, R | 2 |
| Berglund, G | 1 |
| Janzon, L | 1 |
| Agren, A | 1 |
| Takashima, S | 2 |
| Murakata, C | 2 |
| Akinaga, S | 2 |
| Saeki, T | 1 |
| Yue, W | 2 |
| Santen, RJ | 20 |
| Wang, JP | 1 |
| Verderame, MF | 1 |
| Bocchinfuso, WP | 1 |
| Korach, KS | 1 |
| Devanesan, P | 1 |
| Todorovic, R | 1 |
| Bhatnagar, AS | 2 |
| Okada, M | 1 |
| Nakagawa, T | 1 |
| Iwashita, S | 1 |
| Takegawa, S | 1 |
| Fujii, T | 1 |
| Koizumi, N | 1 |
| Yamamoto, C | 1 |
| Matsumoto, T | 1 |
| Watanabe, M | 1 |
| Hitzer, EM | 1 |
| Mataka, S | 1 |
| Thiemann, T | 1 |
| ANDERVONT, HB | 1 |
| LEWISON, EF | 1 |
| LEVI, JE | 1 |
| JONES, GS | 1 |
| JONES, HW | 1 |
| SILBERSTEIN, HE | 1 |
| BAUER, R | 1 |
| Rivera, E | 1 |
| Valero, V | 1 |
| Francis, D | 1 |
| Asnis, AG | 1 |
| Schaaf, LJ | 1 |
| Duncan, B | 1 |
| Hortobagyi, GN | 1 |
| Walter, G | 1 |
| Liebl, R | 1 |
| Schernhammer, ES | 1 |
| Rosner, B | 1 |
| Laden, F | 1 |
| Healey, CS | 1 |
| Tee, L | 1 |
| Luben, RN | 1 |
| Novik, KL | 1 |
| Kelemen, L | 1 |
| Ogata, S | 1 |
| Pharoah, PD | 1 |
| Day, NE | 1 |
| Ponder, BA | 1 |
| Sparks, R | 1 |
| Ulrich, CM | 1 |
| Bigler, J | 1 |
| Porter, P | 1 |
| Yuan, X | 1 |
| Lin, MG | 1 |
| McVarish, L | 1 |
| Aiello, EJ | 1 |
| Fabian, CJ | 1 |
| Kimler, BF | 1 |
| Anderson, J | 1 |
| Tawfik, OW | 1 |
| Mayo, MS | 1 |
| Burak, WE | 1 |
| O'Shaughnessy, JA | 1 |
| Albain, KS | 1 |
| Hyams, DM | 1 |
| Budd, GT | 1 |
| Ganz, PA | 1 |
| Beenken, SW | 1 |
| Grizzle, WE | 1 |
| Fruehauf, JP | 1 |
| Arneson, DW | 1 |
| Bacus, JW | 1 |
| Lagios, MD | 1 |
| Johnson, KA | 1 |
| Browne, D | 1 |
| Suzuki, M | 3 |
| Takahashi, K | 1 |
| Yabuuchi, H | 2 |
| Tsuji, A | 2 |
| MUHLBOCK, O | 1 |
| Newman, SP | 6 |
| van der Schouw, YT | 1 |
| van Gils, CH | 1 |
| Love, RR | 2 |
| Hutson, PR | 2 |
| Havighurst, TC | 2 |
| Cleary, JF | 2 |
| Shields-Botella, J | 1 |
| Chetrite, G | 8 |
| Meschi, S | 1 |
| Pasqualini, JR | 20 |
| Sonne-Hansen, K | 1 |
| Lykkesfeldt, AE | 1 |
| Rzepka-Górska, I | 1 |
| Tarnowski, B | 1 |
| Chudecka-Glaz, A | 1 |
| Górski, B | 1 |
| Ghilchik, MW | 14 |
| Leese, MP | 3 |
| Gaukroger, K | 1 |
| Leblond, B | 1 |
| Noh, JJ | 1 |
| Pagano, I | 1 |
| Cheung, LW | 1 |
| Anker, G | 3 |
| Nagata, C | 1 |
| Nagao, Y | 1 |
| Shibuya, C | 1 |
| Kashiki, Y | 1 |
| Shimizu, H | 1 |
| Rogers, E | 1 |
| Husen, B | 1 |
| Poutanen, M | 3 |
| Kangas, L | 1 |
| Messinger, J | 1 |
| Thole, H | 1 |
| Chetrite, GS | 2 |
| Stanway, SJ | 1 |
| Sufi, S | 1 |
| Vigushin, D | 1 |
| Ward, R | 1 |
| Wilson, RH | 1 |
| Dobbs, N | 1 |
| Kulinskaya, E | 1 |
| Elliott, M | 1 |
| Cribb, AE | 1 |
| Knight, MJ | 1 |
| Dryer, D | 1 |
| Guernsey, J | 1 |
| Hender, K | 1 |
| Tesch, M | 1 |
| Saleh, TM | 1 |
| Pfeiffer, E | 1 |
| Graf, E | 1 |
| Gerstner, S | 1 |
| Metzler, M | 1 |
| Fan, J | 1 |
| McKean-Cowdin, R | 1 |
| Li, AX | 1 |
| Adly, L | 1 |
| Hill, D | 1 |
| Fears, T | 1 |
| Mies, C | 1 |
| Kontos, M | 1 |
| Nikolopoulou, M | 1 |
| Trafalis, DT | 1 |
| Geromichalos, GD | 1 |
| Koukoulitsa, C | 1 |
| Camoutsis, JC | 1 |
| Bastounis, E | 1 |
| Karamanakos, P | 1 |
| Takahashi, N | 1 |
| Yang, DJ | 1 |
| Kohanim, S | 1 |
| Oh, CS | 1 |
| Yu, DF | 1 |
| Azhdarinia, A | 1 |
| Kurihara, H | 1 |
| Chang, JY | 1 |
| Kim, EE | 1 |
| Setiawan, VW | 1 |
| Hirsch, K | 1 |
| Atzmon, A | 1 |
| Danilenko, M | 1 |
| Levy, J | 1 |
| Sharoni, Y | 1 |
| Tanaka, H | 1 |
| Sato, N | 1 |
| Terasaki, Y | 1 |
| Takebayashi, M | 1 |
| Anazawa, H | 1 |
| Kuwabara, T | 1 |
| Ociepa-Zawal, M | 1 |
| Rubiś, B | 1 |
| Laciński, M | 1 |
| Trzeciak, WH | 1 |
| Kloosterboer, HJ | 1 |
| von Schoulz, E | 1 |
| von Schoultz, B | 2 |
| Verheul, HA | 1 |
| Murphy, SP | 1 |
| Bremnes, Y | 1 |
| Bjurstam, N | 1 |
| Gram, IT | 1 |
| Kakugawa, Y | 1 |
| Minami, Y | 1 |
| Tateno, H | 1 |
| Inoue, H | 1 |
| Fujiya, T | 1 |
| Traina, TA | 1 |
| Poggesi, I | 1 |
| Robson, M | 1 |
| Asnis, A | 1 |
| Duncan, BA | 1 |
| Heerdt, A | 1 |
| Dang, C | 1 |
| Lake, D | 1 |
| Moasser, M | 1 |
| Panageas, K | 1 |
| Borgen, P | 1 |
| Norton, L | 1 |
| Hudis, C | 1 |
| Dickler, MN | 1 |
| Foster, PA | 1 |
| Parsons, MF | 1 |
| Brozic, P | 1 |
| Lanisnik Risner, T | 1 |
| Gobec, S | 1 |
| Jannuzzo, MG | 1 |
| Di Salle, E | 3 |
| Spinelli, R | 1 |
| Pirotta, N | 1 |
| Buchan, P | 1 |
| Bello, A | 1 |
| Qin, F | 1 |
| Zhao, YY | 1 |
| Sawyer, MB | 1 |
| Li, XF | 1 |
| Young, O | 1 |
| Murray, J | 1 |
| Macaskill, EJ | 1 |
| McHugh, M | 1 |
| Cameron, DA | 1 |
| Hellman, L | 5 |
| Cassouto, J | 2 |
| Gallagher, TF | 3 |
| Stuart-Harris, R | 4 |
| Bozek, T | 1 |
| McKinna, JA | 1 |
| Gazet, JC | 3 |
| Jeffcoate, SL | 8 |
| Kurkure, A | 1 |
| Carr, L | 1 |
| Osawa, Y | 1 |
| Tochigi, B | 1 |
| Higashiyama, T | 1 |
| Yarborough, C | 1 |
| Nakamura, T | 1 |
| Yamamoto, T | 5 |
| Chilvers, C | 1 |
| Ford, HT | 1 |
| Bettelheim, R | 1 |
| Gordon, C | 1 |
| Powles, TJ | 6 |
| Wilking, N | 6 |
| Sköldefors, H | 4 |
| Theve, NO | 3 |
| Wallgren, A | 1 |
| Harris, AL | 12 |
| Bonney, RC | 6 |
| Scanlon, MJ | 1 |
| Jones, DL | 1 |
| Beranek, PA | 9 |
| James, VH | 17 |
| Jeffcoate, S | 1 |
| Döberl, A | 1 |
| Pousette, A | 2 |
| Rannevik, G | 2 |
| Stuart-Harris, RC | 1 |
| Vignon, F | 2 |
| Terqui, M | 1 |
| Westley, B | 1 |
| Derocq, D | 1 |
| Rochefort, H | 3 |
| Jalůvka, V | 1 |
| Kratzsch, E | 1 |
| Molinatti, GM | 1 |
| Limone, P | 1 |
| Samojlik, E | 10 |
| Worgul, TJ | 3 |
| Davidson, K | 1 |
| Rose, DP | 2 |
| Davis, TE | 2 |
| Adams, J | 1 |
| Garcia, M | 2 |
| Wells, SA | 5 |
| Vallent, K | 1 |
| Fehér, T | 1 |
| Bodrogi, L | 1 |
| Ribai, Z | 1 |
| Poortman, J | 7 |
| Tseng, L | 1 |
| Mazella, J | 1 |
| Lee, LY | 1 |
| Stone, ML | 1 |
| Prost, O | 2 |
| Turrel, MO | 1 |
| Dahan, N | 1 |
| Craveur, C | 1 |
| Adessi, GL | 2 |
| Tilson-Mallett, N | 1 |
| Santner, SJ | 5 |
| Feil, PD | 3 |
| Mason, RC | 2 |
| Hawkins, RA | 3 |
| Brown, MS | 1 |
| Forrest, AP | 1 |
| Trichopoulos, D | 6 |
| Yen, S | 2 |
| Brown, J | 5 |
| Cole, P | 9 |
| MacMahon, B | 10 |
| Perel, E | 6 |
| Stolee, KH | 1 |
| Kharlip, L | 3 |
| Blackstein, ME | 3 |
| Killinger, DW | 6 |
| Iacobelli, S | 2 |
| Scambia, G | 1 |
| Natoli, V | 1 |
| Natoli, C | 1 |
| Sica, G | 1 |
| Singhakowinta, A | 1 |
| Drafta, D | 2 |
| Schindler, AE | 2 |
| Milcu, SM | 1 |
| Keller, E | 1 |
| Stroe, E | 2 |
| Horodniceanu, E | 1 |
| Bălănescu, I | 1 |
| Jozan, S | 2 |
| Kreitmann, B | 1 |
| Bayard, F | 2 |
| Fukushima, DK | 2 |
| O'Connor, J | 3 |
| Rosenfeld, RS | 2 |
| Graepel, GJ | 1 |
| Elston, R | 1 |
| Lynch, H | 1 |
| Prişcu, A | 1 |
| Neacşu, E | 1 |
| Gangură, M | 1 |
| Anghel, C | 1 |
| Panaitescu, G | 1 |
| Rémy-Martin, A | 1 |
| Nicollier, M | 1 |
| Burnod, J | 1 |
| Gunduz, N | 1 |
| Zheng, S | 1 |
| Fisher, B | 1 |
| Pewnim, T | 2 |
| Ho, KP | 1 |
| Brown, JB | 10 |
| Garas, J | 1 |
| Papaioannou, A | 1 |
| Fournier, S | 1 |
| Kuttenn, F | 1 |
| de Cicco, F | 1 |
| Baudot, N | 1 |
| Malet, C | 1 |
| Mauvais-Jarvis, P | 1 |
| Hansen, ER | 1 |
| Kirschner, MA | 3 |
| Ertel, NH | 1 |
| Judd, HL | 3 |
| Barone, RM | 3 |
| Laufer, LR | 1 |
| Gambone, JC | 1 |
| Monfort, SL | 1 |
| Lasley, BL | 1 |
| Zaki, K | 1 |
| El-Kharadly, M | 1 |
| El-Faras, A | 1 |
| Nour, H | 1 |
| Kamel, NI | 1 |
| MacIndoe, JH | 2 |
| Woods, GR | 1 |
| Etre, LA | 1 |
| Gustafsson, SA | 1 |
| Tollbom, O | 1 |
| Andersen, AP | 1 |
| Dewaard, F | 1 |
| Kauraniemi, T | 1 |
| Ravhinar, B | 1 |
| Stormby, N | 1 |
| Westlund, K | 1 |
| Davis, S | 1 |
| Schatz, F | 1 |
| Hochberg, RB | 1 |
| Van Landeghem, AA | 3 |
| Deshpande, N | 1 |
| Di Martino, L | 1 |
| Tarquini, A | 1 |
| Schwarz, F | 4 |
| Vakil, DV | 2 |
| Morgan, RW | 4 |
| Elinson, L | 2 |
| Wilkins, D | 1 |
| Budnick, RM | 1 |
| Dao, TL | 9 |
| Nenci, I | 1 |
| Dandliker, WB | 2 |
| Meyers, CY | 2 |
| Marchetti, E | 1 |
| Marzola, A | 1 |
| Fabris, G | 1 |
| Abul-Hajj, YJ | 2 |
| Hösch, S | 1 |
| Diamandis, EP | 1 |
| Zarghami, N | 1 |
| Grass, L | 1 |
| Helle, SI | 2 |
| Johannessen, DC | 6 |
| Lien, EA | 2 |
| Tally, M | 1 |
| Fotsis, T | 2 |
| Anker, GB | 1 |
| Hall, K | 1 |
| Williams, GJ | 2 |
| Haarstad, H | 1 |
| Gundersen, S | 1 |
| Raabe, N | 1 |
| Kvinnsland, S | 7 |
| Stampfer, MJ | 1 |
| Speizer, FE | 2 |
| Nguyen, BL | 6 |
| Maloche, C | 2 |
| Delalonde, L | 2 |
| Talbi, M | 3 |
| Feinstein, MC | 2 |
| Blacker, C | 2 |
| Botella, J | 1 |
| Paris, J | 1 |
| Duncan, LJ | 2 |
| Roberts, CJ | 1 |
| Gutai, JP | 3 |
| Toniolo, PG | 1 |
| Levitz, M | 1 |
| Banerjee, S | 1 |
| Strax, P | 1 |
| Pasternack, BS | 1 |
| Pommier, RF | 3 |
| Woltering, EA | 3 |
| Fletcher, WS | 3 |
| Pillai, R | 1 |
| Dibbelt, L | 1 |
| Smithers, D | 1 |
| Moore, J | 1 |
| Trunet, PF | 3 |
| Rubens, R | 1 |
| Pelletier, JD | 1 |
| Labrie, F | 6 |
| Mäkelä, S | 2 |
| Lehtimäki, J | 1 |
| Kostian, ML | 2 |
| Santti, R | 2 |
| Vihko, R | 2 |
| Macdiarmid, F | 1 |
| Wang, D | 1 |
| Ghilchick, MW | 1 |
| Demers, LM | 4 |
| Massobrio, M | 1 |
| Migliardi, M | 1 |
| Cassoni, P | 1 |
| Menzaghi, C | 1 |
| Revelli, A | 1 |
| Cenderelli, G | 1 |
| Reichman, ME | 1 |
| Judd, JT | 1 |
| Brown, C | 1 |
| Campbell, WS | 2 |
| Franz, C | 2 |
| Kahle, L | 2 |
| Wada, T | 1 |
| Nomura, Y | 3 |
| Oohashi, Y | 1 |
| Abe, O | 2 |
| Koyama, H | 1 |
| Blumberg-Tick, J | 1 |
| Mehta, RR | 3 |
| Das Gupta, TK | 3 |
| Ferme, I | 1 |
| Couture, P | 1 |
| Thériault, C | 1 |
| Lipton, A | 5 |
| Harvey, HA | 2 |
| Hanagan, J | 2 |
| Mulagha, M | 2 |
| Iveson, TJ | 1 |
| Ahern, J | 1 |
| Smithers, DA | 1 |
| Duncan, L | 1 |
| Kambic, KB | 1 |
| Grossberg, H | 1 |
| Brady, C | 1 |
| Ohlsson-Wilhelm, B | 1 |
| Bagga, D | 1 |
| Ashley, JM | 1 |
| Geffrey, SP | 1 |
| Wang, HJ | 1 |
| Barnard, RJ | 1 |
| Korenman, S | 1 |
| Heber, D | 1 |
| Lai, LC | 6 |
| Erbas, H | 2 |
| Lennard, TW | 1 |
| Peaston, RT | 1 |
| Wang, DY | 3 |
| Hermon, C | 1 |
| Moore, JW | 1 |
| Bulbrook, RD | 3 |
| Lipworth, L | 1 |
| Adami, HO | 4 |
| Mantzoros, C | 1 |
| Azzi, A | 1 |
| Rehse, PH | 1 |
| Campbell, RL | 1 |
| Lu, Q | 1 |
| Nakmura, J | 1 |
| Savinov, A | 1 |
| Dabbs, DJ | 1 |
| Wolz, G | 1 |
| Brodie, A | 1 |
| Biberger, C | 1 |
| Taibi, G | 1 |
| Lo Casto, M | 1 |
| Comito, L | 1 |
| Oliveri, G | 1 |
| Di Falco, M | 1 |
| Nestour, EL | 1 |
| Jagannathan, S | 1 |
| Rhodes, ME | 1 |
| Dikkeschei, LD | 2 |
| Wolthers, BG | 1 |
| Bos-Zuur, I | 1 |
| de la Rivière, GB | 1 |
| Nagel, GT | 1 |
| van der Kolk, DA | 1 |
| Willemse, PH | 3 |
| Hegde, PV | 1 |
| Nagaya, N | 1 |
| Sunahara, S | 1 |
| Kurimoto, F | 1 |
| Cocconi, G | 1 |
| Scaglione, F | 1 |
| Fraschini, F | 1 |
| Pfister, C | 1 |
| Cortes-Prieto, J | 1 |
| Ruiz, A | 1 |
| Stephenson, HE | 1 |
| Miller, R | 1 |
| Tangrea, JA | 1 |
| Lum, SS | 1 |
| de Jong, PC | 1 |
| van de Ven, J | 1 |
| Nortier, HW | 1 |
| Maitimu-Smeele, I | 2 |
| Donker, TH | 1 |
| Slee, PH | 1 |
| Blankenstein, RA | 1 |
| Di Silverio, F | 1 |
| Sciarra, A | 1 |
| Flammia, GP | 1 |
| Mariani, M | 1 |
| De Vico, A | 1 |
| Bajetta, E | 3 |
| Zilembo, N | 3 |
| Noberasco, C | 2 |
| Martinetti, A | 3 |
| Mariani, L | 1 |
| Ferrari, L | 3 |
| Buzzoni, R | 3 |
| Greco, M | 1 |
| Bartoli, C | 1 |
| Spagnoli, I | 1 |
| Danesini, GM | 1 |
| Artale, S | 1 |
| Paolini, J | 2 |
| Barni, S | 1 |
| Schieppati, G | 1 |
| Jirillo, A | 1 |
| Amichetti, M | 1 |
| D'Aprile, M | 1 |
| Comella, G | 1 |
| Bichisao, E | 2 |
| Bolelli, GF | 2 |
| Attili, A | 1 |
| Bombardieri, E | 1 |
| Boccardo, F | 1 |
| Amoroso, D | 1 |
| Irtelli, L | 1 |
| Farris, A | 1 |
| Mustacchi, G | 2 |
| Mesiti, M | 2 |
| Brema, F | 1 |
| Pacini, P | 1 |
| Cortesi, E | 1 |
| Nardini, P | 1 |
| Guida, G | 1 |
| Langenaeken, C | 1 |
| Couillard, S | 3 |
| Gutman, M | 2 |
| Labrie, C | 3 |
| Bélanger, A | 2 |
| Candas, B | 3 |
| Lehtimäki, N | 1 |
| Strauss, L | 1 |
| Pouliot, F | 1 |
| Vernon, KA | 1 |
| Hummelinck, AE | 1 |
| Lundgren, S | 4 |
| Berntsen, H | 2 |
| Greaves, JL | 1 |
| King, N | 1 |
| Ornati, G | 2 |
| Le Nestour, E | 1 |
| Engan, T | 1 |
| Zurlo, MG | 1 |
| Piscitelli, G | 1 |
| Lonning, PE | 4 |
| Jones, A | 3 |
| Johnston, SR | 1 |
| Jacobs, S | 5 |
| Trunet, P | 2 |
| Xiong, Y | 1 |
| Ebert, C | 1 |
| Wright, F | 1 |
| Philippe, JC | 1 |
| Chobanyan, NS | 1 |
| de Giovani, CV | 1 |
| Kiura, P | 1 |
| Abplanalp, W | 1 |
| Rymaszewski, M | 1 |
| Adamski, J | 1 |
| Subbiah, MT | 1 |
| Feutrie, ML | 1 |
| Ito, Y | 1 |
| Gajalakshmi, KC | 1 |
| Sasaki, R | 1 |
| Suzuki, K | 1 |
| Shanta, V | 1 |
| Budai, B | 1 |
| Willemsen, EL | 1 |
| de Winkel, A | 1 |
| Parish, D | 1 |
| Szamel, I | 1 |
| Probst-Hensch, NM | 1 |
| Diep, AT | 1 |
| Haile, RW | 1 |
| Arcuri, F | 2 |
| Sestini, S | 1 |
| Ricci, C | 1 |
| Runci, Y | 1 |
| Carducci, A | 1 |
| Paulesu, L | 1 |
| Cintorino, M | 1 |
| Campagnoli, C | 1 |
| Ambroggio, S | 1 |
| Biglia, N | 1 |
| Sismondi, P | 1 |
| Donaldson, K | 1 |
| Tsuboi, M | 1 |
| Wong, J | 1 |
| Yates, R | 1 |
| Mu, YM | 1 |
| Yanase, T | 1 |
| Nishi, Y | 1 |
| Hirase, N | 1 |
| Goto, K | 1 |
| Takayanagi, R | 1 |
| Nawata, H | 1 |
| Woo, LL | 1 |
| Malini, B | 2 |
| Pozzi, P | 1 |
| Bidoli, P | 1 |
| Celio, L | 1 |
| Barrow, D | 1 |
| Nicholson, RI | 2 |
| Burczynski, ME | 1 |
| Jez, JM | 1 |
| Lin, HK | 1 |
| Ma, H | 1 |
| Moore, M | 1 |
| Ratnam, K | 1 |
| Palackal, N | 1 |
| Wilson, M | 1 |
| Monroe, K | 1 |
| Lee, HP | 1 |
| Seow, A | 1 |
| Yu, MC | 1 |
| Mady, EA | 1 |
| Ramadan, EE | 1 |
| Ossman, AA | 1 |
| Yao, D | 1 |
| Ide, K | 1 |
| Ishida, M | 1 |
| Hooymans, C | 1 |
| Kumar, NB | 1 |
| Cantor, A | 1 |
| Allen, K | 1 |
| Riccardi, D | 1 |
| Cox, CE | 1 |
| Appleby, P | 1 |
| Barnes, I | 1 |
| Reeves, G | 1 |
| Ashok, BT | 1 |
| Pollow, K | 1 |
| Boquoi, E | 1 |
| Baumann, J | 1 |
| Schmidt-Gollwitzer, M | 1 |
| Pollow, B | 1 |
| Wynder, EL | 2 |
| Hill, P | 2 |
| Rimsten, A | 2 |
| Wide, L | 1 |
| Veldhuis, J | 2 |
| Harvey, H | 3 |
| Helman, P | 1 |
| Hickman, R | 1 |
| Rona, G | 1 |
| Kuno, K | 1 |
| Calabresi, E | 1 |
| De Giuli, G | 1 |
| Becciolini, A | 1 |
| Giannotti, P | 1 |
| Lombardi, G | 1 |
| Serio, M | 2 |
| Lachelin, GC | 1 |
| Yen, SC | 1 |
| Alksne, JF | 1 |
| Archibald, L | 2 |
| Clarke, C | 1 |
| Maeyama, M | 1 |
| Mori, N | 1 |
| Miyakawa, I | 1 |
| Higashi, S | 1 |
| Godefroi, VC | 1 |
| Locke, ER | 2 |
| Singh, DV | 1 |
| Sakai, F | 1 |
| Saez, S | 2 |
| Lauritzen, C | 1 |
| Ruby, EB | 1 |
| Kendall, J | 1 |
| Cramer, D | 2 |
| Seller, JC | 1 |
| Wasada, T | 1 |
| Akamine, Y | 1 |
| Kato, K | 1 |
| Ibayashi, H | 1 |
| Brawn, RJ | 1 |
| Hsu, ML | 1 |
| Brawn, PN | 1 |
| Levin, J | 1 |
| Kolb, VM | 1 |
| Nimrod, A | 1 |
| Ryan, KJ | 1 |
| Santner, S | 1 |
| Davis, B | 1 |
| Ruby, E | 1 |
| Morreal, CE | 4 |
| Nemoto, T | 2 |
| Lonergan, PA | 1 |
| Vorherr, H | 1 |
| Messer, RH | 1 |
| Lynch, HT | 3 |
| Moure, C | 1 |
| Gillois, M | 1 |
| Shamonki, IM | 1 |
| Harris, RE | 1 |
| Lynch, JF | 2 |
| Marrero, K | 1 |
| Maloney, K | 2 |
| Chandra, DP | 1 |
| Foo, MS | 1 |
| de Thibault de Boesinghe, L | 2 |
| Eechaute, W | 2 |
| Lacroix, E | 2 |
| D'Agata, R | 1 |
| Monaco, ME | 2 |
| Lippman, ME | 1 |
| Loriaux, DL | 2 |
| Cohen, FB | 1 |
| Ryan, C | 1 |
| Johansson, ED | 1 |
| Vegelius, J | 1 |
| Victor, A | 1 |
| Lipsett, MB | 3 |
| Nisselbaum, JS | 1 |
| Menendez-Botet, CJ | 1 |
| Schwartz, MK | 1 |
| Newsome, HH | 1 |
| Brown, PW | 1 |
| Terz, JJ | 1 |
| Lawrence, W | 1 |
| Paffenbarger, R | 1 |
| Borkowski, A | 1 |
| Dosogne, M | 1 |
| Declercq, P | 1 |
| Murquardt, C | 1 |
| Machin, D | 1 |
| Varela, RM | 1 |
| Martin, PM | 1 |
| Chouvet, CD | 1 |
| Fukushima, D | 1 |
| Guirgis, H | 1 |
| Pratt, JH | 2 |
| Horn, L | 1 |
| Bird, CE | 1 |
| Finnis, W | 1 |
| Boroomand, K | 1 |
| Murphy, J | 1 |
| Clark, AF | 1 |
| de Waard, F | 3 |
| Lippman, M | 1 |
| Bolan, G | 1 |
| Gross, J | 1 |
| Modan, B | 1 |
| Bertini, B | 1 |
| Spira, O | 1 |
| Vestergaard, P | 1 |
| Donegan, WL | 2 |
| Casagrande, JT | 1 |
| Gerkins, V | 2 |
| Kiang, DT | 1 |
| Kennedy, BJ | 1 |
| Arsen'eva, MG | 1 |
| Savchenko, ON | 1 |
| Stepanov, GS | 1 |
| Ryzhova, RK | 1 |
| Swain, MC | 1 |
| Hayward, JL | 1 |
| Kumaoka, S | 1 |
| Takatani, O | 1 |
| Utsunomiya, J | 1 |
| Sherman, MR | 1 |
| Miller, LK | 1 |
| Henderson, BR | 1 |
| Rosario, I | 1 |
| Casagrande, J | 1 |
| Geier, A | 1 |
| Horn, H | 1 |
| Levij, IS | 1 |
| Lichtshtein, E | 1 |
| Finkelstein, M | 1 |
| Tei, N | 2 |
| Kitamura, M | 2 |
| Kudo, Y | 1 |
| Azuma, Y | 1 |
| Tsygan, VM | 1 |
| Russu, ID | 1 |
| Skul'skaia, SF | 1 |
| Donker, GH | 2 |
| Daroszewski, J | 4 |
| Milewicz, A | 3 |
| Jones, AL | 1 |
| MacNeill, F | 1 |
| Hisamatsu, K | 1 |
| Tashiro, H | 1 |
| Varin, C | 1 |
| Riaz, AA | 1 |
| Honjo, H | 3 |
| Newton, CJ | 3 |
| Butta, A | 1 |
| Nicholls, J | 1 |
| Beattie, CW | 1 |
| Szymczak, J | 1 |
| Garland, CF | 1 |
| Friedlander, NJ | 1 |
| Khaw, KT | 1 |
| Lynch, J | 1 |
| Garber, JE | 1 |
| Henderson, IC | 1 |
| Navari, RM | 1 |
| Cantwell, BM | 6 |
| Griggs, L | 1 |
| Powles, T | 2 |
| Mancini, A | 1 |
| Di Pietro, C | 1 |
| De Marinis, L | 1 |
| Rossi, S | 1 |
| Lombardi, CP | 1 |
| Bellantone, R | 1 |
| Liberale, I | 1 |
| Menini, E | 1 |
| Crucitti, F | 1 |
| Jarman, M | 1 |
| Griggs, LJ | 1 |
| Stein, R | 1 |
| Mann, VZ | 1 |
| Tait, GH | 1 |
| Miodrag, A | 1 |
| Ekelund, P | 1 |
| Burton, R | 1 |
| Castleden, CM | 1 |
| Wild, MJ | 1 |
| Rudland, PS | 1 |
| Back, DJ | 1 |
| Aherne, GW | 1 |
| Patel, S | 1 |
| Chakraborty, J | 1 |
| Coldham, NG | 5 |
| Yasumura, T | 4 |
| Akami, T | 1 |
| Mitsuo, M | 1 |
| Oka, T | 2 |
| Naitoh, K | 3 |
| Honjyo, H | 2 |
| Okada, H | 4 |
| Castagnetta, L | 1 |
| Brignone, G | 1 |
| Blasi, L | 1 |
| D'Aquino, A | 1 |
| Preitano, W | 1 |
| Tjabbes, T | 1 |
| van Veelen, H | 2 |
| Sleijfer, DT | 2 |
| Stein, RC | 2 |
| Klepp, R | 1 |
| Bruning, PF | 2 |
| Bonfrèr, JM | 2 |
| Wildiers, J | 1 |
| Jassem, J | 1 |
| Beex, LV | 1 |
| Schornagel, J | 1 |
| Nooijen, WJ | 2 |
| Beretta, KR | 1 |
| Hoeffken, K | 1 |
| Chaudri, HA | 1 |
| Goldhirsch, A | 1 |
| Cavalli, F | 1 |
| Magini, A | 2 |
| Pazzagli, M | 2 |
| Salerno, R | 2 |
| Simonis, M | 1 |
| Islam, S | 1 |
| Owen, AM | 2 |
| Shaikh, NA | 2 |
| Baltali, E | 1 |
| Souadka, A | 1 |
| el Hafed, A | 1 |
| Wydadi, M | 1 |
| Kettani, F | 1 |
| Alamy, H | 1 |
| el Gueddari, B | 1 |
| Morchid, M | 1 |
| Bouih, A | 1 |
| Souadka, F | 1 |
| Utaaker, E | 1 |
| Aakvaag, A | 1 |
| Gelly, C | 7 |
| Urabe, M | 2 |
| Ogino, Y | 2 |
| Kitawaki, J | 1 |
| Yasuda, J | 1 |
| Carmichael, J | 2 |
| Walker, KJ | 1 |
| Walker, RF | 1 |
| Read, GF | 1 |
| Turkes, A | 1 |
| Robertson, JF | 1 |
| Blamey, RW | 1 |
| Thorsen, T | 4 |
| Nambara, T | 1 |
| Fukuoka, M | 1 |
| Schem, B | 1 |
| Hardy, J | 1 |
| Hart, AA | 1 |
| van der Linden, E | 1 |
| de Jong-Bakker, M | 1 |
| Moolenaar, AJ | 1 |
| Eby, NL | 1 |
| Boice, JD | 1 |
| Gold, EB | 1 |
| Pinzani, P | 1 |
| Bassi, F | 1 |
| Messeri, G | 1 |
| Cunningham, DC | 1 |
| Evans, S | 1 |
| Dehennin, L | 1 |
| Hedley, A | 1 |
| Hill, M | 1 |
| Hutchison, G | 1 |
| Brodie, AM | 1 |
| Sainsbury, JR | 1 |
| Needham, G | 1 |
| Farndon, J | 1 |
| Wilson, R | 1 |
| Lal, A | 1 |
| Keenan, EJ | 1 |
| Shultz, TD | 1 |
| Wilcox, RB | 1 |
| Spuehler, JM | 1 |
| Howie, BJ | 1 |
| Schwartz, L | 1 |
| Guiochet, N | 1 |
| Keiling, R | 1 |
| D'Souza, A | 1 |
| Donaldson, A | 1 |
| Lecerf, F | 2 |
| Valcourt, L | 1 |
| Graves, J | 1 |
| Green, R | 1 |
| Sluiter, WJ | 1 |
| Doorenbos, H | 1 |
| Helin, HJ | 1 |
| Isola, JJ | 1 |
| Helle, MJ | 1 |
| Phillips, NS | 1 |
| Hall, R | 1 |
| Vollmer, G | 1 |
| Wünsche, WO | 1 |
| Knuppen, R | 1 |
| Daniilescu, D | 2 |
| Blackstein, M | 1 |
| Ueland, PM | 1 |
| Leszczynski, D | 2 |
| Wright, C | 2 |
| Manni, A | 2 |
| Simberg, N | 1 |
| Murai, J | 2 |
| Ernster, VL | 1 |
| Wrensch, MR | 1 |
| Petrakis, NL | 1 |
| King, EB | 1 |
| Miike, R | 1 |
| Goodson, WH | 1 |
| Benz, C | 1 |
| Gandara, D | 1 |
| Miller, B | 1 |
| Drakes, T | 1 |
| Monroe, S | 1 |
| Wilbur, B | 1 |
| DeGregorio, M | 1 |
| Tilson-Mallet, N | 1 |
| Capony, F | 1 |
| Smith, RE | 1 |
| Bezwoda, WR | 1 |
| Mansoor, N | 1 |
| Dansey, R | 1 |
| Esser, JD | 1 |
| Reddel, RR | 1 |
| Sutherland, RL | 1 |
| Begg, L | 1 |
| Caggiula, AG | 1 |
| Wolmark, N | 1 |
| Watson, CG | 1 |
| McNeill, JM | 2 |
| Robinson, DJ | 1 |
| De Ryck, LM | 1 |
| Ross, JB | 1 |
| Petra, PH | 1 |
| Gurpide, E | 1 |
| Dai, QT | 1 |
| Xing, LY | 1 |
| Lu, WY | 1 |
| Yang, WX | 1 |
| Wang, ZG | 1 |
| Yao, FY | 1 |
| Enriori, CL | 1 |
| Orsini, W | 1 |
| del Carmen Cremona, M | 1 |
| Etkin, AE | 1 |
| Cardillo, LR | 1 |
| Reforzo-Membrives, J | 1 |
| Nabuurs, M | 1 |
| Thomson, ML | 1 |
| Killen, E | 1 |
| Beardwell, CG | 1 |
| Hindley, AC | 1 |
| Wilkinson, PM | 1 |
| St John, J | 1 |
| Bu'lock, D | 1 |
| Eller, J | 1 |
| Aoki, K | 2 |
| Lin, TM | 2 |
| Woo, N | 1 |
| Argüelles, AE | 1 |
| Poggi, UL | 1 |
| Saborida, C | 1 |
| Hoffman, C | 1 |
| Chekherdemian, M | 1 |
| Blanchard, O | 1 |
| Leusen, I | 1 |
| Smith, OW | 1 |
| Smith, GV | 1 |
| Frankenberg, G | 2 |
| Libby, PR | 2 |
| Bordiushkov, IuN | 1 |
| Mindlin, SS | 1 |
| Verkhovtseva, AI | 1 |
| Hayes, C | 1 |
| Millington, D | 1 |
| Jenner, DA | 1 |
| Jones, T | 1 |
| Griffiths, K | 1 |
| Korenman, SG | 1 |
| Dukes, BA | 1 |
| Fechner, RE | 1 |
| Gewant, WC | 1 |
| Goldenberg, IS | 1 |
| Willcox, PA | 1 |
| Thomas, GH | 1 |
| Saez, JM | 1 |
| Morera, AM | 1 |
| Dazord, A | 1 |
| Bertrand, J | 1 |
| Hähnel, R | 1 |
| Twaddle, E | 1 |
| Schwarz, BE | 1 |
| MacDonald, PC | 1 |
| Dickinson, LE | 1 |
| Kaul, P | 1 |
| Prasad, GC | 1 |
| Gupta, RC | 1 |
| Udupa, KN | 1 |
| Woo, NC | 1 |
| Suemasu, K | 1 |
| Okada, T | 1 |
| Izuo, M | 1 |
| Fujimori, M | 2 |
| Takikawa, H | 1 |
| Dickey, RP | 1 |
| Minton, JP | 1 |
| Morreal, C | 1 |
| Scheike, O | 1 |
| Svenstrup, B | 1 |
| Frandsen, VA | 1 |
| Grattarola, R | 1 |
| Secreto, G | 1 |
| Recchione, C | 1 |
| Castellini, W | 1 |
| Sharoukhova, KS | 1 |
| Muraviova, NI | 1 |
| Kurockin, IF | 1 |
| Vishnyakova, VV | 1 |
| Fukayama, GM | 1 |
| Barrett, C | 1 |
| Wood, PD | 1 |
| Braunsberg, H | 2 |
| Carter, AE | 1 |
| Irvine, WT | 2 |
| James, F | 2 |
| Márton, Z | 1 |
| Gáti, I | 1 |
| Doszpod, J | 1 |
| Preisz, J | 1 |
| Kecskés, L | 1 |
| Lonergan, P | 1 |
| Stern, MI | 1 |
| Plunkett, ER | 1 |
| Yuzpe, A | 1 |
| Engel, LL | 1 |
| Konoplia, EF | 1 |
| Grönroos, M | 1 |
| Aho, AJ | 1 |
| Pearlman, WH | 1 |
| De Hertogh, R | 1 |
| Laumas, KR | 1 |
| Pearlman, MR | 1 |
| Wotiz, HH | 1 |
| Mozden, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double Blind, Placebo Controlled, Cross-over Trial Evaluating the Effects of EstroSense®/MD (PNO) vs Placebo in Increasing 2:16α Ratio and Improving the Estrogen Profile in Females[NCT02385916] | 120 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer The Diindolylmethane Efficacy Study[NCT01391689] | 144 participants (Actual) | Interventional | 2011-02-28 | Completed | |||
| Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio in Premenopausal Mexican Women With Risk of Breast Cancer[NCT02525159] | Phase 3 | 60 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of 3,3'-Diindolylmethane (BR-DIM) in Patients With Systemic Lupus Erythematosus (SLE)[NCT02483624] | Phase 1 | 6 participants (Actual) | Interventional | 2016-01-31 | Terminated | ||
| Breast Cancer and Exercise Trial in Alberta: The BETA Trial[NCT01435005] | 400 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer[NCT00040222] | 377 participants (Actual) | Observational | 2002-07-01 | Completed | |||
| Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.[NCT05163106] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-12-01 | Recruiting | ||
| Energy Balance and Breast Cancer Aspects-II Study[NCT02240836] | 545 participants (Actual) | Interventional | 2014-09-30 | Active, not recruiting | |||
| Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial[NCT00522262] | 320 participants (Actual) | Interventional | 2002-06-30 | Completed | |||
| Pharmacogenetics of Aromatase Inhibitors[NCT00283608] | 1,000 participants (Anticipated) | Observational | 2005-07-31 | Completed | |||
| Effects of Moderate Aerobic Exercise Combined With Caloric Restriction on Circulating Estrogens and IGF-I in Premenopausal Women[NCT05107804] | 47 participants (Actual) | Interventional | 2001-03-31 | Completed | |||
| A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer[NCT00005886] | Phase 1 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
46 reviews available for estrone and Breast Neoplasms
| Article | Year |
|---|---|
Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Female; Humans; Models, Molecular; M | 2015 |
Estrogen metabolism and breast cancer.
Topics: Breast Neoplasms; Cell Transformation, Neoplastic; Cytochrome P-450 Enzyme System; Estradiol; Estrog | 2015 |
Epidemiologic studies of estrogen metabolism and breast cancer.
Topics: Breast Neoplasms; Chromatography, Liquid; Epidemiologic Studies; Estrogens; Female; Humans; Hydroxye | 2015 |
[Estrogen-dependent neoplasia - what is the significance of estradiol metabolites].
Topics: 2-Methoxyestradiol; Anticarcinogenic Agents; Breast Neoplasms; Estradiol; Estrogens, Catechol; Femal | 2003 |
2-hydroxyestrone: the 'good' estrogen.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Estrogens, Catechol; Female; Humans; Hydroxyestrones; Hyd | 1996 |
Breast Cancer: Targeting of Steroid Hormones in Cancerogenesis and Diagnostics.
Topics: Androstenedione; Biomarkers, Tumor; Breast Neoplasms; Dehydroepiandrosterone; Dihydrotestosterone; E | 2021 |
Mechanisms of estrogen carcinogenesis: The role of E2/E1-quinone metabolites suggests new approaches to preventive intervention--A review.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinogens; Disease Models, Animal; Estradiol; | 2015 |
Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies.
Topics: Body Mass Index; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Postmenopause; Prospective St | 2015 |
[Steroid sulfatase inhibitor].
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Coumarins; Drug Design; Enzyme Inhibitors; Estr | 2010 |
Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II a | 2011 |
Recent data on intratumor estrogens in breast cancer.
Topics: Aromatase; Breast; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Neoplasms, Hormo | 2011 |
Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen | 2003 |
Comparison between aromatase inhibitors and sequential use.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neopla | 2003 |
Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.
Topics: Animals; Aromatase; Breast Neoplasms; Carcinogens; Catechol O-Methyltransferase; Cell Division; Estr | 2003 |
The pharmacology of letrozole.
Topics: Adrenocorticotropic Hormone; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast | 2003 |
Steroid sulfatase: molecular biology, regulation, and inhibition.
Topics: Animals; Breast Neoplasms; Clinical Trials, Phase I as Topic; Coumarins; Enzyme Inhibitors; Estrone; | 2005 |
Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Topics: 17-Hydroxysteroid Dehydrogenases; Aromatase; Biotransformation; Breast Neoplasms; Cell Line, Tumor; | 2005 |
Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogens; Estrone | 2008 |
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
[Hormone activity of various Brenner tumors].
Topics: Aged; Breast Neoplasms; Brenner Tumor; Estradiol; Estrone; Female; Humans; Neoplasm Metastasis; Neop | 1982 |
[Hormones and breast cancer. Current views].
Topics: Androstenedione; Animals; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; | 1982 |
Steroid hormones in breast cancer.
Topics: Adult; Androgens; Breast Neoplasms; Cytoplasm; Drug Therapy; Endocrine Glands; Estradiol; Estriol; E | 1982 |
Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma.
Topics: Adolescent; Adult; Aged; Animals; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; | 1980 |
The role of cytokines and sulphatase inhibitors in regulating oestrogen synthesis in breast tumours.
Topics: Breast Neoplasms; Cytokines; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol Dehyd | 1995 |
Hormonal profiles in women with breast cancer.
Topics: Adolescent; Adult; Aged; Androgens; Animals; Anovulation; Breast Neoplasms; Child; Estradiol; Estrio | 1994 |
The role of aromatase in breast tumors.
Topics: Androstenedione; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; DNA Polym | 1994 |
Control and expression of oestrone sulphatase activities in human breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrone; Female; Humans; Sulfatases | 1996 |
Role, control and expression of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase activities in human breast cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Neoplasms, H | 1997 |
Regulation of steroid sulphatase and oestradiol 17 beta-hydroxysteroid dehydrogenase in breast cancer.
Topics: Arylsulfatases; Breast Neoplasms; Enzyme Inhibitors; Estradiol Dehydrogenases; Estrogens; Estrone; F | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
Conjugated estrogens and breast cancer risk.
Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estrogens, Conjugated (USP); Estrone; Female; Hormone Repl | 1999 |
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.
Topics: Aged; Androstenedione; Breast Neoplasms; Case-Control Studies; Dehydroepiandrosterone; Dehydroepiand | 2002 |
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy | 1977 |
The role of hormones in the etiology of human breast cancer.
Topics: 17-Ketosteroids; Androgens; Androsterone; Breast Neoplasms; Contraceptives, Oral, Hormonal; Estradio | 1977 |
Breast cancer: potentially predisposing and protecting factors. Role of pregnancy, lactation, and endocrine status.
Topics: Adult; Age Factors; Aged; Animals; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; | 1978 |
Post-menopausal estrogen production, with special reference to patients with mammary carcinoma.
Topics: Age Factors; Aged; Androgens; Androstenedione; Binding, Competitive; Body Weight; Breast Neoplasms; | 1975 |
The metabolism of steroid hormones in breast cancer: a reappraisal.
Topics: Androgens; Androsterone; Breast Neoplasms; Cytochrome P-450 Enzyme System; Estradiol; Estriol; Estro | 1976 |
Hormones, nutrition, and cancer.
Topics: Androstenedione; Anovulation; Breast Neoplasms; Estrogens; Estrone; Female; Hormones; Humans; Neopla | 1975 |
[Endogenous levels and dynamics of estrogen sulfates--physiological and pathological roles of estrone sulfate and estradiol 17-sulfate].
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Breast Neoplasms; Estradiol; Estrone; Female; Huma | 1992 |
Regulation of oestradiol 17 beta hydroxysteroid dehydrogenase in breast tissues: the role of growth factors.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast; Breast Neoplasms; Cells, Cultured; Estradiol; Estrogens; E | 1991 |
Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Topics: 17-Hydroxysteroid Dehydrogenases; Adrenalectomy; Aminoglutethimide; Androstenedione; Animals; Aromat | 1986 |
The 52K estrogen-regulated protein secreted by breast cancer cells and its clinical potential.
Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Division; Cell Line; Cells, Cultured; Diethylstilbest | 1986 |
Dietary fat and breast cancer.
Topics: Breast Neoplasms; Dietary Fats; Estradiol; Estriol; Estrone; Feeding Behavior; Female; Humans; Lipid | 1987 |
Determinants of tissue oestradiol levels in human breast cancer.
Topics: Aromatase; Body Weight; Breast Neoplasms; Estradiol; Estrone; Humans; Kinetics; Models, Biological; | 1986 |
Endocrine influences on human mammary cancer formation. A critique.
Topics: Adrenocorticotropic Hormone; Androgens; Androsterone; Animals; Binding Sites; Breast Diseases; Breas | 1969 |
Endocrine, genetic and viral factors in the etiology of breast cancer.
Topics: Adolescent; Adult; Androsterone; Animals; Breast Diseases; Breast Neoplasms; Castration; Endocrine S | 1972 |
70 trials available for estrone and Breast Neoplasms
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled, cross-over trial to evaluate the effect of EstroSense
Topics: Biomarkers; Breast Neoplasms; Cross-Over Studies; Estrogens; Female; Humans; Hydroxyestrones | 2023 |
A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Double-B | 2017 |
Effect of Dietary Flaxseed Intake on Circulating Sex Hormone Levels among Postmenopausal Women: A Randomized Controlled Intervention Trial.
Topics: Breast Neoplasms; Canada; Diet; Female; Flax; Gonadal Steroid Hormones; Humans; Hydroxyestrones; Lig | 2019 |
The relation of urinary estrogen metabolites with mammographic densities in premenopausal women.
Topics: Adult; Asian People; Breast; Breast Neoplasms; Cell Count; Estrogens; Female; Humans; Hydroxyestrone | 2012 |
Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer.
Topics: Aged; Breast Neoplasms; Dietary Supplements; Estradiol; Estriol; Female; Hormones; Humans; Hydrocort | 2004 |
The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption.
Topics: Bifidobacterium; Breast Neoplasms; Equol; Estrogens; Feeding Behavior; Female; Glycine max; Humans; | 2005 |
Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk.
Topics: Adult; Black People; Breast Neoplasms; Case-Control Studies; Cytochrome P-450 CYP1A1; Estradiol; Est | 1999 |
Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women.
Topics: Aged; Analysis of Variance; Anticarcinogenic Agents; Brassica; Breast Neoplasms; Estrogens; Female; | 2000 |
Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurem
Topics: Breast Neoplasms; Chromatography, Liquid; Estradiol; Estrogens; Estrone; Female; Humans; Letrozole; | 2023 |
Weight Regain and Breast Cancer-Related Biomarkers Following an Exercise Intervention in Postmenopausal Women.
Topics: Aged; Biomarkers, Tumor; Body Composition; Breast Neoplasms; Estradiol; Estrone; Exercise Therapy; F | 2021 |
Urinary excretion of sex steroid hormone metabolites after consumption of cow milk: a randomized crossover intervention trial.
Topics: Aged; Androgens; Animals; Breast Neoplasms; Cattle; Cross-Over Studies; Diet; Dietary Fats; Estradio | 2019 |
Sex hormone levels and risk of breast cancer with estrogen plus progestin.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Estradiol; Estrogen Replacement Therapy; Estrogens; Es | 2013 |
Oestrogen levels in serum and urine of premenopausal women eating low and high amounts of meat.
Topics: Adult; Breast Neoplasms; Cross-Over Studies; Estradiol; Estrogens; Estrone; Female; Hawaii; Humans; | 2014 |
Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B~FIT.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density; Breast Neoplasms; Case-Control Studies; Ch | 2014 |
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms | 2015 |
Women In Steady Exercise Research (WISER) Sister: study design and methods.
Topics: Adiponectin; Adult; Breast; Breast Neoplasms; Estrone; Exercise Therapy; Female; Genes, BRCA1; Genes | 2015 |
Effects of Pomegranate Juice on Hormonal Biomarkers of Breast Cancer Risk.
Topics: Androstenedione; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Estradiol; Estrone; Female; F | 2015 |
Effects of exercise dose on endogenous estrogens in postmenopausal women: a randomized trial.
Topics: Aged; Biomarkers; Body Mass Index; Breast Neoplasms; Canada; Diet; Estradiol; Estrogens; Estrone; Ex | 2015 |
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2016 |
Increases in serum estrone sulfate level are associated with increased mammographic density during menopausal hormone therapy.
Topics: Biomarkers, Tumor; Breast Neoplasms; Contraceptives, Oral, Synthetic; Drug Therapy, Combination; Est | 2008 |
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chromatography, High | 2008 |
Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women.
Topics: Aged; Androstenedione; Breast Neoplasms; Estradiol; Estrone; Exercise; Female; Humans; Middle Aged; | 2010 |
Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women.
Topics: Aged; Androstenedione; Breast Neoplasms; Estradiol; Estrone; Exercise; Female; Humans; Middle Aged; | 2010 |
Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women.
Topics: Aged; Androstenedione; Breast Neoplasms; Estradiol; Estrone; Exercise; Female; Humans; Middle Aged; | 2010 |
Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women.
Topics: Aged; Androstenedione; Breast Neoplasms; Estradiol; Estrone; Exercise; Female; Humans; Middle Aged; | 2010 |
Estrogen and progesterone exposure is reduced in response to energy deficiency in women aged 25-40 years.
Topics: Adult; Body Composition; Breast Neoplasms; Caloric Restriction; Estradiol; Estrogens; Estrone; Exerc | 2010 |
CYP3A variation, premenopausal estrone levels, and breast cancer risk.
Topics: Adult; Age Factors; Androgens; Breast Neoplasms; Case-Control Studies; Cross-Sectional Studies; Cyto | 2012 |
Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors | 2002 |
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progres | 2003 |
Diet and sex hormones in girls: findings from a randomized controlled clinical trial.
Topics: Adolescent; Androstenedione; Breast Neoplasms; Child; Dehydroepiandrosterone; Diet, Fat-Restricted; | 2003 |
Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy | 2004 |
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
Topics: Anticarcinogenic Agents; Biopsy; Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estr | 2004 |
Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; A | 2005 |
Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androstenediol; Breast Neoplasms; Coumarins; D | 2006 |
Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days.
Topics: Aged; Androstenols; Breast; Breast Neoplasms; Chromatography, Liquid; Double-Blind Method; Estradiol | 2007 |
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Therapy, Combination; Estradiol; | 2008 |
Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone.
Topics: Adult; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Estradiol; Estr | 2009 |
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, | 2008 |
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Dehydroepiandrosterone; | 1982 |
Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sul | 1983 |
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone | 1984 |
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
The role of aromatase inhibitors in breast cancer.
Topics: Aged; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as | 1983 |
Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Combined Modality Therapy; Estradio | 1984 |
Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Follicle S | 1995 |
Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer.
Topics: Aged; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogens, Conjugated (USP); Estrone; Femal | 1995 |
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, | 1994 |
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Fadrozole; Female; Humans; Le | 1994 |
[Late phase II study of CGS16949A, a new aromatase inhibitor--a multicentral cooperative study (Western Japan Group)].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Estradiol; Estron | 1994 |
The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Breast Neoplasms; Estradiol; Estrone; Fadrozole; Female; H | 1993 |
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Humans; Letrozole; Microsomes; Middle Ag | 1993 |
The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.
Topics: Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Breast Neoplasms; Cosynt | 1993 |
Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study.
Topics: Adult; Aged; Aldosterone; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhi | 1996 |
Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
Topics: Aged; Antineoplastic Agents; Aromatase; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Hum | 1997 |
The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplas | 1997 |
A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
Topics: Adult; Aged; Aged, 80 and over; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast | 1997 |
Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; E | 1997 |
Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; C | 1998 |
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
Topics: Administration, Oral; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase; Aromatase I | 1998 |
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Topics: Aged; Alprostadil; Androgens; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Ne | 1997 |
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme | 1995 |
Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Topics: Administration, Oral; Aged; Androstenedione; Appetite Stimulants; Area Under Curve; Breast Neoplasms | 1996 |
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhi | 2002 |
The specific role of isoflavones on estrogen metabolism in premenopausal women.
Topics: Administration, Oral; Adult; Anthropometry; Anticarcinogenic Agents; Breast Neoplasms; Estradiol; Es | 2002 |
Adrenal steroids as parameters of the bioavailability of MA and MPA.
Topics: Adrenal Cortex Hormones; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Biological | 1990 |
Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--II. A differential effect of megestrol acetate and medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Estradiol; Estrone; Humans; Medroxyprogesterone; Medroxyp | 1990 |
Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; | 1990 |
Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Dehy | 1990 |
CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Estradiol; | 1990 |
Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Drug Evaluation; | 1989 |
Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
Topics: Administration, Oral; Androstenedione; Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol | 1989 |
Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
Topics: Adrenal Glands; Aged; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; Dehydroepiandrost | 1985 |
621 other studies available for estrone and Breast Neoplasms
| Article | Year |
|---|---|
2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cattle; Cell Line; Female; Humans; Mammary Neoplas | 1991 |
Synthesis and structure-affinity of a series of 7 alpha-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers.
Topics: Animals; Binding, Competitive; Breast Neoplasms; Cattle; Chemical Phenomena; Chemistry; Estradiol; F | 1990 |
Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study.
Topics: Breast Neoplasms; Estradiol; Estrogens; Humans; Models, Molecular; Receptors, Estrogen; Structure-Ac | 1997 |
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2002 |
Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily | 2003 |
Breast cancer resistance protein exports sulfated estrogens but not free estrogens.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; | 2003 |
Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase.
Topics: Benzopyrans; Binding, Competitive; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Screening | 2003 |
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Topics: 17-Hydroxysteroid Dehydrogenases; Amides; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; | 2006 |
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatography, Thin | 2007 |
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Inh | 2008 |
Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Topics: 17-Hydroxysteroid Dehydrogenases; Antineoplastic Agents; Azepines; Breast Neoplasms; Cell Line, Tumo | 2009 |
Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives.
Topics: Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrone; Female; Humans; Kinetics; Placenta; Pregnan | 2011 |
Circulating estrogen metabolites and risk of breast cancer in postmenopausal women.
Topics: Breast Neoplasms; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Estrogens; Estrone; Femal | 2014 |
The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies.
Topics: Adult; Biomarkers; Breast Neoplasms; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Estrad | 2015 |
[Determination of 2-hydroxyestrone /16α-hydroxyestrone ratio in urine of Mexican women as a risk indicator for breast cancer and its relationship with other risk factors].
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Cross-Sectional Studi | 2014 |
Oxidative Metabolism of Estrone Modified by Genistein and Bisphenol A in Rat Liver Microsomes.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Breast Neoplasms; Drug Synergism; Endocrine Disruptors; E | 2015 |
Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast Biopsy.
Topics: Adult; Breast; Breast Neoplasms; Chromatography, Liquid; Cross-Sectional Studies; Estradiol; Female; | 2016 |
A stable epoxide as a potential endogenous estrogen metabolite: Possible significance in breast cancer?
Topics: Animals; Breast Neoplasms; Carcinogens; Chromatography; Cytochrome P-450 Enzyme System; Epoxy Compou | 2016 |
Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States.
Topics: Adult; Breast; Breast Neoplasms; Equol; Female; Gas Chromatography-Mass Spectrometry; Humans; Hydrox | 2009 |
Ethnicity, body size, and estrogen levels in postmenopausal Hispanic and non-Hispanic white women.
Topics: Aged; Body Size; Breast Neoplasms; Cross-Sectional Studies; Female; Follow-Up Studies; Hispanic or L | 2009 |
Urinary estrogen metabolites in women at high risk for breast cancer.
Topics: Adult; Aged; Alcohol Drinking; Body Mass Index; Breast Neoplasms; Female; Humans; Hydroxyestrones; L | 2009 |
Circulating estrogen metabolites and risk for breast cancer in premenopausal women.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Estrogens; Female; Humans; Hydroxyestrones; Middle Age | 2009 |
Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor-positive clinical breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Aggregation; Cell Culture Techniques; Cell | 2012 |
Estrogen metabolism and risk of breast cancer in postmenopausal women.
Topics: Aged; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Chromatography, Liquid; Confounding | 2012 |
Endocrine metabolic disorders in patients with breast cancer, carriers of BRCA1 gene mutations.
Topics: Blood Glucose; BRCA1 Protein; Breast Neoplasms; C-Peptide; Endocrine System; Estradiol; Female; Huma | 2012 |
Tissue content of hydroxyestrogens in relation to survival of breast cancer patients.
Topics: Adult; Aged; Binding Sites; Breast Neoplasms; Chromatography, High Pressure Liquid; Estradiol; Estro | 2002 |
Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection.
Topics: Adult; Breast Neoplasms; Case-Control Studies; China; Estrogens; Female; Humans; Hydroxyestrones; Mi | 2003 |
Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups.
Topics: Administration, Oral; Adolescent; Adult; Black People; Breast Neoplasms; Contraceptive Agents; Estro | 2003 |
Reproducibility over time of measurements of androgens, estrogens and hydroxy estrogens in urine samples from post-menopausal women.
Topics: Aged; Androgens; Breast Neoplasms; Creatinine; Estrogens; Female; Humans; Hydrolysis; Hydroxyestrone | 2003 |
Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cross-Sectional Studies; Estrogen Replacement Therapy; Estrogen | 2003 |
Spectral characterization of catechol estrogen quinone (CEQ)-derived DNA adducts and their identification in human breast tissue extract.
Topics: Breast Neoplasms; Chromatography, High Pressure Liquid; DNA Adducts; Electrochemistry; Electrophores | 2003 |
Estrogen metabolites and the risk of breast cancer in older women.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Cohort Studies; Estrogens; Female; Humans; Hydroxyestr | 2003 |
Differential effects of 16alpha-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells.
Topics: 2-Methoxyestradiol; Activating Transcription Factor 2; Blotting, Western; Breast Neoplasms; Cyclic A | 2005 |
The relationship between physical activity and 2-hydroxyestrone, 16alpha-hydroxyestrone, and the 2/16 ratio in premenopausal women (United States).
Topics: Adolescent; Adult; Biomarkers; Body Mass Index; Breast Neoplasms; Exercise; Female; Humans; Hydroxye | 2005 |
Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study.
Topics: Biomarkers; Breast Neoplasms; Case-Control Studies; Estriol; Female; Hormone Replacement Therapy; Hu | 2005 |
Hormone dependency of breast tumours developing in the Guernsey Cohort study.
Topics: Breast Neoplasms; Cohort Studies; Estradiol; Female; Humans; Hydroxyestrones; Radioimmunoassay; Rece | 2006 |
Estrogen metabolism and breast cancer.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Estrogens; Female; Humans; Hydroxyestrones; Immunoenzy | 2006 |
Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Catechol O-Methyltransferase; Codon; C | 2007 |
Moderate coffee and alcohol consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: a pilot study comparing pre- and post-operative levels.
Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Alcohol Drinking; Breast Neoplasms; Coffee; Cytoch | 2006 |
Involvement of peroxiredoxin IV in the 16alpha-hydroxyestrone-induced proliferation of human MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Huma | 2008 |
Relative rates of 2- and 4-hydroxyestrogen synthesis are dependent on both substrate and tissue.
Topics: Animals; Breast Neoplasms; Equilenin; Equilin; Estradiol; Estrogens; Estrogens, Catechol; Ethinyl Es | 1982 |
Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Cell Line; Estradiol; Estrogen Antagonists; Estrogens, Catechol; Es | 1984 |
Re: Estrogen metabolism and excretion in Oriental and Caucasian women.
Topics: Animals; Asian People; Breast Neoplasms; Estrogens; Estrogens, Catechol; Female; Humans; Hydroxyestr | 1994 |
Radioimmunoassay of 2-hydroxyestrone in urine.
Topics: Adult; Breast Neoplasms; Drug Stability; Female; Humans; Hydrolysis; Hydroxyestrones; Menstruation; | 1994 |
Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: a biologic marker of breast cancer risk.
Topics: Biomarkers; Breast Neoplasms; Estradiol; Estrogens, Catechol; Humans; Hydroxyestrones; Insecticides; | 1995 |
A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer.
Topics: Breast Neoplasms; Case-Control Studies; Estradiol; Estriol; Estrone; Female; Humans; Hydroxyestrones | 1997 |
Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.
Topics: Adult; Biomarkers; Breast Neoplasms; Estrogens; Evaluation Studies as Topic; Female; Follicular Phas | 1997 |
Urinary estrogen metabolites and breast cancer: a case-control study.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Estrogens; Female; Humans; H | 1997 |
Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk.
Topics: Age Factors; Anticarcinogenic Agents; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Cell Tra | 1998 |
Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up.
Topics: Adult; Breast Neoplasms; Cohort Studies; Female; Follow-Up Studies; Humans; Hydroxyestrones; Inciden | 1998 |
Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells.
Topics: Breast Neoplasms; Cathepsin D; Cell Division; Creatine Kinase; Estradiol; Estriol; Female; Humans; H | 1998 |
Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Female; Humans; Hydroxyestrones; Immunoenzyme Techniqu | 1999 |
Re: Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women.
Topics: Adult; Breast Neoplasms; Female; Humans; Hydroxyestrones; Middle Aged; Postmenopause; Research Desig | 1999 |
The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Division; Estrone; Fema | 2000 |
Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Biological Transport, Active; Breast Neoplasms; Deoxygluc | 2000 |
Endocrine characteristics of human breast epithelial cells, MCF-10F.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aromatase; Aryl Hydrocarbon Hydroxylases; Breast; Breast Neoplasms | 1999 |
Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones.
Topics: Adult; Breast Neoplasms; Diet; Female; Glycine max; Humans; Hydroxyestrones; Isoflavones; Neoplasms, | 2000 |
A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines.
Topics: Apoptosis; Breast Neoplasms; Cell Survival; Comet Assay; DNA Damage; DNA Fragmentation; DNA, Neoplas | 2000 |
Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Estrone; Humans; Hydr | 2000 |
Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.
Topics: Adult; Aged; Body Constitution; Body Mass Index; Breast Neoplasms; Case-Control Studies; Estrogens; | 2000 |
Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
Topics: Adolescent; Adult; Asian People; Australia; Black People; Breast Neoplasms; Female; Genotype; Humans | 2001 |
Urinary estrogen metabolites and mammographic parenchymal patterns in postmenopausal women.
Topics: Adult; Aged; Breast Neoplasms; Case-Control Studies; Epidemiologic Studies; Estrogens; Female; Human | 2001 |
Regulation of cell cycle and cyclins by 16alpha-hydroxyestrone in MCF-7 breast cancer cells.
Topics: Breast Neoplasms; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-D | 2001 |
Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers.
Topics: Breast; Breast Neoplasms; Female; Glucuronosyltransferase; Humans; Hydroxyestrones; Immunoblotting; | 2002 |
Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women.
Topics: Adult; Biomarkers; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Genetic Predisp | 2002 |
[Biological effect of estrogen metabolites in human breast cancer].
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cell Division; Cytochrome | 1992 |
Effects of estrogens on MCF-7 cells: positive or negative regulation by the nature of the ligand-receptor complex.
Topics: Breast Neoplasms; Cell Count; Estradiol; Estrogens; Female; Humans; Hydroxyestrones; Ligands; Recept | 1991 |
In vitro synthesis of 16 alpha-hydroxyestrone by female rat liver microsomes: its possible role in the etiology of breast cancer.
Topics: Animals; Breast Neoplasms; Chromatography, High Pressure Liquid; Estrone; Female; Hydroxyestrones; I | 1990 |
Uptake and metabolism of estradiol by normal and abnormal breast tissues.
Topics: Adult; Breast; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Fibrocystic Breast Disease; Hu | 1990 |
Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation.
Topics: Breast Neoplasms; Cells, Cultured; Estradiol; Estrogens, Catechol; Estrone; Female; Humans; Hydroxye | 1989 |
Catecholestrogen binding sites in breast cancer.
Topics: Binding Sites; Breast Neoplasms; Catechol O-Methyltransferase; Cell Fractionation; Chromatography, H | 1985 |
Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization.
Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Division; Cell Line; Cell Nucleus; Electrophoresis, P | 1988 |
Characterization of catecholestrogen membrane binding sites in estrogen receptor positive and negative human breast cancer cell-lines.
Topics: Binding Sites; Breast Neoplasms; Cell Line; Cell Membrane; Centrifugation, Density Gradient; Chromat | 1988 |
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Femal | 2022 |
Associations of established breast cancer risk factors with urinary estrogens in postmenopausal women.
Topics: Breast Neoplasms; Estrogens; Estrone; Female; Humans; Postmenopause; Pregnancy; Risk Factors | 2022 |
Estrogenic Activity and Risk of Invasive Breast Cancer Among Postmenopausal Women in the Nurses' Health Study.
Topics: Breast Neoplasms; Case-Control Studies; Estradiol; Estrone; Female; Humans; Logistic Models; Nurses; | 2022 |
Plasma Aromatase Activity Index, Gonadotropins and Estrone Are Associated with Frailty Syndrome in Post-Menopausal Women with Breast Cancer.
Topics: Aged; Aromatase; Breast Neoplasms; Cross-Sectional Studies; Estrone; Female; Follicle Stimulating Ho | 2022 |
ADAPTOR PROTEIN Ruk/CIN85REGULATES REDOX BALANCE IN 4T1MOUSE BREAST CANCER CELLS EXPOSED TO PLASMIN(OGEN).
Topics: Adaptor Proteins, Signal Transducing; Animals; Breast Neoplasms; Estrone; Female; Fibrinolysin; Glut | 2022 |
Novel estrogen-responsive genes (ERGs) for the evaluation of estrogenic activity.
Topics: Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Estrogens; Estrone; Female; Gene Expres | 2022 |
Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS/MS-Method.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Chromatography, Liquid; Cross-Sectional Studies; Estr | 2023 |
Glyphosate mimics 17β-estradiol effects promoting estrogen receptor alpha activity in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Estrone; Female; | 2023 |
Glyphosate mimics 17β-estradiol effects promoting estrogen receptor alpha activity in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Estrone; Female; | 2023 |
Glyphosate mimics 17β-estradiol effects promoting estrogen receptor alpha activity in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Estrone; Female; | 2023 |
Glyphosate mimics 17β-estradiol effects promoting estrogen receptor alpha activity in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Estrone; Female; | 2023 |
Glyphosate mimics 17β-estradiol effects promoting estrogen receptor alpha activity in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Estrone; Female; | 2023 |
Glyphosate mimics 17β-estradiol effects promoting estrogen receptor alpha activity in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Estrone; Female; | 2023 |
Glyphosate mimics 17β-estradiol effects promoting estrogen receptor alpha activity in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Estrone; Female; | 2023 |
Glyphosate mimics 17β-estradiol effects promoting estrogen receptor alpha activity in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Estrone; Female; | 2023 |
Glyphosate mimics 17β-estradiol effects promoting estrogen receptor alpha activity in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Estrone; Female; | 2023 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Δ
Topics: Breast Neoplasms; Cell Movement; Dronabinol; Estrogens; Estrone; Female; Humans; MCF-7 Cells; Recept | 2023 |
Synthesis, antiproliferative evaluation and in silico studies of a novel steroidal spiro morpholinone.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2023 |
Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Line, Tumor; Endometriosis; Enzyme Inhibito | 2023 |
Small change - big consequence: The impact of C15-C16 double bond in a D‑ring of estrone on estrogen receptor activity.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrone; Female; Fulvestrant | 2023 |
Antiproliferative and Antimetastatic Properties of 16-Azidomethyl Substituted 3-
Topics: Aneuploidy; Biological Assay; Breast Neoplasms; Estradiol; Estrone; Female; Humans | 2023 |
Simultaneous quantification of estrogens and glucocorticoids in human adipose tissue by liquid-chromatography-tandem mass spectrometry.
Topics: Adipose Tissue; Breast Neoplasms; Chromatography, Liquid; Cortisone; Estradiol; Estrogens; Estrone; | 2019 |
Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug De | 2020 |
A-FABP and oestrogens are independently involved in the development of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Comorbidity; Double-Blind Method; Estradiol; Estri | 2019 |
Estrone-Decorated Polyion Complex Micelles for Targeted Melittin Delivery to Hormone-Responsive Breast Cancer Cells.
Topics: Animals; Breast Neoplasms; Drug Carriers; Estrone; Female; Humans; Melitten; Micelles; Polyethylene | 2020 |
Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trial.
Topics: Breast Neoplasms; Chemoprevention; Estradiol; Estrogens; Estrone; Female; Humans; Postmenopause | 2020 |
Influence of breast cancer risk factors and intramammary biotransformation on estrogen homeostasis in the human breast.
Topics: 17-Hydroxysteroid Dehydrogenases; Aromatase; Biotransformation; Breast; Breast Neoplasms; Estradiol; | 2020 |
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Female; Genetic Pred | 2021 |
Dual cancer targeting using estrogen functionalized chitosan nanoparticles loaded with doxorubicin-estrone conjugate: A quality by design approach.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviva | 2020 |
CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.
Topics: Alleles; Breast Neoplasms; Case-Control Studies; Cytochrome P-450 CYP3A; Estrone; Female; Genome-Wid | 2021 |
The E-Morph Assay: Identification and characterization of environmental chemicals with estrogenic activity based on quantitative changes in cell-cell contact organization of breast cancer cells.
Topics: Animals; Biological Assay; Breast Neoplasms; Endocrine Disruptors; Estrogens; Estrone; Humans | 2021 |
The multi-specific human 17 beta-hydroxysteroid dehydrogenase type 7: Non-competitive inhibitors can target different catalyses to facilitate breast cancer treatment.
Topics: 17-Hydroxysteroid Dehydrogenases; Allosteric Site; Androgens; Breast Neoplasms; Catalysis; Cholester | 2021 |
Estrogenicity assessment of membrane concentrates from landfill leachate treated by the UV-Fenton process using a human breast carcinoma cell line.
Topics: Breast Neoplasms; Cell Line, Tumor; Estrogens; Estrone; Humans; Hydrogen Peroxide; Iron; Oxidation-R | 2017 |
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
Topics: Adult; Aged; Breast Neoplasms; Estrone; Female; Genetic Predisposition to Disease; Genome-Wide Assoc | 2017 |
In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines.
Topics: Androstenedione; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Dihyd | 2018 |
Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy.
Topics: Biological Transport; Breast Neoplasms; Doxorubicin; Drug Liberation; Estrogens; Estrone; Fluorescei | 2018 |
Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer.
Topics: Animals; Apoptosis; Biocompatible Materials; Breast Neoplasms; Chitosan; Drug Delivery Systems; Estr | 2018 |
In Vitro and In Vivo Anti-Breast Cancer Activities of Some Synthesized Pyrazolinyl-estran-17-one Candidates.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Estrone; Female; Humans; MCF-7 Cells; Pyrazoles; X | 2018 |
Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Density; Breast Neoplasms; Case-Control Studies; Estrogen Rep | 2018 |
Estrone-3-sulphate, a potential novel ligand for targeting breast cancers.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrone; Female; Humans; Ligands; MCF-7 Cell | 2013 |
Intratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor.
Topics: 17-Hydroxysteroid Dehydrogenases; Aged; Aged, 80 and over; Breast Neoplasms; Carcinoma, Non-Small-Ce | 2013 |
The effect of grapefruit intake on endogenous serum estrogen levels in postmenopausal women.
Topics: Aged; Beverages; Body Mass Index; Body Weight; Breast Neoplasms; Citrus paradisi; Dehydroepiandroste | 2013 |
Serum estrogen receptor bioactivity and breast cancer risk among postmenopausal women.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Estradiol; Estrogen Receptor alpha; | 2014 |
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.
Topics: Adult; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carcinogenesis; Estradiol; Estrone; Female; H | 2014 |
Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Body Mass Index; Breast | 2014 |
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Topics: Aged; Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Es | 2014 |
Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Disease-Free Survival; Estradiol; Estrone; Female; | 2014 |
Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy.
Topics: Antineoplastic Agents; Antitussive Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug D | 2014 |
Expression of membrane transporters and metabolic enzymes involved in estrone-3-sulphate disposition in human breast tumour tissues.
Topics: 17-Hydroxysteroid Dehydrogenases; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bindi | 2014 |
Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer.
Topics: Aged; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Estradiol; Estrone; Female; Hormones; Humans | 2014 |
Oestetrol stimulates proliferation and oestrogen receptor expression in breast cancer cell lines: comparison of four oestrogens.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estetrol; Estradiol; Estriol; Estrogen Recep | 2015 |
Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytoc | 2014 |
Synergistic dual-targeting hydrogel improves targeting and anticancer effect of Taxol in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Coloring Agents; Drug C | 2014 |
Concerns about methods for determination of estrogens in body fluids.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Estradiol; Estrone; Female; Humans | 2014 |
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Estradiol; Estrone; Female; Humans | 2014 |
New method for recognition of sterol signalling molecules: methinium salts as receptors for sulphated steroids.
Topics: Animals; Antineoplastic Agents; Benzothiazoles; Breast Neoplasms; Carbocyanines; Cholesterol Esters; | 2015 |
One platform comparison of estrone and folic acid anchored surface engineered MWCNTs for doxorubicin delivery.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Delivery Sy | 2015 |
(125)I-Labelled 2-Iodoestrone-3-sulfate: synthesis, characterization and OATP mediated transport studies in hormone dependent and independent breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Chemistry Techniques, Synthetic; Estrone; Hormones; Humans; Iodi | 2015 |
In vitro screening of inhibition of PPAR-γ activity as a first step in identification of potential breast carcinogens.
Topics: Acetates; Breast Neoplasms; Carcinogens; Cell Line, Tumor; Estradiol; Estrone; Ethylene Glycol; HEK2 | 2015 |
Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells.
Topics: Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor | 2015 |
An estrogen-associated dietary pattern and breast cancer risk in the Swedish Mammography Cohort.
Topics: Aged; Breast Neoplasms; Diet; Estradiol; Estrone; Feeding Behavior; Female; Humans; Mammary Glands, | 2015 |
Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Androgens; Apoptosis; Apoptosis Regulatory Proteins; Breast Neopla | 2015 |
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosi | 2015 |
Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, T | 2015 |
Estrone - a partial estradiol antagonist in the normal breast.
Topics: Aged; Breast; Breast Density; Breast Neoplasms; Contraceptives, Oral; Drug Combinations; Estradiol; | 2015 |
Mimicking postmenopausal steroid metabolism in breast cancer cell culture: Differences in response to DHEA or other steroids as hormone sources.
Topics: 17-Hydroxysteroid Dehydrogenases; Apoptosis; Breast; Breast Neoplasms; Cell Cycle; Cell Proliferatio | 2016 |
Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer.
Topics: Adult; Breast Neoplasms; Co-Repressor Proteins; Estradiol; Estrogens; Estrone; Female; Humans; Middl | 2015 |
Associations of sex steroid hormones with mortality in women with breast cancer.
Topics: Adult; Androstenedione; Breast Neoplasms; Estradiol; Estrone; Female; Gonadal Steroid Hormones; Huma | 2016 |
Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cytochrome | 2016 |
A MALDI-MS-based quantitative analytical method for endogenous estrone in human breast cancer cells.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estrogens; Estrone; Female; Humans; MCF-7 Cells; Metabolomic | 2016 |
Endogenous Estrogens, Estrogen Metabolites, and Breast Cancer Risk in Postmenopausal Chinese Women.
Topics: Aged; Asian; Breast Neoplasms; Case-Control Studies; China; Estradiol; Estrogens; Estrone; Female; H | 2016 |
Systemic Levels of Estrogens and PGE
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Breast Neoplasms; Case-Control Studies; C | 2017 |
Design, synthesis, and biological evaluation of steroidal analogs as estrogenic/anti-estrogenic agents.
Topics: Breast Neoplasms; Cell Proliferation; Estrogens; Estrone; Female; Humans; Magnetic Resonance Spectro | 2017 |
CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites.
Topics: Adolescent; Adult; Alleles; Breast Neoplasms; Cytochrome P-450 CYP3A; Down-Regulation; Estrogens; Es | 2017 |
Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2017 |
Acetylation targets HSD17B4 for degradation via the CMA pathway in response to estrone.
Topics: Acetylation; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Movement; CREB-Binding Protein; Dow | 2017 |
Associations between serum testosterone levels, cell proliferation and progesterone receptor content in normal and malignant breast tissue in postmenopausal women.
Topics: Antibodies, Antinuclear; Antibodies, Monoclonal; Biopsy, Fine-Needle; Breast Neoplasms; Cell Divisio | 2008 |
Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women.
Topics: Adult; Breast Neoplasms; Case-Control Studies; Estrone; Female; Humans; Logistic Models; Middle Aged | 2008 |
Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Estradiol; | 2009 |
Improvement of advanced carcinoma of the breast following oral administration of estrogenic hormone.
Topics: Administration, Oral; Breast; Breast Neoplasms; Carcinoma; Estrone; Humans | 1948 |
Structural basis for the selective inhibition of human 3beta-hydroxysteroid dehydrogenase 1 in human breast tumor MCF-7 cells.
Topics: 3-Hydroxysteroid Dehydrogenases; Arginine; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms | 2009 |
Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer.
Topics: Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Const | 2008 |
A prospective study of relative telomere length and postmenopausal breast cancer risk.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; DNA, Neop | 2009 |
Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Inh | 2009 |
Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Menopa | 2009 |
Breast cancer patients unknowingly dosing themselves with estrogen by using topical moisturizers.
Topics: Administration, Cutaneous; Breast Neoplasms; Chromatography, High Pressure Liquid; Emollients; Estra | 2009 |
Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Topics: 17-Hydroxysteroid Dehydrogenases; Benzamides; Breast Neoplasms; Cell Line; Cell Line, Tumor; Crystal | 2009 |
Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transp | 2010 |
Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Topics: 20-alpha-Dihydroprogesterone; 3-Hydroxysteroid Dehydrogenases; 5-alpha-Dihydroprogesterone; Aldo-Ket | 2010 |
Liquid chromatography tandem mass spectrometry assay for fast and sensitive quantification of estrone-sulfate.
Topics: Breast Neoplasms; Chromatography, High Pressure Liquid; Estrone; Female; Humans; Male; Reproducibili | 2010 |
Dietary fat, tamoxifen use and circulating sex hormones in postmenopausal breast cancer survivors.
Topics: Adult; Breast Neoplasms; Diet; Dietary Fats; Dietary Fats, Unsaturated; Estradiol; Estrogen Antagoni | 2010 |
Intratumoral estrogen disposition in breast cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Adult; Aged; Aged, 80 and over; Aldo-Keto Reductase Family 1 Member | 2010 |
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Cohort Studies; Dose-Response Relatio | 2010 |
A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell S | 2010 |
Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
Topics: 17-Hydroxysteroid Dehydrogenases; Antineoplastic Agents, Hormonal; Biomimetics; Breast Neoplasms; Co | 2010 |
Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer.
Topics: Animals; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrone; Fema | 2010 |
Low salivary testosterone levels in patients with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estriol; Estron | 2010 |
Docking, synthesis, and in vitro evaluation of antimitotic estrone analogs.
Topics: Antigens, Neoplasm; Antimitotic Agents; Binding Sites; Breast Neoplasms; Carbonic Anhydrase II; Carb | 2011 |
Binding features of steroidal and nonsteroidal inhibitors.
Topics: Amino Acids; Androgens; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Binding Si | 2011 |
Diets and hormonal levels in postmenopausal women with or without breast cancer.
Topics: Aged; Body Weight; Breast Neoplasms; Diet; Diet, Vegetarian; Dietary Fats; Dietary Fiber; Estradiol; | 2011 |
Breast ductal lavage for assessment of breast cancer biomarkers.
Topics: Adult; Aged; Analysis of Variance; Androstenedione; Antineoplastic Agents, Hormonal; Biomarkers, Tum | 2010 |
Sex steroid hormones in pairs of tumor and serum from breast cancer patients and pathobiological role of androstene-3β, 17β-diol.
Topics: Adult; Androstenediol; Androstenedione; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dehy | 2011 |
Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women.
Topics: Adipose Tissue; Adult; Aged; Androstenedione; Body Mass Index; Breast Neoplasms; Estradiol; Estrone; | 2012 |
Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women.
Topics: Aromatase; Base Sequence; Breast Neoplasms; Case-Control Studies; Estrogens; Estrone; Female; Geneti | 2012 |
Effect of simvastatin on the pharmacokinetics of anastrozole.
Topics: Aged; Anastrozole; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2012 |
Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Topics: Animals; Antibiotics, Antineoplastic; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell | 2012 |
Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women.
Topics: Adult; Breast Neoplasms; Case-Control Studies; Cell Transformation, Neoplastic; Chromatography, Liqu | 2012 |
Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women.
Topics: Aged; Androstenedione; Breast Neoplasms; Case-Control Studies; Cohort Studies; Dehydroepiandrosteron | 2012 |
A dietary pattern derived to correlate with estrogens and risk of postmenopausal breast cancer.
Topics: Adult; Breast Neoplasms; Cohort Studies; Diet; Estradiol; Estrogens; Estrone; Female; Humans; Middle | 2012 |
The contribution of 17beta-hydroxysteroid dehydrogenase type 1 to the estradiol-estrone ratio in estrogen-sensitive breast cancer cells.
Topics: Biocatalysis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Enzyme Activation; Estradiol; E | 2012 |
Unraveling genes, hormones, and breast cancer.
Topics: Breast Neoplasms; Cytochrome P-450 CYP3A; Estrone; Female; Glucuronides; Humans; Mammography; Polymo | 2012 |
Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Dogs; Epithelial Cells; Estrogens; Estrone; Female; HEK | 2012 |
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Ma | 2012 |
A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
Topics: 17-Hydroxysteroid Dehydrogenases; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2012 |
Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy.
Topics: Breast Neoplasms; Case-Control Studies; Cohort Studies; Estradiol; Estrogen Receptor alpha; Estrogen | 2012 |
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neopl | 2013 |
Alcohol and breast cancer risk among Asian-American women in Los Angeles County.
Topics: Adult; Aged; Alcohol Drinking; Androgens; Androstenedione; Asian; Breast Neoplasms; Case-Control Stu | 2012 |
Genotoxic effects of oestrogens in breast cells detected by the micronucleus assay and the Comet assay.
Topics: Adult; Breast; Breast Neoplasms; Carcinoma; Cell Survival; Cells, Cultured; Comet Assay; Dose-Respon | 2002 |
Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues.
Topics: Aged; Breast; Breast Neoplasms; Estrone; Female; Humans; Middle Aged; Postmenopause | 2002 |
In vitro pro- and antioxidant properties of estrogens.
Topics: Antioxidants; Breast Neoplasms; Chromatography, High Pressure Liquid; Copper; DNA; DNA Damage; Elect | 2002 |
The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells.
Topics: Aromatase; Arylsulfatases; Breast Neoplasms; Cell Division; Estrogens; Estrone; Female; Humans; Inte | 2002 |
Inhibition of steryl sulfatase activity in LNCaP human prostate cancer cells.
Topics: Arylsulfatases; Breast Neoplasms; Danazol; Dehydroepiandrosterone Sulfate; Enzyme Inhibitors; Estron | 2002 |
Estrone 3-sulfate mimics, inhibitors of estrone sulfatase activity: homology model construction and docking studies.
Topics: Animals; Binding Sites; Breast Neoplasms; Crotalid Venoms; Drug Screening Assays, Antitumor; Enzyme | 2002 |
Steroidal oxathiazine inhibitors of estrone sulfatase.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Evaluation, Preclinical; Enzym | 2003 |
The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estriol; Estrone; Fema | 2003 |
A proposed mechanism of tamoxifen in breast cancer prevention.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; DNA Adducts; Epoxy Compounds; Estradiol; Estrone | 2002 |
A facile synthesis of C(2)-symmetric 17 beta-estradiol dimers.
Topics: Alkylation; Binding, Competitive; Breast Neoplasms; Colorimetry; Coloring Agents; Estradiol; Estrone | 2003 |
Plasma sex steroid hormones and breast cancer risk in Chinese women.
Topics: Adult; Breast Neoplasms; Case-Control Studies; China; Dehydroepiandrosterone Sulfate; Estradiol; Est | 2003 |
Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity.
Topics: Animals; Arylsulfatases; Breast Neoplasms; Chromatography, Thin Layer; Enzyme Inhibitors; Estrogens; | 2003 |
Adiposity and sex hormones in postmenopausal breast cancer survivors.
Topics: Absorptiometry, Photon; Adipose Tissue; Anthropometry; Body Mass Index; Breast Neoplasms; Cohort Stu | 2003 |
Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cohort Studies; Estradiol; Estrone; Female; Follow-Up Studies; France | 2003 |
Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.
Topics: Aged; Breast Neoplasms; Estrone; Female; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Ri | 2003 |
Identification of steroid sulfate transport processes in the human mammary gland.
Topics: Algorithms; Animals; Biological Transport, Active; Blotting, Northern; Breast; Breast Neoplasms; CHO | 2003 |
5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
Topics: Androgen Receptor Antagonists; Animals; Benzylidene Compounds; Binding, Competitive; Breast Neoplasm | 2003 |
Relation of iron content of mouse mammary gland to estrogenic factors.
Topics: Animals; Breast; Breast Neoplasms; Estrogens; Estrone; Humans; Iron; Mammary Glands, Human; Mice | 1957 |
The use of the weanling male mouse breast for the assay of oestrone and prolactin.
Topics: Animals; Breast; Breast Neoplasms; Estrogens; Estrone; Hormones; Humans; Male; Mice; Pituitary Gland | 1958 |
[Androgenic and estrogenic activity in the urine in ovariectomized women with breast cancer].
Topics: Androgens; Breast Neoplasms; Castration; Estrogens; Estrone; Female; Humans; Mastectomy | 1961 |
The effect of oestrone on the incidence of mammary carcinoma and adenoma in C3Hf breeders after late ovariectomy.
Topics: Adenoma; Animals; Breast Neoplasms; Castration; Estrogens; Estrone; Female; Humans; Incidence; Male; | 1961 |
A study of urinary estrogen excretion in relation to breast cancer.
Topics: Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Humans; Pregnanediol | 1963 |
TOXIC EFFECTS OF STERIOD HORMONES ON ORGAN CULTURES OF MOUSE MAMMARY TUMORS, WITH A COMMENT ON THE OCCURRENCE OF VIRAL INCLUSION BODIES.
Topics: Adenocarcinoma; Alcohols; Aldosterone; Animals; Breast Neoplasms; Cholesterol; Corticosterone; Desox | 1963 |
THE EXCRETION OF OESTRONE, PREGNANEDIOL AND PREGNANETRIOL IN BREAST CANCER PATIENTS. I. EXCRETION AFTER SPONTANEOUS MENOPAUSE.
Topics: Breast Neoplasms; Estrone; Geriatrics; Humans; Menopause; Pregnanediol; Pregnanetriol; Urine | 1963 |
THE EXCRETION OF OESTRONE, PREGNANEDIOL AND PREGNANETRIOL IN BREAST CANCER PATIENTS. II. EFFECT OF OVARIECTOMY, OVARIAN IRRADIATION AND CORTICOSTEROIDS.
Topics: Adrenal Cortex Hormones; Breast Neoplasms; Castration; Estrone; Female; Geriatrics; Humans; Neoplasm | 1963 |
MEDICAL TREATMENT OF CANCER OF THE BREAST.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adrenalectomy; Antineoplastic Agents; Breast Neoplasms; Es | 1963 |
[STUDIES ON THE EXTRAGONADAL ESTROGENS].
Topics: Adrenal Cortex Hormones; Adrenalectomy; Adrenocorticotropic Hormone; Animals; Breast Neoplasms; Cast | 1963 |
AUGMENTATION OF 6-AMINONICOTINAMIDE ANTAGONISM OF TUMOR GROWTH BY COMPOUNDS WITH ESTROGENIC ACTIVITY.
Topics: 6-Aminonicotinamide; Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cortisone; Di | 1964 |
ABDOMINOVAGINAL POTENTIAL DIFFERENCE IN POSTMENOPAUSAL PATIENTS WITH AND WITHOUT BREAST CANCER.
Topics: Abdominal Wall; Adolescent; Androgens; Breast Neoplasms; Castration; Climacteric; Electrophysiology; | 1964 |
"PROPHYLACTIC" OVARIECTOMY AND OVARIAN IRRADIATION IN BREAST CANCER.
Topics: Breast Neoplasms; Castration; Estrone; Female; Humans; Mastectomy; Menopause; Neoplasms; Ovariectomy | 1964 |
ENDOCRINE TREATMENT OF BREAST CANCER.
Topics: Anabolic Agents; Androgens; Breast Neoplasms; Castration; Estrone; Female; Humans; Menopause; Nandro | 1964 |
HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Aged; Androsterone; Breast Neoplasms; Creatine; Creatinine | 1964 |
RADIOACTIVE ESTROGENS IN TISSUES OF POSTMENOPAUSAL WOMEN WITH BREAST NEOPLASMS.
Topics: Abdomen; Adipose Tissue; Breast; Breast Neoplasms; Carbon Isotopes; Estradiol; Estrogens; Estrone; F | 1964 |
THE EFFECT OF TRANSPLANTED MAMMARY TUMOURS ON THE CALCIUM BALANCE OF THE RAT.
Topics: Acid Phosphatase; Aging; Alkaline Phosphatase; Animals; Bone and Bones; Bone Marrow; Breast Neoplasm | 1964 |
OOPHORECTOMY AND CORTISONE TREATMENT AS A METHOD OF ELIMINATING OESTROGEN PRODUCTION IN PATIENTS WITH BREAST CANCER.
Topics: 17-Hydroxycorticosteroids; Breast Neoplasms; Castration; Cortisone; Estradiol; Estriol; Estrogens; E | 1964 |
ESTRONE-INDUCED MAMMARY TUMORS IN THE RAT. I. INDUCTION AND BEHAVIOR OF TUMORS.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinogens; Carcinoma; Estrone; Humans; Lung Neoplasms; | 1964 |
STUDIES ON URINARY ESTROGENS IN PATIENTS WITH ADVANCED BREAST CANCER IN REFERENCE TO OOPHORECTOMY AND ADRENALECTOMY.
Topics: Adrenalectomy; Biomedical Research; Breast Neoplasms; Castration; Estradiol; Estriol; Estrogens; Est | 1964 |
THE EFFECTS OF HORMONAL ENVIRONMENT ON MAMMARY CARCINOGENESIS IN C3HB MICE BY 1,2:5,6-DIBENZANTHRACENE.
Topics: Animals; Benz(a)Anthracenes; Breast Neoplasms; Carcinogenesis; Estrone; Female; Humans; Mammary Neop | 1964 |
HEPATOMA IN INTACT C3HF MALE AND VIRGIN FEMALE MICE AND AFTER GONADECTOMY ALONE OR SEBSEQUENT TREATMENT WITH OESTROGEN.
Topics: Animals; Body Weight; Breast Neoplasms; Carcinoma, Hepatocellular; Castration; Diet; Estradiol; Estr | 1964 |
ENZYMIC SYNTHESIS OF STEROID SULFATES. II.
Topics: Adenine Nucleotides; Androsterone; Breast Neoplasms; Cortisone; Dehydroepiandrosterone; Drug Therapy | 1964 |
DIFFERENCES OF STEROID METABOLISM IN BREAST CANCER AFTER HORMONE STIMULATION.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Androgens; Androsterone; Breast Diseases; Breast Neoplasms | 1964 |
ENDOCRINE RELATIONSHIPS OF LEUKOCYTE ALKALINE PHOSPHATASE.
Topics: Alkaline Phosphatase; Androgens; Breast Neoplasms; Castration; Child; Enzyme Inhibitors; Estradiol; | 1965 |
THE EXCRETION OF OESTROGENS AND PREGNANEDIOL IN PATIENTS WITH MAMMARY CARCINOMA.
Topics: Breast Neoplasms; Drug Therapy; Estradiol; Estriol; Estrogens; Estrone; Female; Fluids and Secretion | 1964 |
EXCRETION PATTERNS OF URINARY METABOLITES OF ESTRADIOL-4-C-14 IN POSTMENOPAUSAL WOMEN WITH BENIGN AND MALIGNANT DISEASE OF THE BREAST.
Topics: Breast; Breast Diseases; Breast Neoplasms; Carbon Isotopes; Estradiol; Estriol; Estrone; Ethinyl Est | 1965 |
II. URINARY EXCRETION OF ESTRONE, ESTRADIOL, AND ESTRIOL BY PATIENTS WITH BREAST CANCER AND BENIGN BREAST DISEASE.
Topics: Breast Diseases; Breast Neoplasms; Contraceptive Agents, Female; Estradiol; Estriol; Estrogens; Estr | 1965 |
Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden).
Topics: Androstenedione; Breast Neoplasms; Case-Control Studies; Dehydroepiandrosterone; Estradiol; Estrone; | 2003 |
Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Enzyme Inhibitors | 2003 |
Development of novel steroid sulfatase inhibitors. I. Synthesis and biological evaluation of biphenyl-4-O-sulfamates.
Topics: Animals; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Estradiol; Estro | 2003 |
6-[3-Hydroxy-17-oxoestra-1,3,5(10)-trien-7beta-yl]hexanenitrile.
Topics: Binding Sites; Breast Neoplasms; Crystallography, X-Ray; Estranes; Estrone; Female; Humans; Hydrogen | 2004 |
Attempt to detect a mammary tumor-agent in strain C mice by estrogenic stimulation.
Topics: Animals; Breast Neoplasms; Estrone; Humans; Mice; Neoplasms | 1950 |
Tracer studies of radioactive sodium estrone sulfate (S35) in cases of advanced breast cancer.
Topics: Breast; Breast Neoplasms; Estrogens; Estrone; Humans; Neoplasms | 1951 |
[Clinical observations and research on the effect of folliculin in mammary cancer].
Topics: Breast Neoplasms; Estrogens; Estrone; Humans; Neoplasms; Research | 1951 |
2-phenylindole sulfamates: inhibitors of steroid sulfatase with antiproliferative activity in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Enzyme Inhibitors; Estrone; Female; Gene Exp | 2004 |
Epidemiology of urinary melatonin in women and its relation to other hormones and night work.
Topics: Adult; Androstenedione; Androstenols; Biological Availability; Biomarkers; Body Mass Index; Breast N | 2004 |
Polymorphisms associated with circulating sex hormone levels in postmenopausal women.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Androstenedione; Aromatase; Aryl Hydrocarbon Hydroxylases; Breas | 2004 |
UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients.
Topics: Adult; Aged; Arylsulfotransferase; Asian People; Breast Neoplasms; Estradiol; Estrone; Female; Genot | 2004 |
Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells.
Topics: Breast Neoplasms; Cations; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; E | 2004 |
Smoking is associated with postmenopausal breast cancer in women with high levels of estrogens.
Topics: Aged; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Middle Aged; Postmenopause; Prospective | 2004 |
The sensitivity of the mammary gland to oestrone in different strains of mice with and without mammary tumour agent.
Topics: Animals; Breast; Breast Neoplasms; Estrogens; Estrone; Humans; Mammary Glands, Human; Mammary Neopla | 1949 |
Alcohol and endogenous sex steroid levels in postmenopausal women: a cross-sectional study.
Topics: Aged; Alcohol Drinking; Androstenedione; Breast Neoplasms; Cross-Sectional Studies; Dehydroepiandros | 2005 |
Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
Topics: Aged; Androgens; Androstenedione; Breast Neoplasms; Case-Control Studies; Confidence Intervals; Dehy | 2004 |
Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Topics: Androgens; Androstenedione; Aromatase; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Ce | 2005 |
BRCA1 mutation, leptin and estrogen levels in breast cancer patients.
Topics: Adolescent; Adult; Body Mass Index; Breast Neoplasms; Estradiol; Estrone; Female; Genes, BRCA1; Huma | 2005 |
Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues.
Topics: Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cell Line, Tumor; Cytokines; Dinoprostone | 2005 |
The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Estradiol; Estrone; Female; Humans; Steryl-Sulfat | 2005 |
Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Estrone; Female; Humans; K | 2005 |
Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women.
Topics: Adult; Body Weight; Breast Neoplasms; Cross-Sectional Studies; Estradiol; Estrone; Female; Hormone R | 2006 |
Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Topics: Aged; Aged, 80 and over; Androgens; Androstenedione; Breast Neoplasms; Diethylstilbestrol; Drug Admi | 2005 |
Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells.
Topics: Alkaline Phosphatase; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relation | 2005 |
Fat intake is associated with serum estrogen and androgen concentrations in postmenopausal Japanese women.
Topics: Adult; Alcohol Drinking; Androgens; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Dietary Fats; | 2005 |
Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme.
Topics: 17-Hydroxysteroid Dehydrogenases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor | 2006 |
Estradiol as an anti-aromatase agent in human breast cancer cells.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chromatography, Thin Layer; DNA, Complementary; E | 2006 |
The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Topics: Breast Neoplasms; Drug Design; Enzyme Inhibitors; Estradiol; Estradiol Dehydrogenases; Estrone; Fema | 2006 |
Role of polymorphic human cytochrome P450 enzymes in estrone oxidation.
Topics: Biomarkers, Tumor; Breast Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A1; | 2006 |
Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk?
Topics: Adult; Breast Neoplasms; Case-Control Studies; Estradiol; Estrone; Female; Genetic Predisposition to | 2006 |
Stimulation of estradiol glucuronidation: a protective mechanism against estradiol-mediated carcinogenesis?
Topics: Breast Neoplasms; Endometrial Neoplasms; Estradiol; Estrone; Female; Glucuronides; Humans; Isoflavon | 2006 |
An association between a common variant (G972R) in the IRS-1 gene and sex hormone levels in post-menopausal breast cancer survivors.
Topics: Black or African American; Breast Neoplasms; C-Reactive Protein; Cohort Studies; Estradiol; Estrone; | 2006 |
Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women.
Topics: Aged; Androgens; Androstenediol; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Estrone; Femal | 2006 |
The effect of an estrone D-lactam steroid ester derivative on breast cancer cells and its predicted binding interactions with the ligand binding domain of estrogen receptor-alpha.
Topics: Aged; Aged, 80 and over; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Design; Esters; Estroge | 2005 |
Targeted functional imaging of estrogen receptors with 99mTc-GAP-EDL.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Drug Delivery Systems; Estrone; Female; Humans; Image | 2007 |
Racial/ethnic differences in postmenopausal endogenous hormones: the multiethnic cohort study.
Topics: Aged; Aged, 80 and over; Androgens; Androstenedione; Asian; Black or African American; Breast Neopla | 2006 |
Lycopene and other carotenoids inhibit estrogenic activity of 17beta-estradiol and genistein in cancer cells.
Topics: Breast Neoplasms; Carotenoids; Cell Cycle; Cell Proliferation; Estrogen Antagonists; Estrone; Female | 2007 |
A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models.
Topics: Administration, Oral; Animals; Breast Neoplasms; Cell Proliferation; Coumarins; Cricetinae; Disease | 2007 |
The effect of indole-3-carbinol on the expression of CYP1A1, CYP1B1 and AhR genes and proliferation of MCF-7 cells.
Topics: Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cell Division; Cell Line, Tu | 2007 |
Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
Topics: Aged; Androstenedione; Aromatase; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estradiol | 2007 |
Dietary fiber intake and endogenous serum hormone levels in naturally postmenopausal Mexican American women: the Multiethnic Cohort Study.
Topics: Aged; Biomarkers; Breast Neoplasms; Citrus paradisi; Cohort Studies; Dietary Fiber; Estradiol; Estro | 2007 |
Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women.
Topics: Aged; Androstenedione; Breast; Breast Neoplasms; Cross-Sectional Studies; Dehydroepiandrosterone Sul | 2007 |
Relation of serum levels of estrogen and dehydroepiandrosterone sulfate to hormone receptor status among postmenopausal women with breast cancer.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Dehydroepiandrosterone Sulfate; Est | 2007 |
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell L | 2008 |
An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples.
Topics: Aromatase Inhibitors; Blood Chemical Analysis; Breast Neoplasms; Estradiol; Estrone; Humans; Postmen | 2008 |
Hydrophilic interaction liquid chromatography-tandem mass spectrometry determination of estrogen conjugates in human urine.
Topics: Adult; Breast Neoplasms; Chromatography, Liquid; Estradiol; Estriol; Estrogens, Conjugated (USP); Es | 2008 |
Studies of estradiol transformation in women with breast cancer.
Topics: Aged; Biotransformation; Breast Neoplasms; Chromatography; Estradiol; Estriol; Estrogens; Estrone; F | 1967 |
Low-dose aminoglutethimide in treatment of advanced breast cancer.
Topics: Adrenal Glands; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Dehydroepiandrosterone; Drug | 1984 |
Multiple forms of aromatase and response of breast cancer aromatase to antiplacental aromatase II antibodies.
Topics: Adult; Aged; Antibodies; Antibody Formation; Aromatase; Breast Neoplasms; Carcinoma, Intraductal, No | 1982 |
Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients.
Topics: Adrenal Cortex Hormones; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrogens; Estrone; Fe | 1982 |
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Cos | 1983 |
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Fe | 1984 |
Adrenal androgen concentrations in breast tumours and in normal breast tissue. The relationship to oestradiol metabolism.
Topics: 17-Hydroxysteroid Dehydrogenases; Adenocarcinoma; Adult; Aged; Androstenediol; Androstenediols; Brea | 1984 |
Inhibition of steroid sulfatase activity by danazol.
Topics: Aminoglutethimide; Breast Neoplasms; Carcinoma; Culture Techniques; Danazol; Dehydroepiandrosterone; | 1984 |
Effects of plasma estrogen sulfates in mammary cancer cells.
Topics: Animals; Breast Neoplasms; Castration; Cell Nucleus; Cytosol; Estradiol; Estrogens, Conjugated (USP) | 1980 |
Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Estrogens, Conjugated (USP); Estron | 1982 |
The relationship between 17 beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue.
Topics: 17-Hydroxysteroid Dehydrogenases; Adenocarcinoma; Adenofibroma; Adult; Aged; Breast; Breast Neoplasm | 1983 |
17 Beta-hydroxysteroid dehydrogenase and aromatase activity in breast fat from women with benign and malignant breast tumours.
Topics: 17-Hydroxysteroid Dehydrogenases; Adipose Tissue; Adult; Age Factors; Aged; Androstenedione; Aromata | 1984 |
Potency of the effect of D-stereoisomer of aminoglutethimide on adrenal and extraadrenal steroidogenesis.
Topics: Adrenal Glands; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydr | 1980 |
Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
Topics: Adrenal Cortex; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Dehydroepiandrosterone; Dr | 1980 |
Estrogenic effects of physiological concentrations of 5-androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells.
Topics: Androstenediol; Androstenediols; Biotransformation; Breast Neoplasms; Cell Line; Cell Nucleus; Cytos | 1981 |
How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
Topics: Adrenalectomy; Aged; Aldosterone; Androgens; Androstenedione; Breast Neoplasms; Dehydroepiandrostero | 1982 |
[Steroid hormone content of the breast tissue in breast tumors].
Topics: Adolescent; Adult; Aged; Androstenedione; Breast; Breast Neoplasms; Dehydroepiandrosterone; Estradio | 1982 |
[Oestrogens in the cell: differences between uterine and mammary tissue].
Topics: Breast; Breast Neoplasms; Cell Nucleus; Cytosol; Endometrium; Estradiol; Estrogens; Estrone; Female; | 1983 |
Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma.
Topics: Breast Neoplasms; Cytosol; Estradiol; Estrone; Female; Humans; Substrate Specificity; Sulfatases; Su | 1983 |
Estrone and dehydroepiandrosterone sulfatase activities and plasma estrone sulfate levels in human breast carcinoma.
Topics: Breast Neoplasms; Estradiol; Estrone; Female; Humans; Menopause; Middle Aged; Progesterone; Receptor | 1984 |
Biological significance of aromatase activity in human breast tumors.
Topics: Aminoglutethimide; Androstenedione; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrone; Fema | 1983 |
Effects of drugs associated with hyperprolactinemia on plasma steroids and on steroid receptors and metabolism in human breast cancer.
Topics: Aged; Breast Neoplasms; Estriol; Estrone; Female; Hormones; Humans; Methyldopa; Middle Aged; Neoplas | 1983 |
The effect of westernization on urine estrogens, frequency of ovulation, and breast cancer risk. A study of ethnic Chinese women in the Orient and the USA.
Topics: Adolescent; Adult; Boston; Breast Neoplasms; China; Climate; Culture; Epidemiologic Methods; Estradi | 1984 |
The intracellular control of aromatase activity by 5 alpha-reduced androgens in human breast carcinoma cells in culture.
Topics: Androstenedione; Aromatase; Breast Neoplasms; Cell Line; Estrone; Feedback; Female; Humans; Oxidatio | 1984 |
Estrogen stimulates cell proliferation and the increase of a 52,000 dalton glycoprotein in human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Cell Line; Dexamethasone; Diethylstilbestrol; Electrophoresis, Poly | 1984 |
Estradiol formation and estrogen receptors in breast tumor tissue: effects of tamoxifen on estrogen interconversions in breast tumor homogenate in vitro.
Topics: Breast Neoplasms; Estrone; Female; Humans; In Vitro Techniques; Receptors, Estrogen; Tamoxifen | 1984 |
Resistance of the ovary to blockade of aromatization with aminoglutethimide.
Topics: Adult; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Female; Follic | 1980 |
Plasma hormones in pre- and postmenopausal breast cancer.
Topics: Adult; Age Factors; Aged; Breast Neoplasms; Cortisone; Estradiol; Estrone; Female; Follicle Stimulat | 1980 |
Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture.
Topics: Breast Neoplasms; Cell Division; Cell Line; Estetrol; Estradiol; Estriol; Estrone; Female; Humans; L | 1981 |
Abnormal estrogen conjugation in women at risk for familial breast cancer at the periovulatory stage of the menstrual cycle.
Topics: Androgens; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Luteinizing Hor | 1983 |
Estradiol and progesterone receptor levels in human breast cancer in relation to cytosol and plasma estrogen level.
Topics: Adenocarcinoma; Breast; Breast Neoplasms; Cytosol; Estradiol; Estrone; Female; Humans; Kinetics; Men | 1983 |
Estrogen excretion and plasma levels in vegetarian and omnivorous women.
Topics: Breast Neoplasms; Diet; Diet, Vegetarian; Estrogens; Estrone; Female; Humans; Pseudotumor Cerebri | 1983 |
Estrone sulfate concentrations in plasma of normal individuals, postmenopausal women with breast cancer, and men with cirrhosis.
Topics: Adult; Aged; Breast Neoplasms; Chromatography; Estrone; Female; Humans; Liver Cirrhosis; Male; Menop | 1983 |
Fluoresceinated estrone binding by cells from human breast cancers obtained by needle aspiration.
Topics: Adult; Aged; Biopsy, Needle; Breast Neoplasms; Cytosol; Estrone; Female; Fluorescent Dyes; Humans; M | 1983 |
A relationship between estrogen sulfurylation and estrogen and progesterone receptor status in human mammary carcinoma.
Topics: Adult; Aged; Breast Neoplasms; Cytosol; Estrogens; Estrone; Female; Humans; Middle Aged; Neoplasms, | 1980 |
Socioeconomic status, urine estrogens, and breast cancer risk.
Topics: Adolescent; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Follicular Phase; Huma | 1980 |
Elevated urine estrogen and pregnanediol levels in daughters of breast cancer patients.
Topics: Adolescent; Adult; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Menstru | 1981 |
Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas.
Topics: 17-Hydroxysteroid Dehydrogenases; Adenofibroma; Adolescent; Adult; Breast Neoplasms; Estradiol Dehyd | 1982 |
Estrone receptor formation during the processing of estradiol-receptor complex in MCF-7 cells.
Topics: Binding, Competitive; Breast Neoplasms; Cell Line; Cell Nucleus; Cytosol; Estradiol; Estrone; Female | 1982 |
Relationship of obesity to blood estrogens.
Topics: Aromatase; Body Weight; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Male; Obesi | 1982 |
Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Topics: Adrenal Glands; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Castration; Estradiol; Es | 1982 |
Aromatase in human breast carcinoma.
Topics: Adipose Tissue; Androgens; Androstenedione; Aromatase; Breast Neoplasms; Cells, Cultured; Estrogens; | 1982 |
In vivo effects of delta 1-testololactone on peripheral aromatization.
Topics: Aged; Androstenedione; Aromatase; Breast Neoplasms; Dexamethasone; Dose-Response Relationship, Drug; | 1982 |
Urinary oestrogens and pregnandiol in breast cancer patients.
Topics: Adult; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Mastectomy; Middle | 1982 |
The specific binding of estradiol and estrone and the subsequent distribution of estrogen-receptor complexes within MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Line; Cell Nucleus; Cold Temperature; Cytosol; Estradiol; Estrone; Female; Hu | 1982 |
Cigarette smoking and urinary estrogens.
Topics: Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Menopause; Menstruation; M | 1982 |
Oestrogen receptors and metabolism of oestrone sulphate in human mammary carcinoma.
Topics: Adult; Age Factors; Aged; Breast Neoplasms; Culture Techniques; Cytosol; Estradiol; Estrone; Female; | 1980 |
Urine estrogen profiles in European countries with high or low breast cancer rates.
Topics: Adolescent; Adult; Age Factors; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Europe; Fe | 1980 |
Androgen metabolism in male and female breast tissue.
Topics: Adolescent; Adult; Aged; Androstenedione; Breast; Breast Neoplasms; Estradiol; Estrone; Female; Fibr | 1981 |
Lipoidal derivative of estradiol: the biosynthesis of a nonpolar estrogen metabolite.
Topics: Animals; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Mammary Neoplasms, Experimental; Orga | 1981 |
Plasma concentration gradient of steroid hormones across human mammary tumours in vivo.
Topics: Adult; Androgens; Androstenedione; Arteries; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female | 1981 |
Studies of oestrogen metabolism in postmenopausal women with cancer.
Topics: Adipose Tissue; Aged; Androstenedione; Body Weight; Breast Neoplasms; Endometrial Hyperplasia; Estra | 1981 |
Benign breast disease: estriol proportions and family history of breast cancer.
Topics: Adult; Age Factors; Breast Diseases; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Humans | 1981 |
The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue.
Topics: Adipose Tissue; Adult; Aged; Androstenedione; Breast; Breast Neoplasms; Estradiol; Estrone; Female; | 1980 |
Inhibition of estrogen synthesis in human breast tumors by testololactone and bromoandrostenedione.
Topics: Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Kinetic | 1980 |
Estrogen receptor cytochemistry by fluorescent estrogen.
Topics: Animals; Breast; Breast Neoplasms; Cell Line; Estrone; Fluoresceins; Fluorescent Dyes; Histocytochem | 1980 |
Inhibition of androgen aromatization in human breast cancer.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Carbon Radioisotopes; Es | 1980 |
Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines.
Topics: Blotting, Western; Breast Neoplasms; Chromatography, High Pressure Liquid; Estradiol; Estrone; Human | 1994 |
Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients.
Topics: Aged; Androstenedione; Breast Neoplasms; Carrier Proteins; Estradiol; Estrogens; Estrone; Female; Go | 1995 |
Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate.
Topics: Arylsulfatases; Binding Sites; Breast Neoplasms; Enzyme Inhibitors; Estrone; Female; Humans; Hydroge | 1995 |
Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States).
Topics: Adult; Alcohol Drinking; Body Mass Index; Breast Neoplasms; Cohort Studies; Cross-Sectional Studies; | 1995 |
Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Estrogens; Estrone; Female; Gene Expression Regu | 1995 |
Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020).
Topics: 17-Hydroxysteroid Dehydrogenases; Biotransformation; Breast Neoplasms; Danazol; Estradiol; Estrogen | 1995 |
Re: A prospective study of endogenous estrogens and breast cancer in postmenopausal women.
Topics: Aged; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Middle Aged; Obesity; Postmen | 1995 |
A prospective study of endogenous estrogens and breast cancer in postmenopausal women.
Topics: Breast Neoplasms; Case-Control Studies; Estradiol; Estrogens; Estrone; Female; Humans; Middle Aged; | 1995 |
Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients.
Topics: Aged; Androgens; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Follicle Stimulating Hormo | 1995 |
Changes in serum sex steroid levels during megestrol acetate therapy.
Topics: Adrenalectomy; Aged; Antibodies; Breast Neoplasms; Cross Reactions; Dehydroepiandrosterone; Estradio | 1994 |
Estrone sulfate analogs as estrone sulfatase inhibitors.
Topics: Binding Sites; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Mesylates; Placenta; | 1995 |
N-butyl, N-methyl, 11-[3',17' beta-(dihydroxy)-1',3',5'(10')-estratrien-16' alpha-yl]-9(R/S)-bromo undecanamide: synthesis and 17 beta-HSD inhibiting, estrogenic and antiestrogenic activities.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrone; Humans | 1994 |
Estrogen-specific 17 beta-hydroxysteroid oxidoreductase type 1 (E.C. 1.1.1.62) as a possible target for the action of phytoestrogens.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Division; Coumarins; Estradiol; Estrogens, | 1995 |
Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha.
Topics: Androstenedione; Aromatase; Breast; Breast Neoplasms; Culture Media, Conditioned; Cytosol; Dexametha | 1994 |
Steroid gradients across the cancerous breast: an index of altered steroid metabolism in breast cancer?
Topics: Adult; Aged; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfa | 1994 |
The relation of reported alcohol ingestion to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States).
Topics: Adult; Alcohol Drinking; Androgens; Androstenedione; Body Mass Index; Body Weight; Breast Neoplasms; | 1994 |
Metabolism of estrone sulfate by normal breast tissue: influence of menopausal status and oral contraceptives.
Topics: Adolescent; Adult; Aged; Breast; Breast Neoplasms; Contraceptives, Oral; Endometrial Neoplasms; Estr | 1994 |
Effect of triptorelin (Decapeptyl) combined with heparin on estradiol levels in MCF-7 mammary cancer cells after incubation with estrone sulfate.
Topics: Breast Neoplasms; Estradiol; Estrone; Heparin; Humans; Triptorelin Pamoate; Tumor Cells, Cultured | 1993 |
Regulation of 17 beta-hydroxysteroid dehydrogenase in a newly-established human breast carcinoma cell line.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Adhesion; Cell Division; Estradiol; Estrone | 1993 |
Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential.
Topics: Breast Neoplasms; Cell Division; Drug Screening Assays, Antitumor; Estrone; Humans; Sulfatases; Sulf | 1994 |
Action of danazol on the conversion of estrone sulfate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells.
Topics: Breast Neoplasms; Danazol; Estradiol; Estrone; Humans; Sulfatases; Tumor Cells, Cultured | 1993 |
Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Dexamethasone; Dihydrotestosterone; Estradiol; E | 1993 |
Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell-Free System; Estrone; Humans; In Vitro Techni | 1993 |
Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures.
Topics: Biological Transport; Breast Neoplasms; Cell Division; Cell Nucleus; Cells, Cultured; Estradiol; Est | 1993 |
A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 1995 |
Effects of a very low fat, high fiber diet on serum hormones and menstrual function. Implications for breast cancer prevention.
Topics: Adult; Breast Neoplasms; Dietary Fats; Dietary Fiber; Estradiol; Estrone; Female; Gonadal Steroid Ho | 1995 |
Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.
Topics: Adult; Aged; Aromatase; Breast; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Men | 1996 |
Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Adenocarcinoma; Body Fluids; Breast Neoplasms; Cell Division; Cell | 1996 |
A prospective study of urinary oestrogen excretion and breast cancer risk.
Topics: Adult; Breast Neoplasms; Case-Control Studies; Estradiol; Estriol; Estrogens; Estrone; Female; Human | 1996 |
Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer.
Topics: Aged; Androstenedione; Body Mass Index; Breast Neoplasms; Case-Control Studies; Estrone; Female; Hum | 1996 |
Crystal structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiol.
Topics: Binding Sites; Breast Neoplasms; Carcinoma; Catalysis; Crystallography; Estradiol; Estrone; Female; | 1996 |
Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers.
Topics: Aromatase; Base Sequence; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; DNA Prime | 1996 |
2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumor activity.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cattle; Cell Division; Estradiol; Estrog | 1996 |
17 beta-hydroxysteroid oxidoreductase activity in intact cells significantly differs from classical enzymology analysis.
Topics: 17-Hydroxysteroid Dehydrogenases; Animals; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Estro | 1996 |
Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Division; Danazol; Dose-Response Relationship, Drug; Enzyme I | 1996 |
Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma.
Topics: Adenoma; Androstenedione; Aromatase; Breast; Breast Neoplasms; Carcinoma; Estradiol; Estrone; Female | 1996 |
Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines.
Topics: Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estrogens; Estrone; Humans; Neopl | 1997 |
[Determination of intratumoral estrone (E1) and estradiol (E2) in primary breast cancer tissues by sensitive HPLC-RIA].
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chromatography, High Pressure Liquid; Estradiol; E | 1997 |
Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma.
Topics: Adolescent; Adult; Aromatase; Breast Neoplasms; Estradiol; Estrone; Fibroadenoma; Humans; Neoplasms, | 1997 |
Serum sex hormone levels are related to breast cancer risk in postmenopausal women.
Topics: Aged; Androstenedione; Breast Neoplasms; Case-Control Studies; Dehydroepiandrosterone Sulfate; Estra | 1997 |
Changes in serum estrogen levels in women during tamoxifen therapy.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrogens; Estr | 1997 |
Multiple primary tumors: 17 cases of renal-cell carcinoma associated with primary tumors involving different steroid-hormone target tissues.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Renal Cell; Endometrial Neoplasms; Estradiol; Estrone; Fem | 1997 |
Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
Topics: Aromatase Inhibitors; Biological Assay; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Estrone; Fem | 1997 |
Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Hormonal; Benzopyrans; Breast Neoplasms; Cell | 1998 |
Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrone; Female; F | 1998 |
Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Benzopyrans; Breast Neoplasms; Dehydroepia | 1998 |
The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity.
Topics: Animals; Arylsulfatases; Breast Neoplasms; Enzyme Inhibitors; Estrone; Female; Microsomes; Molecular | 1998 |
Human estrogen sulfotransferase (hEST1) activities and its mRNA in various breast cancer cell lines. Effect of the progestin, promegestone (R-5020).
Topics: Breast Neoplasms; Estrone; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neop | 1998 |
The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone.
Topics: Animals; Breast Neoplasms; Cytochrome P-450 Enzyme System; Equilenin; Equilin; Estradiol Congeners; | 1999 |
Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.
Topics: 17-Hydroxysteroid Dehydrogenases; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response R | 1999 |
Re: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.
Topics: Adult; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrogens, Conjugated (USP); Estrone; Fe | 1999 |
The regulation of oestrone sulphate formation in breast cancer cells.
Topics: Breast Neoplasms; Cytokines; Epidermal Growth Factor; Estrone; Female; Fibroblast Growth Factor 1; F | 1999 |
Reproducibility and validity of radioimmunoassays for urinary hormones and metabolites in pre- and postmenopausal women.
Topics: Adult; Asian; Bias; Breast Neoplasms; Case-Control Studies; Estradiol; Estriol; Estrone; Female; Gas | 1999 |
Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: x-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5(10)-estratriene.
Topics: Animals; Antineoplastic Agents; Arylsulfatases; Breast Neoplasms; Crystallography, X-Ray; Drug Scree | 1999 |
Evidence for interference in estradiol-17beta inactivation to estrone by oxidized low-density lipoprotein and selected lipid peroxidation products.
Topics: 17-Hydroxysteroid Dehydrogenases; Base Sequence; Breast Neoplasms; Cell Line; DNA Primers; Estradiol | 1999 |
A study on serum carotenoid levels in breast cancer patients of Indian women in Chennai (Madras), India.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Antioxidants; beta Carotene; Breast Neoplas | 1999 |
Modulation of oestrone sulphate formation and hydrolysis in breast cancer cells by breast cyst fluid from British and Hungarian women.
Topics: Breast Neoplasms; Cyst Fluid; Estrogens; Estrone; Female; Fibrocystic Breast Disease; Humans; Hungar | 2000 |
Aromatase and breast cancer susceptibility.
Topics: Aged; Androstenedione; Aromatase; Breast Neoplasms; Disease Susceptibility; Estrogens; Estrone; Ethn | 1999 |
Progestin regulation of 11beta-hydroxysteroid dehydrogenase expression in T-47D human breast cancer cells.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Breast Neoplasms; Carcinoma; Corticosterone; Dose-Respo | 2000 |
A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, High Pressure Liquid | 2000 |
Effect of transforming growth factor beta 2 on oestrogen metabolism in the MCF-7 breast cancer cell line.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrone; Female; Humans; Transforming Growth Fact | 2000 |
A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.
Topics: Alleles; Aromatase; Breast Neoplasms; Case-Control Studies; Estradiol; Estrone; Female; Genotype; Hu | 2000 |
Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neopl | 2000 |
A nuclear receptor system constituted by RAR and RXR induces aromatase activity in MCF-7 human breast cancer cells.
Topics: Aromatase; Base Sequence; Benzoates; Breast Neoplasms; DNA Primers; Enzyme Induction; Estrone; Exons | 2000 |
Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates.
Topics: Alanine; Antineoplastic Agents; Arylsulfatases; Binding Sites; Breast Neoplasms; Coumarins; Dehydroe | 2000 |
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; | 2000 |
Non-steroidal and steroidal sulfamates: new drugs for cancer therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Coumarins; Enzyme Inhibitors; Estrogens; Estrone; | 2001 |
Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Topics: 17-Hydroxysteroid Dehydrogenases; 20-alpha-Dihydroprogesterone; 3-alpha-Hydroxysteroid Dehydrogenase | 2001 |
Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women?
Topics: Aged; Black People; Breast Neoplasms; China; Cohort Studies; Estradiol; Estriol; Estrogens; Estrone; | 2001 |
Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients.
Topics: Adult; Aged; Biomarkers; Breast Diseases; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Ca | 2000 |
Synthesis and reactivity of the catechol metabolites from the equine estrogen, 8,9-dehydroestrone.
Topics: Animals; Breast Neoplasms; Catechols; DNA Adducts; Estrogens, Conjugated (USP); Estrone; Female; Hum | 2001 |
Response of MCF-7 human breast cancer cells to some binary mixtures of oestrogenic compounds in-vitro.
Topics: Benzhydryl Compounds; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Intera | 2001 |
Inhibition of oestrone sulphatase activity by tibolone and its metabolites.
Topics: Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Estrone; Female; Human | 2002 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultu | 2001 |
Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
Topics: Animals; Breast Neoplasms; Cell Division; Cell Size; Cinnamates; Endometrium; Epithelial Cells; Estr | 2002 |
Association of CYP1B1 polymorphisms and breast cancer risk.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Cyt | 2002 |
Abrogation of estrogen-mediated cellular and biochemical effects by indole-3-carbinol.
Topics: Brassicaceae; Breast Neoplasms; Cell Division; Cytochrome P-450 CYP1A1; Estradiol; Estrogen Antagoni | 2001 |
Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast tissue.
Topics: Breast; Breast Neoplasms; Endoplasmic Reticulum; Estradiol; Estradiol Dehydrogenases; Estrone; Femal | 1977 |
Oestrogen profiles of parous and nulliparous women.
Topics: Adult; Age Factors; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Follicular Phase; Humans; | 1976 |
Ovarian function in patients receiving adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dehydroepia | 1977 |
Prolactin, oestrogen, and lipids in breast fluid.
Topics: Body Fluids; Breast; Breast Neoplasms; Cholesterol; Estradiol; Estrogens; Estrone; Female; Humans; L | 1977 |
Adipose tissue and aetiology of breast cancer.
Topics: Adipose Tissue; Aged; Body Weight; Breast Neoplasms; Estrone; Female; Humans; Menopause; Middle Aged | 1978 |
Pineal gland, F.S.H., and breast-cancer aetiology.
Topics: Aged; Breast Neoplasms; Estrone; Female; Follicle Stimulating Hormone; Humans; Melatonin; Menopause; | 1978 |
Mechanism of action of aminoglutethimide in breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Estradiol; Estrogen Antagonists; | 1979 |
Clinical and experimental aspects of the anti-mammary carinogenic activity of estriol.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Breast Neoplasms; Estriol; Estrone | 1977 |
7beta,17alpha-Dimethyltestosterone (calusterone)-induced changes in the metabolism, production rate, and excretion of estrogens in women with breast cancer: a possible mechanism of action.
Topics: Adult; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Humans; Methyltestosterone; Middle Age | 1976 |
Plasma hormone levels in different ethnic populations of women.
Topics: Adrenal Glands; Adult; Africa; Androstenedione; Animals; Asian People; Black People; Breast Neoplasm | 1976 |
Plasma estrogens and androgens in male breast cancer.
Topics: Adult; Aged; Androgens; Androstenedione; Breast Neoplasms; Castration; Dehydroepiandrosterone; Dihyd | 1976 |
Hormonal changes following hypophysectomy in humans.
Topics: Androstenedione; Arginine; Breast Neoplasms; Cold Temperature; Dehydroepiandrosterone; Estradiol; Es | 1977 |
Adrenal dehydroepiandrosterone and human mammary cancer.
Topics: Adrenal Glands; Androstenediol; Animals; Binding, Competitive; Breast Neoplasms; Cell Nucleus; Cytos | 1978 |
Urinary steroid excretion in an oophorectomized and adrenalectomized woman in the second trimester of pregnancy.
Topics: 17-Hydroxycorticosteroids; Adrenalectomy; Adrenocorticotropic Hormone; Breast Neoplasms; Castration; | 1975 |
The steroid alcohol and estrogen sulfotransferases in rodent and human mammary tumors.
Topics: Alcohols; Animals; Breast Neoplasms; Castration; Chick Embryo; Dehydroepiandrosterone; Estrogens; Es | 1975 |
Androgens in postmenopausal breast cancer: excretion, production and interaction with estrogens.
Topics: 17-Ketosteroids; Aged; Androgens; Androstenedione; Binding, Competitive; Breast Neoplasms; Dehydroep | 1975 |
Existence of receptors bound to endogenous estradiol in breast cancers of premenopausal and postmenopausal women.
Topics: Adenocarcinoma; Breast; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Nucleus; Cytosol; Estradiol | 1976 |
Proceedings: Androgens in human postmenopausal breast cancer.
Topics: Androgens; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Female; Humans; Menopause; | 1975 |
Oestrogens and endometrial cancer: a point of view.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Breast Neoplasms; Climacteric; Contraceptives, Oral, Seque | 1977 |
Diet and cancer of endocrine target organs.
Topics: Adult; Age Factors; Aged; Boston; Breast Neoplasms; Diet; Estrogens; Estrogens, Conjugated (USP); Es | 1977 |
Estrogens for the menopause. Maximizing benefits, minimizing risks.
Topics: Affective Symptoms; Arteriosclerosis; Breast Neoplasms; Climacteric; Cystitis; Estradiol; Estrogens; | 1977 |
Adrenal contribution to circulating estrogens in woman.
Topics: Adrenal Glands; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Aged; Breast Neoplasms; Estradiol | 1978 |
Investigation of hormone-receptor interactions by means of fluorescence labeling.
Topics: Animals; Binding, Competitive; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cytosol; D | 1978 |
Aromatization of androgens by human abdominal and breast fat tissue.
Topics: Abdomen; Adipose Tissue; Androgens; Androstenedione; Androstenols; Axilla; Breast; Breast Neoplasms; | 1975 |
Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma.
Topics: Adult; Aminoglutethimide; Androstenedione; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; | 1978 |
Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer.
Topics: Aged; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Humans; Menopause; Middle Aged; Risk | 1979 |
Inhibition of peripheral aromatization in postmenopausal women with breast cancer.
Topics: Androstenedione; Breast Neoplasms; Estrone; Female; Humans; Menopause; Radioimmunoassay; Testolacton | 1978 |
Low urinary estrogen glucuronides in women at risk for familial breast cancer.
Topics: Adult; Age Factors; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Menopa | 1979 |
Effects of estrone on cell proliferation of a human breast cancer (MCF-7) in long term tissue culture.
Topics: Breast Neoplasms; Cell Division; Culture Techniques; DNA, Neoplasm; Estradiol; Estrone; Female; Huma | 1979 |
Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using delta 1-testololactone.
Topics: Aged; Androstenedione; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Mastectomy; Menopause; | 1979 |
Relationship between estrogen receptors, 17 beta-hydroxysteroid dehydrogenase and estrogen content in human breast cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; R | 1979 |
Endocrine profile in a patient with familial breast cancer: a case-control study.
Topics: Adult; Breast Neoplasms; Endocrine Glands; Estradiol; Estriol; Estrone; Female; Follicle Stimulating | 1979 |
A correlation between estrogen sulfotransferase levels and estrogen receptor status in human primary breast carcinoma.
Topics: Breast Neoplasms; Cytosol; Estrogens; Estrone; Female; Humans; Neoplasms, Hormone-Dependent; Phospho | 1979 |
Androgen--oestrogen transformation in female patients with metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Menopause; Testosterone | 1979 |
Failure of breast cancer cells in long-term culture to aromatize androstenedione.
Topics: Androstenedione; Animals; Breast Neoplasms; Carbon Radioisotopes; Cell Line; Estradiol; Estrone; Mam | 1978 |
Androgen-estrogen production rates in postmenopausal women with breast cancer.
Topics: Aged; Androstenedione; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Menopause; Metabolic Cl | 1978 |
Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls.
Topics: Age Factors; Aged; Androstenedione; Body Weight; Breast Neoplasms; Estrone; Female; Humans; Menopaus | 1979 |
Estrogen use and cancer risk.
Topics: Administration, Oral; Breast Neoplasms; Diethylstilbestrol; Dose-Response Relationship, Drug; Estrad | 1977 |
Estrone and estradiol content in human breast tumors: relationship to estradiol receptors.
Topics: Breast Neoplasms; Cytosol; Estradiol; Estrone; Female; Humans; Receptors, Estrogen | 1977 |
Medical adrenalectomy and plasma steroids in advanced breast carcinoma.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Adrenalectomy; Aminoglutethimide; Androstenedione; Breast N | 1978 |
Estrogen profiles of premenopausal women with breast cancer.
Topics: Adult; Breast Neoplasms; Contraceptives, Oral; Estradiol; Estriol; Estrogens; Estrone; Female; Human | 1978 |
Estrogen profiles in young women: effect of maternal history of breast cancer.
Topics: Adolescent; Adult; Breast Neoplasms; Child; Estradiol; Estriol; Estrogens; Estrone; Family Character | 1978 |
Estrone to estradiol conversion by blood mononuclear cells in normal subjects and in patients with mammary and nonmammary carcinomas.
Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estrone; Female; Humans; In Vitro Techniques; Kinetics; Le | 1978 |
Estrogen synthesis and estradiol binding by human mammary tumors.
Topics: 17-Hydroxysteroid Dehydrogenases; Adult; Age Factors; Aged; Androstenedione; Breast Neoplasms; Estra | 1978 |
Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels.
Topics: Adenocarcinoma; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Menopause; Menstrua | 1978 |
Plasma hormone profiles of young women at risk for familial breast cancer.
Topics: Adult; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Family Characteristics; Female; Fol | 1978 |
Relationship between urine and plasma estrogen ratios.
Topics: Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Follicular Phase; Humans; Luteal P | 1978 |
Metabolism of 17beta-estradiol during receptor-mediated nuclear migration in breast cancer cells.
Topics: Breast Neoplasms; Cell Nucleus; Cells, Cultured; Cytosol; Estradiol; Estrone; Ethanol; Neoplasms, Ex | 1978 |
Kinetics of testosterone metabolism in normal postmenopausal women and women with breast cancer.
Topics: Aged; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Kinetics; Menopause; Metabolic Clearance | 1978 |
Estriol production rates and breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Humans; Menopause; Middle Aged | 1978 |
Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture.
Topics: Binding, Competitive; Breast Neoplasms; Cell Nucleus; Culture Techniques; Cytoplasm; Drug Interactio | 1977 |
Relationship between steroid excretion patterns and breast cancer incidence in Israeli women of various origins.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Aged; Androgens; Breast Neoplasms; Environment; Estriol; E | 1977 |
Breast cancer and pregnancy.
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Antineoplastic Agents; Breast Neoplasms; Cast | 1977 |
Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
Topics: Adrenal Glands; Aminoglutethimide; Androstenedione; Breast Neoplasms; Castration; Estradiol; Estroge | 1977 |
Comparison of urinary and plasma hormone levels in daughters of breast cancer patients and controls.
Topics: Adolescent; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Follicular Phase; Huma | 1977 |
Tamoxifen (antiestrogen) therapy in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Menopause; Middle Aged; Neoplasm | 1977 |
[Hormonal function of the ovaries in women with breast hyperplasia].
Topics: Adult; Breast Neoplasms; Endometrium; Estradiol; Estrone; Female; Gonadal Steroid Hormones; Humans; | 1976 |
Breast cancer in Britain and Japan: plasma oestradiol-17beta, oestrone and progesterone,and their urinary metabolites in normal British and Japanese women.
Topics: Adolescent; Adult; Age Factors; Asian People; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estro | 1976 |
Fractionation of diverse steroid-binding proteins: basic and clinical applications.
Topics: Animals; Binding, Competitive; Breast Neoplasms; Carrier Proteins; Charcoal; Chickens; Chromatograph | 1976 |
Protection of estrogenic hormones by ascorbic acid during chromatography.
Topics: Aged; Ascorbic Acid; Breast Neoplasms; Chromatography, Gas; Chromatography, Thin Layer; Estradiol; E | 1975 |
Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer.
Topics: Adolescent; Adult; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Menarche; Pregna | 1975 |
The metabolism of 3-H-estradiol-17 beta in human breast cancer in organ culture.
Topics: Adenofibroma; Amino Acids; Breast; Breast Neoplasms; DNA; Estradiol; Estrone; Female; Humans; Mastit | 1975 |
Urinary excretion of steroids by Japanese women with breast cancer.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Asian People; Breast Neoplasms; Estradiol; Estrio | 1975 |
Urinary excretion of steroids and response to oophorectomy in premenopausal women with advanced breast cancer.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Cortex Hormones; Adult; Breast Neoplasms; Castra | 1975 |
[Estrogen excretion and sex chromatin content in the tumor cells of breast cancer patients].
Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Menstruation; | 1975 |
On the significance of in situ production of oestrogens in human breast cancer tissue.
Topics: Adipose Tissue; Aromatase; Breast Neoplasms; Estradiol; Estrogens; Estrogens, Conjugated (USP); Estr | 1992 |
The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
Topics: Aged; Aged, 80 and over; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neopla | 1992 |
[Aminoglutethimide and aminoglutethimide+tamoxifen treatment for advanced breast cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminoglutethimide; Androstenedione; Breast Neo | 1992 |
Effect of the progestagen R5020 (promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in the MCF-7 and T-47d human mammary cancer cells: correlation with progesterone receptor levels.
Topics: Biotransformation; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Neoplasms, Hormone-Dependen | 1992 |
The origin of oestrone sulphate in normal and malignant breast tissues in postmenopausal women.
Topics: Aged; Breast; Breast Neoplasms; Danazol; Estrone; Female; Humans; Menopause; Middle Aged; Sulfatases | 1992 |
Oestradiol synthesis from oestrone in malignant breast epithelial cells: studies on a high affinity, 80 kDa form of oestradiol dehydrogenase.
Topics: Adipose Tissue; Breast; Breast Neoplasms; Cell-Free System; Epithelium; Estradiol; Estradiol Dehydro | 1992 |
Endocrine profile in breast cancer patients receiving chemotherapy.
Topics: Adult; Age Factors; Amenorrhea; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Bre | 1992 |
Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons.
Topics: Abdomen; Adipose Tissue; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Menopause | 1992 |
Sex hormones and postmenopausal breast cancer: a prospective study in an adult community.
Topics: Aged; Analysis of Variance; Androstenedione; Breast Neoplasms; California; Chi-Square Distribution; | 1992 |
Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Topics: 17-alpha-Hydroxyprogesterone; Adrenocorticotropic Hormone; Aldosterone; Androstenedione; Aromatase I | 1991 |
Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.
Topics: 17-alpha-Hydroxyprogesterone; Adrenocorticotropic Hormone; Aminoglutethimide; Androstenedione; Breas | 1991 |
Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo.
Topics: Aminoglutethimide; Androstenedione; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Es | 1991 |
The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
Topics: Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Estrone; Fadrozole; Female; Humans; | 1991 |
Endocrine status in patients with mammary gland diseases: correlation between steroid hormones and sex steroid binding globulin.
Topics: Adult; Aged; Aged, 80 and over; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroep | 1991 |
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogens, Conjugated (USP); | 1991 |
Age at menarche and estrogen concentrations of adult women.
Topics: Adult; Age Factors; Asian People; Breast Neoplasms; China; Estradiol; Estrone; Female; Humans; Menar | 1991 |
17 Beta-hydroxysteroid dehydrogenases in human breast tissues: purification and characterization of soluble enzymes and the distribution of particulate and soluble forms in adipose, non-adipose and tumour tissues.
Topics: 17-Hydroxysteroid Dehydrogenases; Adipose Tissue; Breast; Breast Neoplasms; Chemical Fractionation; | 1991 |
Tamoxifen and partial oestrogen agonism in postmenopausal women.
Topics: Aged; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Follicle Stimulating Hormone; Humans; | 1991 |
Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal (Huma 7) and malignant (MCF-7 and ZR-75-1) human breast cells in culture.
Topics: Breast; Breast Neoplasms; Cell Line; Contraceptives, Oral; Estradiol; Estrone; Ethinyl Estradiol; Fe | 1991 |
Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues.
Topics: Aged; Androstenedione; Aromatase Inhibitors; Breast; Breast Neoplasms; DNA Polymerase II; Estrone; F | 1991 |
Endogenous steroid hormones and local aromatase activity in the breast.
Topics: Adipose Tissue; Aromatase; Breast; Breast Neoplasms; DNA, Neoplasm; Estradiol; Estrone; Female; Horm | 1991 |
The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy | 1990 |
Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Female; Human | 1990 |
Steroid patterns of benign breast disease.
Topics: Adenofibroma; Breast Neoplasms; Chromatography, High Pressure Liquid; Dehydroepiandrosterone; Dehydr | 1990 |
Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estrone; Fadrozole; Humans; Imi | 1990 |
Ovarian function in premenopausal women affected by breast cancer: the measurement of glucuronoconjugate metabolites of 17 beta-estradiol and progesterone throughout one entire menstrual cycle.
Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Estrone; Female; Humans; Luteal Phase; Menstrual Cycle; | 1990 |
Effect of breast cyst fluid on oestrogen 17-oxidoreductase activity in MCF-7 breast cancer cells.
Topics: Body Fluids; Breast Neoplasms; Cell Division; Chromatography, Gel; Chromatography, High Pressure Liq | 1990 |
Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
Topics: Aged; Androstenedione; Antineoplastic Agents; Aromatase; Breast Neoplasms; DNA Polymerase II; Estron | 1990 |
[Fixation of fluorescent estrone derivative on human breast cancer cells. Correlation with age, menopause status and histopathology].
Topics: Adult; Age Factors; Aged; Binding Sites; Breast Neoplasms; Carcinoma; Estrone; Female; Fluorescence; | 1990 |
Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings.
Topics: Aged; Androgens; Breast Neoplasms; Estrogens; Estrone; Female; Hormones; Humans; Medroxyprogesterone | 1990 |
Metabolism and biologic response of estrogen sulfates in hormone-dependent and hormone-independent mammary cancer cell lines. Effect of antiestrogens.
Topics: Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Humans; Menstruation; Polyunsaturated Alkamid | 1990 |
Steroids in normal and neoplastic breast tissues.
Topics: Androgens; Breast; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Menopause; Steroids | 1990 |
[Tissue culture and estrogen, to clarify the roles of estrone sulfate].
Topics: Alzheimer Disease; Breast Neoplasms; Culture Techniques; Endometrial Neoplasms; Endometrium; Estradi | 1989 |
Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Buserelin; Estradiol; Estrone; Female; Goserelin; | 1989 |
Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
Topics: Adult; Androstenedione; Breast Neoplasms; Buserelin; Estrone; Female; Goserelin; Humans; Middle Aged | 1989 |
Zoladex: therapeutic effects in postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Buserelin; Estradiol; Estrone; Female; Goserelin; | 1989 |
The effect of medroxyprogesterone acetate on aromatase and DNA polymerase alpha activities in breast tumours.
Topics: Aged; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Division; | 1989 |
Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Estrogens, Conjugated (USP); Estrone; Female; Humans; Mid | 1989 |
Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer.
Topics: Adipose Tissue; Breast Neoplasms; Estradiol; Estrogens, Conjugated (USP); Estrone; Female; Humans; M | 1989 |
In vivo and in vitro effects of the antifungal agent miconazole on estrogen biosynthesis in human breast cancer.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens | 1989 |
Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women.
Topics: Androstenedione; Breast Neoplasms; Circadian Rhythm; Estradiol; Estrone; Female; Humans; Menopause; | 1989 |
[Biological action of the antiestrogen ICI 164.384 in the MCF-7 mammary cancer cell line].
Topics: Breast Neoplasms; Cell Division; DNA; Estradiol; Estrogen Antagonists; Estrone; Humans; Polyunsatura | 1989 |
Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues.
Topics: Androgens; Breast; Breast Neoplasms; Endometrium; Estradiol; Estrogens; Estrone; Female; Humans; Men | 1989 |
In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione.
Topics: Aged; Androstenedione; Aromatase; Breast; Breast Neoplasms; DNA Polymerase II; Estrone; Female; Huma | 1989 |
Estrogen and androgen levels in women treated with radiation for cervical cancer--possible influence on breast cancer risk.
Topics: Adult; Aged; Androstenedione; Breast Neoplasms; Cross-Sectional Studies; Estradiol; Estrone; Female; | 1989 |
[Local production of estrogen via aromatase and estrone sulfatase in breast cancer tissue].
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Aromatase; Breast; Breast Neoplasms; Estrone; Female | 1989 |
Measurement of estrone-3-glucuronide and pregnanediol-3 alpha-glucuronide in early morning urine samples to monitor ovarian function.
Topics: Abortion, Habitual; Adolescent; Adult; Breast Neoplasms; Child; Estrone; Female; Humans; Immunoassay | 1989 |
Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition.
Topics: Adult; Aged; Aminoglutethimide; Analysis of Variance; Aromatase Inhibitors; Breast Neoplasms; Estron | 1989 |
Effect of tamoxifen and tamoxifen derivatives on the conversion of estrone-sulfate to estradiol in the R-27 cells, a tamoxifen-resistant line derived from MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Line; Drug Resistance; Estradiol; Estrogens, Conjugated (USP); Estrone; Femal | 1988 |
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroep | 1985 |
Uptake and concentration of steroid hormones in mammary tissues.
Topics: Adult; Androgens; Androstenediol; Biopsy; Breast; Breast Diseases; Breast Neoplasms; Cell Nucleus; C | 1986 |
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Topics: Adult; Aged; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone; Drug E | 1986 |
Endocrine treatment of breast cancer: effects upon intratumoral estrone sulfate metabolism and peripheral steroid levels.
Topics: Aminoglutethimide; Breast Neoplasms; Danazol; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate | 1986 |
Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1986 |
The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
Topics: Androstenedione; Antineoplastic Agents; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandroste | 1987 |
The mechanism of hormone-sensitive breast cancer progression on antiestrogen therapy. Implications for treatment and protocol planning.
Topics: Adrenal Glands; Adrenalectomy; Adult; Aged; Breast Neoplasms; Castration; Dehydroepiandrosterone; Es | 1987 |
Dietary and hormonal interrelationships in premenopausal women: evidence for a relationship between dietary nutrients and plasma prolactin levels.
Topics: Adult; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Diet, Vegetarian; D | 1987 |
The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estrone; Female; Humans; H | 1988 |
Two partial remissions induced by an LHRH analogue in two postmenopausal women with metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Follicle Stimulating | 1988 |
High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aged, 80 and over; Androstenedione; Breast Neoplasms; Dehydroepi | 1988 |
Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Topics: Adrenocorticotropic Hormone; Aged; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast | 1985 |
Estrogen sulfates: biological and ultrastructural responses and metabolism in MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Line; Dose-Response Relationship, Drug; Estradiol; Estrogens, Conjugated (USP | 1986 |
Subcellular concentrations of estrone, estradiol, androstenedione and 17 beta-hydroxysteroid dehydrogenase (17-beta-OH-SDH) activity in malignant and non-malignant human breast tissues.
Topics: 17-Hydroxysteroid Dehydrogenases; Androstenedione; Body Weight; Breast; Breast Neoplasms; Estradiol; | 1987 |
[Cancer of the breast, mechanism of action of anti-estrogens].
Topics: Breast Neoplasms; Cell Line, Transformed; Estradiol; Estrone; Neoplasms, Hormone-Dependent; Polyunsa | 1988 |
Oestrogen production and metabolism in peri-menopausal women.
Topics: Breast Neoplasms; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Luteinizing Horm | 1986 |
[Serum estrone sulfate levels in patients with breast cancer].
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Estrone; Female; Humans; Kinetics; Menopau | 1988 |
Influence of endocrine status on biochemical and immunocytochemical estrogen and progesterone receptor assays in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Immunohistoche | 1988 |
Metabolic fate of estradiol in human mammary cancer cells in culture: estrogen sulfate formation and cooperativity exhibited by estrogen sulfotransferase.
Topics: Breast Neoplasms; Cell Line; Estradiol; Estrone; Female; Humans; Receptors, Estrogen; Sulfotransfera | 1988 |
Quantitative determination of oestradiol-17 beta hydroxysteroid dehydrogenase: increased sensitivity by HPLC separation of the hormones permits the measurement of enzyme activity in cryostat sections.
Topics: 17-Hydroxysteroid Dehydrogenases; Biomarkers, Tumor; Breast Neoplasms; Chromatography, High Pressure | 1988 |
[Biological responses, ultrastructural changes and metabolism of estrone sulfate in line cells of human breast cancer: MCF-7].
Topics: Breast Neoplasms; Cell Line; Estrone; Female; Humans; Hydrolysis; Receptors, Progesterone; Tamoxifen | 1987 |
Re: "Sex hormone levels in serum in relation to the development of breast cancer".
Topics: Breast Neoplasms; Estradiol; Estrone; Female; Gonadal Steroid Hormones; Humans; Menopause | 1988 |
Steroid modulation of aromatase activity in human cultured breast carcinoma cells.
Topics: Androstenedione; Aromatase; Breast Neoplasms; Carcinoma; Cell Division; Estradiol; Estrone; Humans; | 1988 |
Effect of tamoxifen and tamoxifen derivatives on the conversion of estrone sulfate to estradiol in the MCF-7 mammary cancer cell line.
Topics: Breast Neoplasms; Cell Line; Estradiol; Estrone; Female; Humans; Tamoxifen; Tumor Cells, Cultured | 1988 |
Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Estradiol; Estrogens; Estrone; Humans; Male; Middle Aged; | 1987 |
Estrone sulfate: a potential source of estradiol in human breast cancer tissues.
Topics: 17-Hydroxysteroid Dehydrogenases; Animals; Breast Neoplasms; Cells, Cultured; Chromatography, Thin L | 1986 |
Estrogens and breast cancer.
Topics: Adult; Aged; Blood Specimen Collection; Breast Neoplasms; Epidemiologic Methods; Estradiol; Estrogen | 1986 |
Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens.
Topics: Adult; Aged; Analysis of Variance; Body Fluids; Breast; Breast Diseases; Breast Neoplasms; Estradiol | 1987 |
Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrone; F | 1987 |
Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance.
Topics: Androstenedione; Aromatase; Breast Neoplasms; Estrone; Female; Humans; In Vitro Techniques; Menopaus | 1987 |
Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cell Line; Diethylstilbestrol; Estradiol; Estrogens; Es | 1987 |
Endogenous sex hormone levels and breast cancer risk.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cholesterol; Cholesterol, HDL; Estradiol; Estrone; Female | 1987 |
Metabolism of [3H]oestradiol in vivo by normal breast and tumour tissue in postmenopausal women.
Topics: Aged; Androgens; Breast; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Menopause; Middle Age | 1986 |
A comparison of the in vivo uptake and metabolism of 3H-oestrone and 3H-oestradiol by normal breast and breast tumour tissues in post-menopausal women.
Topics: Aged; Breast; Breast Neoplasms; Estradiol; Estradiol Dehydrogenases; Estrone; Female; Humans; Menopa | 1986 |
Aminoglutethimide as an inducer of microsomal enzymes. Part 2: Endocrine aspects.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Administration Schedule; Estradiol; Estrogens; Estrone; Fe | 1986 |
Role of aminoglutethimide in male breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrone; Humans; Hydrocor | 1986 |
The role of tissue steroids in regulating aromatase and oestradiol 17 beta-hydroxysteroid dehydrogenase activities in breast and endometrial cancer.
Topics: Aromatase; Breast; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Kinetics; Reference Values; | 1986 |
Estrogen production and metabolism in normal postmenopausal women and postmenopausal women with breast or endometrial cancer.
Topics: Aged; Body Weight; Breast Neoplasms; Endometrial Hyperplasia; Estradiol; Estrone; Female; Humans; Me | 1986 |
The relationship between growth and androstenedione metabolism in four cell lines of human breast carcinoma cells in culture.
Topics: 17-Hydroxysteroid Dehydrogenases; Androgens; Androstenedione; Aromatase; Breast Neoplasms; Cell Divi | 1985 |
The relationship between 17 beta hydroxysteroid dehydrogenase and breast tumour site and size.
Topics: 17-Hydroxysteroid Dehydrogenases; Adipose Tissue; Adult; Aged; Body Weight; Breast Neoplasms; Estrad | 1985 |
Kinetic studies of oestradiol 17 beta-hydroxysteroid dehydrogenase in MCF-7 mammary cancer cells.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Line; Estradiol Dehydrogenases; Estrone; Hu | 1985 |
Estradiol entry into endometrial cells in suspension.
Topics: Adenocarcinoma; Biological Transport; Breast Neoplasms; Carbon Radioisotopes; Carrier Proteins; Cell | 1985 |
A study on plasma sex hormone levels in patients with breast cancer.
Topics: Adult; Breast Neoplasms; Estradiol; Estrone; Female; Gonadal Steroid Hormones; Humans; Middle Aged; | 1985 |
Decrease of circulating level of SHBG in postmenopausal obese women as a risk factor in breast cancer: reversible effect of weight loss.
Topics: Aged; Androstenedione; Body Weight; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Hydrocorti | 1986 |
Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue.
Topics: Adolescent; Adult; Aged; Breast; Breast Neoplasms; Cell Nucleus; Cytosol; Estradiol; Estrogens; Estr | 1985 |
Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
Topics: Aged; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estrone; Female; H | 1985 |
Oestrone sulphate, adipose tissue, and breast cancer.
Topics: Adipose Tissue; Animals; Breast; Breast Neoplasms; Cattle; Estrone; Female; Fibrocystic Breast Disea | 1985 |
Plasma oestrogens and oestrogen receptors in breast cancer patients.
Topics: Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Menopause; Receptors, Estrogen | 1985 |
Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone.
Topics: Adrenal Cortex Hormones; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1985 |
Effects of the antiandrogen cyproterone acetate on estradiol production and metabolism in man.
Topics: 17-Hydroxycorticosteroids; Acetates; Aged; Breast Neoplasms; Castration; Estradiol; Estriol; Estrone | 1970 |
Oestrogen profiles of Asian and North American women.
Topics: Adolescent; Adult; Age Factors; Asia; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Fema | 1971 |
Estrogen profiles and breast cancer.
Topics: Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Pregnancy | 1971 |
Endocrine profiles and breast cancer.
Topics: 11-Hydroxycorticosteroids; Adult; Aged; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estriol | 1973 |
Letter: Oestrogen synthesis by human breast carcinomas.
Topics: Breast Neoplasms; Culture Techniques; Estradiol; Estrogens; Estrone; Female; Humans; Microtomy; Test | 1974 |
Urinary oestrogen profiles and aetiology of breast cancer.
Topics: Adult; Age Factors; Animals; Asian People; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; | 1970 |
[Comparing metabolic studies following infusion of dehydroepiandrosterone sulfate and dehydroepiandrosterone phosphate].
Topics: 17-Ketosteroids; Adult; Androgens; Androsterone; Breast Neoplasms; Dehydroepiandrosterone; Estradiol | 1965 |
[Comparing metabolic studies following infusion of delta-4-androstene-3,17-dione, testosterone phosphate and dehydroepiandrosterone phosphate].
Topics: 17-Ketosteroids; Adult; Androgens; Androsterone; Breast Neoplasms; Dehydroepiandrosterone; Estradiol | 1965 |
Conjugation of steroid hormones by breast cancer tissue and selection of patients for adrenalectomy.
Topics: Adrenalectomy; Aged; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Humans; Liver; Li | 1969 |
Increase in urinary excretion of oestrogen on administration of dehydroepiandrosterone sulphate to an adrenalectomized, oophorectomized patient with breast cancer.
Topics: Adrenalectomy; Adult; Breast Neoplasms; Castration; Chromatography; Dehydroepiandrosterone; Estradio | 1971 |
Androgen production and conversion to estrogens in normal postmenopausal women and in selected breast cancer patients.
Topics: 17-Ketosteroids; Aged; Androgens; Androstenedione; Androsterone; Breast Neoplasms; Carbon Isotopes; | 1973 |
[The mechanism of action of hydrocortisone administered by lumbar puncture in breast cancer].
Topics: 11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Aged; Androsterone; Br | 1973 |
Steroid sulfatase activities in human breast tumors.
Topics: Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Female; Humans; Sulfatases; Testostero | 1974 |
Endogenous steroid concentrations in human breast tumours determined by high-resolution mass fragmentography.
Topics: Androsterone; Breast Neoplasms; Chromatography, Gas; Dehydroepiandrosterone; Estradiol; Estriol; Est | 1974 |
Specific estrogen binding by the cytoplasm fof human breast carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Binding Sites; Breast Neoplasms; Carcinoma, I | 1970 |
Carcinoma of the breast during estrogen replacement therapy.
Topics: Adult; Aged; Breast Diseases; Breast Neoplasms; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; | 1972 |
Effect of drugs on carcinoma of the breast in tissue culture.
Topics: Adenofibroma; Biopsy; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Culture Techniques; | 1972 |
Oestrogen metabolism in cultured human breast tumours.
Topics: Adenocarcinoma, Scirrhous; Adenofibroma; Breast Neoplasms; Carcinoma; Carcinoma, Intraductal, Noninf | 1972 |
Adrenal and testicular contribution to plasma oestrogens.
Topics: 17-Ketosteroids; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Androstanes; Breast Neopl | 1972 |
The steroid specificity of the estrogen-receptor of human breast carcinoma.
Topics: Androstanes; Androstenols; Binding Sites; Breast; Breast Neoplasms; Carcinoma; Cytosol; Dehydroepian | 1974 |
Estrogen receptors and the estrone hypothesis in relation to endometrial and breast cancer.
Topics: Animals; Binding, Competitive; Breast Neoplasms; Centrifugation, Density Gradient; Endometrium; Estr | 1974 |
Estrogen profiles of Oriental and Caucasian women in Hawaii.
Topics: Adolescent; Adult; Age Factors; Asian People; Breast Neoplasms; China; Estradiol; Estriol; Estrogens | 1974 |
A comparative study of urinary oestrogens in the cancer of breast and prostate.
Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Male; Middle | 1974 |
Urine oestrogen profiles of Asian and North American women.
Topics: Adolescent; Adult; Age Factors; Body Weight; Breast Neoplasms; Canada; Corpus Luteum; Estradiol; Est | 1974 |
[Proceedings: Radioimmunoassay of blood estrone and estradiol in patients with mammary gland diseases (with special reference to breast cancer].
Topics: Breast Neoplasms; Estradiol; Estrone; Female; Humans; Radioimmunoassay | 1974 |
L-Dopa effect on prolactin, follicle-stimulating hormone, and luteinizing hormone in women with advanced breast cancer: a preliminary report.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Bone Neoplasms; Breast Neoplasms; Dihydroxyphenyl | 1972 |
Urinary estrogen excretion in men with breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chromatography, Thin Layer; Estradiol; Estriol; Estrogens; Estrone; H | 1973 |
Male breast cancer. II. Metabolism of oestradiol-17 beta in men with breast cancer.
Topics: Aged; Breast Neoplasms; Chromatography, Gas; Chromatography, Thin Layer; Estradiol; Estriol; Estroge | 1973 |
Androgens in breast cancer. II. Endometrial adenocarcinoma and breast cancer in married postmenopausal women.
Topics: Adenocarcinoma; Age Factors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Hyperp | 1974 |
The study of the excretion of estrogens in patients with breast cancer treated with androgens.
Topics: Adult; Androgens; Breast Neoplasms; Castration; Estradiol; Estriol; Estrogens; Estrone; Female; Huma | 1972 |
Genetic predisposition to carcinoma of the breast: multiple human genotypes for estrogen 16 alpha hydroxylase activity in Caucasians.
Topics: Breast Diseases; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Genital Neoplasms, Female; G | 1972 |
Extraction of radioactive estrogens and metabolites from small amounts of human or animal tissues excised following intravenous administration of 6,7-3H-17beta-estradiol.
Topics: Adipose Tissue; Breast Neoplasms; Chemical Precipitation; Chromatography, Thin Layer; Crystallizatio | 1971 |
Estrogens in breast tumors.
Topics: Adipose Tissue; Androstanols; Breast; Breast Neoplasms; Colon; DNA, Neoplasm; Estradiol; Estrogens; | 1971 |
[Examination of the luteotropic hormone activity of blood and urinary steroid excretion in diseases of the breast].
Topics: 17-Ketosteroids; Adenofibroma; Adolescent; Adult; Aged; Animals; Breast Diseases; Breast Neoplasms; | 1969 |
Oestradiol production rates in man before and after orchiectomy for cancer.
Topics: Aged; Breast Neoplasms; Castration; Estradiol; Estriol; Estrone; Humans; Male; Middle Aged; Prostati | 1970 |
A method for the separation of polar androgens from estrogens.
Topics: Adrenal Glands; Adrenalectomy; Androgens; Breast Neoplasms; Carbon Isotopes; Castration; Countercurr | 1970 |
Radioactivity in human breast tumours after infusion of 3H-oestradiol: effect of androgen treatment.
Topics: Androstanols; Breast Neoplasms; Carbon Isotopes; Chromatography, Thin Layer; Estradiol; Estrone; Fem | 1970 |
Relationship between hormonal cytology and steroid excretion in post-menopausal women.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Aged; Androsterone; Breast Neoplasms; Estriol; Estrogens | 1970 |
Studies on the human metabolism of 6:7 3 H oestradiol.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Estradiol; Estriol; Estrone; Female; Humans; Male; | 1970 |
Peripheral metabolism of 3H-estradiol and the excretion of endogenous estrone and estriol glucosiduronate in women with breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Carbon Isotopes; Chromatography, Paper; Crystallization; Estradiol; E | 1971 |
[Role of estrogens in breast tumors].
Topics: Adenofibroma; Breast Neoplasms; Chromatography; Estradiol; Estriol; Estrogens; Estrone; Humans; In V | 1967 |
Epidemiology of mammary cancer.
Topics: Age Factors; Animals; Breast; Breast Feeding; Breast Neoplasms; Epidemiologic Methods; Estradiol; Es | 1967 |
Effect of clomiphene citrate upon pituitary gonadotropins. Clomiphene and pituitary gonadotropins.
Topics: Adult; Breast Neoplasms; Castration; Clomiphene; Cobalt Isotopes; Estradiol; Estriol; Estrone; Femal | 1968 |
Steroid hormones and cancer. Some biochemical approaches.
Topics: Breast Neoplasms; Estradiol; Estrone; Models, Biological; Protein Binding; Testosterone | 1968 |
[The urinary excretion of estrogens in patients with far advanced breast cancer during treatment with prednisolone].
Topics: Adrenal Glands; Breast Neoplasms; Castration; Chromatography; Estradiol; Estriol; Estrogens; Estrone | 1968 |
Isolation and identification of estriol in urine of castrated and adrenalectomized women receiving 4-14C-testosterone.
Topics: Adrenal Glands; Adrenalectomy; Breast Neoplasms; Carbon Isotopes; Castration; Chromatography, Paper; | 1968 |
Estrogen metabolism in postmenopausal women with primary and recurrent breast cancer.
Topics: Aging; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Menopause; Middle A | 1968 |
Metabolism and tissue uptake of estrogen in women with advanced carcinoma of the breast.
Topics: Adipose Tissue; Breast; Breast Neoplasms; Chromatography, Thin Layer; Estradiol; Estrone; Female; Hu | 1969 |
Estradiol transformation in men with breast cancer.
Topics: Aged; Biotransformation; Breast Neoplasms; Carbon Isotopes; Castration; Estradiol; Estrone; Humans; | 1966 |
Reduced estriol excretion in patients with breast cancer prior to endocrine therapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Androgens; Breast Neoplasms; Castration; Estradiol; Estrogens; | 1966 |